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solubility at 24 hours in compendial media. The excipient brands are shown as: i. 
CPV(L) (blue colour) and ii. CPV(H) (red colour). Light and dark colours correspond 
to low and high excipient level, respectively. (Mean (white line), Median (black 
diamond), n = 3) 
Figure 4.10: Box plots of the relative effects (%) of the studied CPV brands on drug 
solubility at 24 hours in biorelevant media. The excipient brands are shown as: i. 
CPV(L) (blue colour) and ii. CPV(H) (red colour). Light and dark colours correspond 
to low and high excipient level, respectively. (Mean (white line), Median (black 
diamond), n = 3) 
Figure 4.11: Theoretical pH-solubility profiles of the studied drugs in compendial and 
biorelevant media and experimental drug solubility values in absence (squares) and 
presence of excipients (i. CPV(L) (blue colour), ii. CPV(H) (red colour)). Dashed lines 
indicate drug intrinsic solubility. 
Figure 4.12: Relative effects (%) of the studied SSG (i. Glycolys LV (green colour), 
ii. Explotab CLV (blue colour), iii. Glycolys (red colour)), CCS (i. CCS(L) (blue 
colour), ii. CCS(H) (red colour)) and CPV (i. CPV(L) (blue colour), ii. CPV(H) (red 
colour)) brands on drug solubility at 24 hours as a function of drug ionization (%) and 
drug lipophilicity (log P) in a. compendial and b. biorelevant media. Light and dark 
colours correspond to low and high excipient level, respectively. 
Figure 4.13: Classification gradient maps of the relative excipient effects of the a. 
SSG, b. CCS and c. CPV brands on the solubility of highly and poorly soluble 
compounds at 24 hours. Y-axes are set in an increasing viscosity and level order for 
SSG and increasing particle size and level order for CCS and CPV. The x-axes are set 
in a decreasing drug aqueous solubility order (red colours for highly soluble and blue 
colours for poorly soluble drugs). 
Figure 4.14: Standardized coefficients of the studied variables (and interaction terms) 
in compendial (blue colour) and biorelevant (red colour) media for SSG. * denotes 
coefficients of VIP > 1. * denotes coefficients of 0.8 < VIP < 1. (Mean, - SE) 
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Figure 4.15: Standardized coefficients of the studied variables (and interaction terms) 
in compendial (blue colour) and biorelevant (red colour) media for CCS. * denotes 
coefficients of VIP > 1. * denotes coefficients of 0.8 < VIP < 1. (Mean, - SE) 
Figure 4.16: Standardized coefficients of the studied variables (and interaction terms) 
in compendial (blue colour) and biorelevant (red colour) media for CPV. * denotes 
coefficients of VIP > 1. * denotes coefficients of 0.8 < VIP < 1. (Mean, - SE) 
Figure 4.17: Road map of the effects of the studied a. SSG, b. CCS and c. CPV brands 
on drug solubility at 24 hours. Red boxes and green boxes indicate significant and 
insignificant changes in drug solubility by excipient presence, respectively. 
Figure 5.1: Cumulative % dissolved of PRC from tablet formulations in compendial 
and biorelevant media using the a. USP 2 apparatus (500 mL, 50 rpm, 37°C), b. USP 
4 apparatus (closed mode, small cells, 500 mL, 4 mL/min, 37°C) and c. USP 4 
apparatus (closed mode, large cells, 500 mL, 4 mL/min, 37°C). The different tablets 
are shown as: i. control tablets (black circles), ii. HPMC variant tablets (blue 
diamonds), iii. SSG variant tablets (green triangles) and iv. MgSt variant tablets (red 
squares). (Mean ± SD, n = 3) 
Figure 5.2: Relative effects of excipients on the AUCs of the dissolution profiles 
between acidic and basic conditions for PRC and CBZ from the control tablets in 
compendial (green colour) and biorelevant (blue colour) media. (Mean ± SD, n = 3) 
Figure 5.3: Cumulative % dissolved of CBZ from tablet formulations in compendial 
and biorelevant media using the a. USP 2 apparatus (500 mL, 50 rpm, 37°C) and b. 
USP 4 apparatus (open mode, small cells, 4 mL/min, 37°C). The different batches are 
shown as: i. control tablets (black circles, ii. HPMC variant tablets (blue diamonds), 
iii. SSG variant tablets (green triangles) and iv. MgSt variant tablets (red squares). 
(Mean ± SD, n = 3) 
Figure 5.4: a. Relatives effects of excipients on the AUCs of the dissolution profiles 
between the control and HPMC variant tablets for the dissolution of PRC and CBZ in 
compendial (green colour) and biorelevant (blue colour) media in the studied 
apparatuses. Light and dark colours correspond to acidic and basic conditions, 
respectively (Mean ± SD, n = 3). b. Relative effects of excipients on the AUCs of the 
dissolution profiles between acidic and basic conditions for the dissolution of PRC 
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and CBZ from the HPMC variant tablets in compendial (green colour) and biorelevant 
(blue colour) media. (Mean ± SD, n = 3) 
Figure 5.5: a. Relatives effects of excipients on the AUCs of the dissolution profiles 
between the control and SSG variant tablets for the dissolution of PRC and CBZ in 
compendial (green colour) and biorelevant (blue colour) media in the studied 
apparatuses. Light and dark colours correspond to acidic and basic conditions, 
respectively. (Mean ± SD, n = 3). b. Relative effects of excipients on the AUCs of the 
dissolution profiles between acidic and basic conditions for the dissolution of PRC 
and CBZ from the SSG variant tablets in compendial (green colour) and biorelevant 
(blue colour) media. (Mean ± SD, n = 3) 
Figure 5.6: a. Relatives effects of excipients on the AUCs of the dissolution profiles 
between the control and MgSt variant tablets for the dissolution of PRC and CBZ in 
compendial (green colour) and biorelevant (blue colour) media in the studied 
apparatuses. Light and dark colours correspond to acidic and basic conditions, 
respectively (Mean ± SD, n = 3). b. Relative effects of excipients on the AUCs of the 
dissolution profiles between acidic and basic conditions for the dissolution of PRC 
and CBZ from the MgSt variant tablets in compendial (green colour) and biorelevant 
(blue colour) media. (Mean ± SD, n = 3) 
Figure 5.7: Real-time surface dissolution UV images for a. PRC and b. CBZ tablets 
in 0.1 N HCl pH 1. 
Figure 5.8: Dissolution profiles of PRC and CBZ from the i. Control tablets (black 
circles), ii. HPMC variant tablets (blue diamonds), iii. SSG variant tablets (green 
triangles) and iv. MgSt variant tablets (red squares) in 0.1 N HCl pH 1 using surface 
dissolution UV Imaging (SDi2, 6.16 mL/min, 37 °C, open mode). (Mean ± SD, n = 3) 
Figure 5.9: Relative effects of the studied excipients on the AUCs of the dissolution 
profiles (REAUC) as a function of relative effects of the studied excipients on drug 
solubility (RES) in a. compendial and b. biorelevant media. The drugs are portrayed 
as: i. PRC (circles) and ii. CBZ (squares). The dissolution profiles with the studied 
apparatuses are shown as: i. USP 2 apparatus (blue colour), ii. USP 4 apparatus – small 
cells (red colour) and iii. USP 4 apparatus - large cells (green colour). (Mean ± SD, n 
= 3) 
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Figure 5.10: Standardized coefficients of the studied variables (and interaction terms) 
in compendial (blue colour) and biorelevant (red colour) media. * denotes coefficients 
of VIP > 1. * denotes coefficients of 0.8 < VIP < 1. (Mean, - SE) 
Figure 6.1: Chemical structure of a. Sodium Starch Glycolate and b. Croscarmellose 
Sodium (ChemDraw Professional 15) 
Figure 6.2: Absorbance values (Abs) of the studied superdisintegrant types and brands 
as a function of distance from the center of the sample cup (mm) in 0.1 N HCl pH 1 
(SDi1, 0 mL/min, 37 °C, 254 nm) presented up to 2.5 min. 
Figure 6.3: Absorbance values (Abs) of the studied superdisintegrant types and brands 
as a function of distance from the center of the sample cup (mm) in phosphate buffer 
pH 6.8 (SDi1, 0 mL/min, 37 °C, 254 nm) up to 2.5 min. 
Figure 6.4: Cumulative % dissolved (top) and dissolution rates (bottom) of PRC from 
compacts in a. 0.1 N HCl pH 1 and b. phosphate buffer pH 6.8 using real-time surface 
dissolution UV imaging (SDi1, 1 mL/min, 37°C) in absence (control: black 
circles/colour) and presence of the studied SSG brands (Glycolys LV: green 
squares/colour, Explotab CLV: blue diamonds/colour, Glycolys: red triangles/colour). 
(Mean ±SD, n =3) 
Figure 6.5: Relative effects of excipients on the AUCs of the dissolution profiles for 
a. PRC and b. CBZ in presence of the studied SSG brands (Glycolys LV: green colour, 
Explotab CLV: blue colour, Glycolys: red colour) in 0.1 N HCl pH 1 and phosphate 
buffer pH 6.8. 
Figure 6.6: Cumulative % dissolved (top) and dissolution rates (bottom) of CBZ from 
compacts in a. 0.1 N HCl pH 1 and b. phosphate buffer pH 6.8 using real-time surface 
dissolution UV imaging (SDi1, 1 mL/min, 37°C) in absence (control: black 
circles/colour) and presence of the studied SSG brands (Glycolys LV: green 
squares/colour, Explotab CLV: blue diamonds/colour, Glycolys: red triangles/colour). 
(Mean ±SD, n =3) 
Figure 6.7: Cumulative % dissolved (top) and dissolution rates (bottom) of PRC from 
compacts in a. 0.1 N HCl pH 1 and b. phosphate buffer pH 6.8 using real-time surface 
dissolution UV imaging (SDi1, 1 mL/min, 37°C) in absence (control: black 
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circles/colour) and presence of the studied CCS brands (AcDiSol: blue squares/colour, 
Primellose: red diamonds/colour). (Mean ±SD, n =3) 
Figure 6.8: Relative effects of excipients on the AUCs of the dissolution profiles for 
a. PRC and b. CBZ in presence of the studied CCS brands (AcDiSol: blue colour, 
Primellose: red colour) in 0.1 N HCl pH 1 and phosphate buffer pH 6.8. 
Figure 6.9: Cumulative % dissolved (top) and dissolution rates (bottom) of CBZ from 
compacts in a. 0.1 N HCl pH 1 and b. phosphate buffer pH 6.8 using real-time surface 
dissolution UV imaging (1 mL/min, 37°C) in absence (control: black circles/colour) 
and presence of the studied CCS brands (AcDiSol: blue squares/colour, Primellose: 
red diamonds/colour). (Mean ±SD, n =3) 
Figure 6.10: Standardized coefficients corresponding to the studied variables (and 
their interactions) for SSG (blue colour) and CCS (red colour). * denotes coefficients 
with p < 0.05. (Mean, - SE) 
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(small and large cells) apparatuses. Bold values indicate significant differences 
between the test and the reference dissolution profiles (f2 < 50). 
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List of Abbreviations 
Abbreviation Full Description 
3D 3 dimensional 




ANDA Abbreviated New Drug Application 
API Active Pharmaceutical Ingredient 
AU Absorbance unit 
AUC  Area Under the Curve 
AUCC Control Area Under the Curve 
AUCR Reference Area Under the Curve 
AUCT Test Area Under the Curve 




CCS Croscarmellose Sodium 
CMA Critical Material Attribute 
CPP Critical Process Parameter 
CPV Crospovidone 
CQA Critical Quality Attribute 
CRS Crystallinity 
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CV Coefficient of Variation 
Dcrit(Y) Maximum Tolerance Volume in the Y-plane 
DmodY Distance of observation to the model in the Y-
plane 
DoE Design of Experiments 
DP Dicalcium Phosphate 
DPA Dicalcium Phosphate Anhydrous 
DPD Dicalcium Phosphate Dihydrate 
DPL Dipyridamole 
Drugaq.sol Drug Aqueous Solubility 
Exc.  Excipient 
FaSSGF Fasted State Simulated Gastric Fluid 
FaSSIF-V2  Fasted State Simulated Intestinal Fluid (version 
2) 
FDA Food and Drug Administration 
FeSSGF Fed State Simulated Gastric Fluid 
FeSSIF Fed State Simulated Intestinal Fluid 
Fion % of drug ionized 
FRC Functionality Related Characteristics 
FRS Furosemide 
GC Gas Chromatography 
GF/D Glass Microfiber Filter 
GF/F Glass Fiber Filter 
GI Gastrointestinal 
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HCl Hydrochloric Acid 
HCTZ Hydrochlorothiazide 
HPC Hydroxypropyl Cellulose 
HPLC High-Performance Liquid Chromatography 
HPMC Hypromellose 
IBU Ibuprofen 
ICH International Conference on Harmonization 
Inj. Vol Injection Colume 
IPEC International Pharmaceutical Excipient Council 
ITZ Itraconazole 
IVIVC In vitro-In vivo Correlation 
LED Light Emitting Diodes 
log P log{octanol-water partition coefficient (P)} 
LOWESS Locally Weighed Scatterplot Smoothing 
MCC Microcrystalline Cellulose 
MeOH Methanol 
Mg2+ Magnesium 
MgSt Magnesium Stearate 
Min Minutes 
MRI Magnetic Resonance Imaging 
MTF Metformin 
n Number of replicates 
NaCl Sodium Chloride 
NDA New Drug Application 
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PEEK Polyetheretherketone 
PEG Polyethylene Glycol 
P-gp P Glycoprotein 
pKa Logarithmic acid dissociation constant 
PLS  Partial Least Squares 
PRC Paracetamol 
PRESS Minimum Predictive Residual Sum Of Squares  
PSD  Particle Size Distribution 
PTFE Polytetrafluoroethylene 
Q2 Goodness of Prediction 
QbD Quality by Design 
R2 Goodness of Fit 
RE Relative Effect 
Reauc Relative Effect on AUC 
REs Relative Effect on drug solubility 
RH Relative Humidity 
RS Reference solubility 
Rt Retention Time 
RT Reference Cumulative Profile 
S Solubility 
SA Surface Area 
SD Standard Deviation 
SDi Surface Dissolution 
SE Standard Error 
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SGF Simulated Gastric Fluid 
SLS Sodium Lauryl Sulfate 
SMX  Sulfamethoxazole 
SSA  Specific Surface Area 
SSG Sodium Starch Glycolate 
St  Standardized 
Temp Temperature 
TT Test Cumulative Profile 
USP United States Pharmacopeia 
UV  Ultraviolet 
VIP Variable Influence on Projection 
Vis Visible 
Vs Versus 
WHO World Health Organization 





























rpm Rotations per minute 
s Seconds 
Spm Strokes per minute 
v/v volume per volume 
w/v weight per volume 







Excipients present a challenge for oral drug bioavailability and it is recognized that 
excipient variability needs to be implemented in Quality by Design (QbD) approaches. 
The purpose of this thesis was to identify the biopharmaceutical implications of 
excipient variability on product performance. A systematic literature review identified 
the critical excipients (lubricants: magnesium stearate (MgSt), binders: hypromellose 
(HPMC), superdisintegrants: (sodium starch glycolate (SSG), croscarmellose sodium 
(CCS), crospovidone (CCS)) for oral drug performance and their critical material 
attributes that were further selected for experimentation. The impact of excipient 
variability on drug solubility and drug dissolution was examined using model 
compounds of different physicochemical properties. The effects of the varying 
composition of the gastrointestinal tract on the impact of excipients on product 
performance were examined by selecting compendial and biorelevant media and 
apparatuses of diverse hydrodynamics. Real – time surface dissolution UV imaging 
was used to characterize excipient behaviour under physiological conditions and to 
understand the mechanistic role of excipient variability on product performance. 
Excipient presence and variability affected drug solubility. MgSt and HPMC were 
considered excipients of high criticality for oral drug performance compared to 
superdisintegrants. Excipient effects on drug solubility strongly depended on drug 
physicochemical properties and medium characteristics. Cases where excipient 
variability may be critical for product performance were demonstrated with the design 
of roadmaps. Dissolution studies for a highly and a poorly soluble drug from tablets 
containing variant excipients revealed the criticality of MgSt variability (compared to 
HPMC and SSG) as faster drug dissolution for a highly soluble compound was 
observed when decreasing the particle size of MgSt. The influential role of pH, 
presence of solubilizing components and hydrodynamics on the impact of excipient 
variability on drug dissolution was revealed. Finally, the visualization of the surface 
events of superdisintegrant (SSG, CCS) swelling and their impact on drug dissolution 
revealed that the effects of superdisintegrants on drug dissolution strongly depend on 
excipient critical material attributes, drug aqueous solubility and pH of the medium. 
Throughout the studies of this thesis, the use of multivariate data analysis identified 
the critical biopharmaceutical factors of excipient variability with a potential risk for 
oral drug absorption. 
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Aims and Objectives 
The aim of this project was to design biorelevant tests to understand the impact of key 
formulation excipients on drug solubility and dissolution performance and use these 
tests to generate a body of knowledge on the impact of varying excipient material 
attributes on product performance. 
The key objectives included: 
Chapter 1: Present the current knowledge on the issue of excipient variability. 
Identify the critical material attributes of key excipients currently used in immediate 
release formulations and their implications for oral drug performance. 
Chapter 2 – 4: Investigate the effects and criticality of lubricant (chapter 2), binder 
(chapter 3) and superdisintegrant (chapter 4) variability on the apparent drug solubility 
in a biopharmaceutical perspective. Identify the biopharmaceutical implications of 
excipients on product performance by selecting model compounds of various 
physicochemical properties and media simulating the gastrointestinal conditions. 
Assess excipient criticality on oral drug performance with the use of multivariate data 
analysis and design of roadmaps. 
Chapter 5: Delineate the impact of excipient variability on in vitro drug dissolution 
by producing immediate release tablets with excipient variants using a highly and a 
poorly soluble model compound. Identify the role of excipients on drug dissolution in 
a biorelevant perspective by selecting diverse media (compendial/biorelevant) and 
hydrodynamic conditions (compendial apparatuses and surface dissolution UV 
imaging). Assess excipient criticality for drug dissolution using multivariate data 
analysis. 
Chapter 6: Assess the effects of critical material attributes of superdisintegrants on 
the excipient swelling performance and on drug dissolution. The impact of 
superdisintegrant variability on excipient performance and drug dissolution in acidic 






Chapter 1 Preface 
Based on the pharmaceutical Quality by Design (QbD), the scientific understanding 
and risk assessment of the components and processes affecting final product 
specifications is a prerequisite for achieving final product quality. Critical material 
properties or process parameters are identified and controlled to assure the delivery of 
safe and efficient final dosage forms. Excipients are substances, commonly used in 
solid oral dosage forms, as they enhance drug product processing during 
manufacturing and/or assist the effectiveness and delivery of the drug into the systemic 
circulation. Variation in material properties of excipients can impact drug dissolution 
and thereby in vivo performance and it is widely recognised that the impact of 
excipient variability should be considered as part of a QbD approach to product 
development. The mechanisms by which excipients affect product performance and 
how this may be influenced by changes in excipient material properties is poorly 
understood during formulation selection for both immediate or extended release 
formulations. It is, therefore, beneficial to gain a detailed understanding of the impact 
of the molecular, structural, particle properties and level of excipients on product 
performance. The biopharmaceutical implications of excipient presence and 
variability need also to be considered in the QbD concept, as excipient performance 
may alter or be altered by the heterogeneity of the gastrointestinal lumen. Towards 
this goal, a literature review (Chapter 1) is presented summarizing the current 
knowledge of the issue of excipient variability on product performance. Commonly 
used excipients in immediate release formulation (diluents, binders, lubricants, 
superdisintegrants) are discussed in order to understand their critical material 




Chapter 1. Biopharmaceutical aspects and implications of excipient variability in 
drug product performance (Literature Review) 
 
Abstract 
Implementation of Quality by Design approaches in pharmaceutical industry requires 
a sound understanding of the parameters triggering final product variability. 
Excipients, although generally regarded as inert components, are of great significance 
in terms of solid dosage form development and any variation in the material attributes 
may impact drug product performance. Sourcing, production and processing are 
contributing factors to excipient variability. Interchange between different suppliers 
can lead to final products with different quality attributes. Identification of excipient 
critical material attributes is not straightforward, as criticality must be linked to 
functionality and it is well recognized that the mechanisms by which excipients exert 
their action are not fully understood. Investigating the impact of excipient variability 
on in vitro dissolution could enable scientists to get an insight on the in vivo behaviour 
of drug products and potentially tolerate variability. A thorough understanding of 
excipient material properties, product components interactions and the effect of the 
gastrointestinal tract heterogeneity on excipients and drug release is recommended. 
This review aims to present current knowledge on excipient critical material attributes 
and their link to biopharmaceutical behaviour and dissolution characteristics. Attempts 
to describe the impact of physiological conditions on excipient functionality are also 
addressed. Excipient properties that are considered crucial to drug product 
performance in a biorelevant perspective are elucidated. 
 





Pharmaceutical development is now entering the new era of quality build. The 
traditional three batch validation is currently fading as batch failures, product recalls, 
drug shortages are still present in the pharmaceutical market. Regulatory agencies tend 
to impose more strict product specifications for new drug applications (NDAs), 
abbreviated new drug applications (ANDAs), biowaiver extensions and require a 
profound understanding of active pharmaceutical ingredient (API), excipient and 
product manufacturing, as well as, any interaction between these parameters that may 
affect final product safety and efficacy. In an attempt of amelioration, pharmaceutical 
industry is implementing the principles of Quality by Design (QbD). The aim is to 
build robust manufacturing processes in order to assure that the desirable product is 
constantly delivered to the patient through the establishment of a design space that 
defines the permissible area where variability and/or variations of input materials will 
not affect the outcome of the production process. Reducing or tolerating final product 
variation requires a profound understanding of all factors playing a crucial role in 
finished dosage forms. Controlling these crucial parameters will allow the design of 
products that will consistently meet final requirements, contribute to minimization of 
regulatory constraints and enable the safe passage from batch to continuous 
manufacturing, a beneficial production technique to address industrial deficiencies [1]. 
Excipients constitute a major component of final products and it is recognized that 
variability in their material properties can impact product processing, manufacturing 
and performance [2, 3]. The exact mechanisms by which excipients exert their action 
are still to be discovered, especially when drug product performance is concerned [4, 
5]. The gastrointestinal heterogeneity and its effect on excipient functionality is an 
additional challenge in understanding and controlling the role of excipients in drug 
release. 
A comprehensive overview of the current knowledge on excipient variability 
and its effect on solid dosage form performance is presented in this review. The 
biopharmaceutical parameters that impact the functional role of key excipients used in 
solid formulations is discussed. The aim is to gain a basic understanding of potential 
critical material attributes and their link to excipient and final drug product variability. 
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1.2. Excipient variability in drug development 
As mentioned in the International Conference on Harmonization (ICH) Q8 
“the aim of pharmaceutical development is to design a quality product and its 
manufacturing process to consistently deliver the intended performance of the 
product” [6]. A final dosage form should meet a number of specifications to justify its 
efficacy and safe use. Deviation from these acceptance criteria indicates variability of 
final dosage forms. Variation is difficult to control since random distribution prevails 
in everything [7]. QbD aims towards controlling variability by i. defining the final 
product attributes that will justify the intended use of final products and ii. deliberately 
designing the production process and establishing the design space and control 
strategy to always meet these final attributes. Aspects whose variability can 
compromise product quality are characterized by high criticality. Critical quality 
attributes refer to aspects of the output product while critical material attributes to 
input materials [8]. In terms of pharmaceutical development, factors that may trigger 
final product variability include: active pharmaceutical ingredients (APIs), excipients 
and process parameters [8]. The physicochemical properties of the two former, any 
deviations or alterations in the latter and the complex interplay of process parameters 
and material attributes contribute to the incline in quality specifications. It becomes 
clear that in order to control the outcome we must have a fundamental understanding 
and control of all input materials. The required understanding of the reasons triggering 
product variability and batch failures is needed towards continuous pharmaceutical 
production and may not always be an easy task [9]. 
The impact of manufacturing processes on drug product quality has been 
addressed [10-12] but a more comprehensive approach towards drug product 
components is yet to be made. Examining the effect of input materials (e.g. APIs and 
excipients) on finished solid dosage forms requires a linkage of material properties to 
product quality attributes [13]. A thorough understanding of molecular, structural and 
particle properties of a substance is necessary. The limited knowledge on the role of 
physical and chemical properties of pharmaceutical components hinders the 
possibility to further optimize the behavior of oral solid dosage forms throughout 
manufacturing, but this gap is more pronounced in drug product performance. A 
change in a critical attribute for dissolution will not only cause production or 
regulatory failures, but it may strongly affect drug bioavailability. The complexity of 
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the gastrointestinal environment adds a further challenge in investigating the effect of 
material attributes variability in drug dissolution. Although the API is considered the 
most substantial product component for disease treatment, it has to be noted that 
excipients can be more important in processes prior to oral drug absorption and also 
can induce even treatment failure if the drug is not appropriately released and 
dissolved according to product specifications. From manufacturing through to in vivo 
functional performance, excipients exert their action but their properties can affect 
drug dissolution, as it will be revealed by the critical analysis performed in this review. 
Since excipients constitute a large portion of a solid dosage form, comprising up to 
99% of the total formulation mass [14], their impact on quality attributes can be 
statistically significant. The broad range of the excipient level used in solid dosage 
forms along with a possible alteration in excipient functionality by level variation, 
complicates further the excipient variability issue. In vitro and/ or in vivo excipient 
effects on drug solubility, dissolution and permeability could impact oral 
bioavailability and bioequivalence. The use of a different type of excipient with the 
same intended functionality could also be problematic as the diversity of material 
properties may result in a change of the overall product performance. Understanding 
and integrating excipient variability in the production’s design space and control 
strategy will pave the way for building robust production processes both in batch and 
continuous manufacturing [15]. 
1.3. Sources of excipient variability 
Final product variability either preexists or is created during manufacturing. In 
this review, we are focusing on inherent excipient variability and its effect on final 
drug product. The main reasons for excipient variability are: i. raw material sourcing 
which includes environmental variations that may lead to different raw material 
properties and ii. manufacturing which refers to excipient variability caused by a 
change during excipient production and can be divided into inter and intra-supplier. 
Natural sourcing: The majority of excipients are naturally derived products 
or semi-synthetic compounds (produced after chemical modification of a natural 
product). They are bound, therefore, with inevitable variability caused by 
environmental alterations (natural, regional, seasonal) [16]. Sourcing of raw materials 
is a major factor for excipient variability. For example, microcrystalline cellulose can 
be produced by wood (softwood/hardwood) or cotton. A first study on four brands of 
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microcrystalline cellulose (two brands derived from softwood and two from 
hardwood) examining lignin and hemicellulose content determined excipient origins. 
Significant variations in chemical structure, crystal structure and particle size were 
observed [17]. Differences in lignin content may be the cause for the increased 
dissolution rate of prednisone tablets manufactured with microcrystalline cellulose 
from different sources [18]. Controlling the source of excipients can reduce variation 
but still any unavoidable natural complications may lead to production of different raw 
materials. 
Manufacturing: Excipients are manufactured by chemical companies for use 
in pharmaceutical, chemical, and food industry. A common strategy for 
pharmaceutical companies is to have more than one supplier in order to constantly 
meet market demands [14]. Changes in excipient supplier has been shown to 
contribute to excipient variability. Supplier to supplier variability may arise either 
from different natural sourcing or different manufacturing processes. For instance, 
significant intersupplier variability was observed in anhydrous lactose solid state 
properties (specific surface area, tensile strength, yield pressure) that could impact 
final dosage forms according to the amount of excipient used and the interplay with 
the other dosage form components [19]. Other examples of intersupplier variability 
are reporting differences in intrinsic viscosity, mean molecular weight, mean particle 
size and water uptake rate between two interchangeable Hydroxypropyl cellulose 
(HPC) brands [20], and in particle size and surface area between different magnesium 
stearate suppliers [21]. Although, intersupplier variability may seem more reasonable, 
intrasupplier variability referring to batch-to-batch or lot-to-lot variation in excipient 
production has been reported as well. A notable example of interlot excipient 
variability and its effect on final dosage form refers to a study by Perez et al. on lot to 
lot variability of Carbomer 943. The two dissimilar lots were found to greatly affect 
in vitro release rates of hydrochlorothiazide (HCTZ) matrix tablets, due to differences 
in mean molecular weight of carbomer [22]. Even a slight change in manufacturing 
procedures or parameters may have an effect on the product functionality. For 
example, two batches of soluble starch differing only in one additional washing step 
with acetone were studied. Although, in terms of routine characterization the two 
batches were found identical, their compaction properties showed large variation due 
to their differences in the surface area caused by the extra washing step [23]. 
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Inadequate specifications: Pharmacopeial specifications clearly address 
excipient identification but functionality specifications are not straightforward since 
excipient function is formulation/application dependent [3]. For instance, when 
hypromellose is used as a binder, viscosity and degree of substitution are considered 
functional properties, but additional properties (particle size distribution, powder 
flow) need to be controlled when the excipient is used as a release modifier [24]. 
Excipient demand is increased in the Food/Chemical/Cosmetic Industry, and the 
quality tests prescribed to suppliers assuring excipient quality (identity, quality, purity) 
[3] focus mainly on their needs. This minimum of regulatory specifications may 
suffice for these industries, but pharmaceutical companies have to deal more strictly 
with excipient variability and be assured that the properties rendering excipients 
functional are “present” in every batch within appropriate limits. A first issue that 
arises from current monograph specifications is that they cannot adequately set the 
appropriate limits in functional specifications (“one-point” limits [25] or a wide range 
of acceptance values). Without prior mechanistic knowledge of the actual excipient 
role, variability could be detrimental, even if excipient property values meet 
monograph specifications [25]. The need for functional evaluation is encouraged with 
the introduction of Excipient Functionality Related Characteristics (FRCs) by the 
European Pharmacopeia and the General Information Chapter on “Excipient 
Performance <1059>” by the United States Pharmacopeia. Still, the terminology of 
excipient functionality is not straight-forward. The underlying mechanisms of 
excipient use in several cases are not known and further investigations are necessary 
in order to establish functionality tests, as excipient role should be addressed in case-
by-case, function-by-function and product component interactive perspective. The 
proposed FRC tests are not mandatory and mostly address chemical identification 
rather linking physical and chemical properties to excipient function [3]. Drug product 
manufacturers should gain a more thorough knowledge on excipient production and 
characteristics to get an insight when changing excipient suppliers in order to assure 
that excipient functionality and material properties remain consistent. 
1.4. Biopharmaceutical aspects of excipients 
Formulation scientists recognize the importance of excipient variability in drug 
product design. Reports in literature though address mainly drug product 
processing/manufacturability [26] and not drug product performance in terms of drug 
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release from a solid dosage form and drug bioavailability. An interplay between in 
vitro conditions (i.e. dissolution medium composition, temperature, agitation) and in 
vivo physiological factors (i.e. gastrointestinal factors) and excipient functionality can 
impact drug bioavailability (Figure 1.1). Excipient presence in the luminal fluids 
triggers modifications in the gastrointestinal environment and gastrointestinal 
conditions may alter excipient material attributes leading to different functionality, 
with an effect in drug absorption in both cases. This strong interplay will complicate 




1.4.1 Effect of excipients on physiological conditions 
Traditionally the effect of excipients, on drug product performance was 
considered of minor importance, due to their pharmacological inactivity. Only after 
the beginning of 90s, and with the foundation of the International Pharmaceutical 
Excipient Council (IPEC), investigation of their significance on finished drug products 
started [27]. An increased number of case studies indicate that excipients may 
influence bioavailability and impede the establishment of bioequivalence between 
products. Novel formulations addressing the poor aqueous solubility of drugs, contain 
excipients that affect drug solubility, permeability (passive or active) and metabolism 
[28]. Solubilizers enhance the solubility of poorly soluble drugs and may decrease 
drug permeation through the intestinal epithelium due to the lower free drug fraction 
available for absorption [29]. A number of excipient classes have been demonstrated 
to affect tight junction integrity [30], active transporters, [31, 32] and cytochrome 
P450 activity [33, 34]. Excipient effects on other physiological factors, e.g. gastric 
residence time, small intestinal transit time, mucus integrity, physiological pH and 
motility, have been extensively reviewed [35]. These interactions present a challenge 
on current considerations about the role of excipients on product performance and 
regulatory guidelines require extensive proofs of excipient inertness in each product 
[36, 37]. Biowaivers have been correlated to the Biopharmaceutical Classification 
System (BCS), and qualitatively and quantitatively similar excipients are required for 
biowaivers for immediate release formulations of BCS Class III compounds [37, 38]. 
According to WHO guidelines, an excipient can be used in multisource (generic) 
products requesting biowaiver even if it is not present in the comparator product, as 
long as it is present to other products containing the same API and have marketing 
authorization in countries participating in the International Committee of 
Harmonization [39]. Even in cases where excipients were not implied to affect 
bioequivalence, human bioavailability was altered with a change in the amount of an 
excipient or the addition of a new excipient in the generic product [40]. The addition 
of Sodium Lauryl Sulfate in a generic alendronate immediate release tablet (absent in 
the innovator alendronate (BCS III) tablet but present in generic alendronate tablets 
approved in USA) led to a 5-6 fold increase of alendronate’s bioavailability resulting 
in bioinequivalence [40]. Drug permeability can be affected or not by the presence of 
excipients as revealed by in vitro permeability studies (Caco-2 models). The presence 
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of lactose, HPMC and PEG did not alter the permeability of BCS Class III compounds 
[41]. A drug dependent excipient effect has been shown in the case of Tween 80 due 
to its P- glycoprotein (P-gp) inhibitory effect, as it increases the apparent permeability 
(Papp) of drugs that are P-gp substrates (e.g. cimetidine) while other drugs remain 
unaffected (e.g. atenolol, acyclovir) [42]. Sodium Lauryl Sulfate (SLS) shows a 
concentration-dependent effect on the permeation of low permeability drugs with an 
increase in the Papp when present in low concentrations (0.139 mM) [42] while at 
increased concentrations drug permeation is even greater due to excipient-mediated 
disruption of the cell monolayer [41, 42]. The in vivo impact of excipients on drug 
permeability has to be further investigated, as in vitro permeation models (such as 
Caco-2 monolayers) are more sensitive in excipient effects and may overestimate their 
impact [41]. Generalized conclusions should be avoided without prior scientific 
knowledge on the biopharmaceutical aspects of excipients. Although, there is a 
tendency to investigate the effect of excipients with a prominent role on dissolution 
and bioavailability (surfactants, carriers, bioadhesives, polymers, copolymers etc.), the 
intended product performance can be compromised even from excipients whose initial 
role is not related to drug release/dissolution [40]. 
1.4.2 Effect of physiological conditions on excipients 
When formulating a solid dosage form, the varying composition and 
heterogeneity of the gastrointestinal tract need to be considered. Factors such as 
properties of the gastrointestinal contents (i.e. pH, ionic strength, temperature, 
viscosity, bile salts concentration) and gastrointestinal motility will have an impact on 
drug release. Gastric emptying will influence drug, excipient and product 
characteristics. Moving from the acidic stomach to the more basic small intestine 
affects the ionization and solubility of weak acidic/basic drugs and subsequently their 
absorption. Moreover, the changes in physiological conditions by the presence of meal 
(fed state) can alter solid dosage form performance. Excipient properties and their 
functionality will be impacted by this heterogeneous environment (data indicating the 
effect of physiological conditions on excipient functionality is discussed in detail in 
the next sections of this review). Excipient variability should be addressed in a 
biorelevant perspective reflected in in vitro dissolution testing. The use of biorelevant 
media mimicking physiological gastrointestinal aspects in fasted and fed state (i.e. bile 
secretion, meal components, surface tension, osmolality) [43, 44] could enable the 
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investigation of the gastrointestinal effect on excipient functionality and drug release. 
A better understanding of the complex excipient effects taking place in the 
gastrointestinal tract and their impact in product performance could be achieved by 
the combination of biorelevant in vitro dissolution testing with imaging techniques, 
where applicable [45]. 
1.5. Excipients in solid dosage forms 
Particle size distribution, pore size distribution and surface area are critical 
properties for dissolution of solid dosage forms [13], but not the sole ones. In the 
following sections material properties of commonly used excipients in solid dosage 
forms are discussed, revealing their functional role on drug product performance. 
Excipients are categorized according to their function in solid dosage forms (Table 






Diluents, referred also as fillers, are incorporated into solid dosage forms to 
adjust their mass. When low drug doses are required, fillers may comprise up to 90% 
of the total dosage weight to ensure adequate product processability throughout 
manufacturing. Despite the simplicity of their role, their high concentrations may 
render them high risk factors for product performance. Their physical and chemical 
properties are significant attributes for their functionality and may trigger dosage 
variability, but their impact is usually related to other product components. Diluents 
can be either inorganic or organic materials. Typically used diluents include: lactose, 
mannitol, microcrystalline cellulose and dicalcium phosphate [46]. 
1.5.1.1 Lactose 
Lactose is a disaccharide consisted of D-galactose and D-glucose units linked 
through a β (1-4) glycosidic bond and is produced from bovine milk. Lactose is mainly 
used as soluble diluent in formulations, but it possesses binding properties as well [47]. 
Molecular Properties 
Two anomeric forms of lactose, referred as α and β, are present, according to 
glucose stereochemistry. An interchange between the two isomers, called 
mutarotation, is observed in aqueous solution. When in equilibrium (0-100 °C), the 
ratio between the two forms is approximately 60:40 for β and α lactose, respectively. 
They differ in physical properties such as melting point, density, specific optical 
rotation, and on solubility with β lactose being more soluble in water (20 °C; 0.5 g/mL) 
than the α anomer (0.075 g/mL) [48]. The α isomer, according to temperature, may 
exist as monohydrate (<120 °C) or anhydrous (>120 °C) form, while β lactose is 
anhydrous [48]. These molecular differences affect lactose’s solid state properties and 
products with varying attributes are available on the market. Presence of impurities in 
lactose brands may catalyze drug hydrolysis, affecting drug stability [49]. 
Structural Properties 
Varying crystallization patterns are observed due to the presence of the two 
anomers and their solubility difference. The α isomer crystallizes as a monohydrate in 
low temperatures (<93 °C) in a variety of shapes (prism, pyramidal, tomahawk) [47]. 
Uneven-diamond shape crystals of 80% β-lactose anhydrous with a small portion of 
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α-lactose anhydrous are formed with increased temperature (>93 °C) [48]. Spray-dried 
lactose, consisted of α-lactose monohydrate and amorphous lactose, in a spherical 
shape with excellent flow properties has also been produced. The structural differences 
lead to products with varying compactions forces [19]. Higher initial solubility and 
dissolution rate for the β-form was observed from different crystalline lactose powders 
in water at 37 °C, followed by a decrease in the order β-lactose (0.5 g/mL water) >α-
lactose anhydrous (0.27 g/mL water) >α-lactose monohydrate (0.13 g/mL water) but 
due to mutarotation, final solubility for all lactose types was the same [47, 50]. 
Monohydrate α and β lactose disintegrated faster compared to anhydrous lactose and 
an increase in compression force resulted in increased disintegration time. The fast 
disintegration was attributed to the increased porosity of lactose tablets which allowed 
quick water penetration [50]. 
Particle Properties 
Particle size distribution of lactose is not specified in pharmacopeias. Lactose 
brands with varying size distribution are available in the market [47]. When the effect 
of lactose particle size in product manufacturing was studied, it was shown that in 
direct compression, an increase in lactose particle size will enhance blend flowability 
and form weaker tablets [51], due to decreased cohesiveness of particles. Studies on 
wet granulation behaviour of lactose linked particle size and size distribution to 
granule porosity. Small particle sizes (53 µm) give granules with higher porosity, as a 
result of the higher resistance of small particles to densification [52]. Narrow ranges 
of particle size (40-75 μm, 212-250 μm) produced granules of higher porosity due to 
the absence of fine particles that tend to occupy void volumes between larger particles 
[52]. As porosity is considered an important parameter for water penetration, particle 
properties of lactose can have a major impact on dissolution. 
Level 
Lactose may greatly enhance dissolution of poorly soluble drugs as the soluble 
diluent improves powder and tablet wettability. Studies on ethinamate capsules 
showed a decrease in drug release when 10% w/w lactose was used in the formulation 
but improved dissolution when diluent concentrations reached levels of 50% w/w [53]. 
Increasing the percentage of fine lactose in indomethacin formulations (interactive 
mixture of API and coarse lactose) resulted in improvement of the drug’s dissolution 
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rate, as rapid dissolution of lactose leaving open structures enables deagglomeration 
of indomethacin particles [54]. For a soluble drug (chloramphenicol) inclusion of 
lactose at 50% w/w in the capsule formulation had no effect on drug’s dissolution. 
Increasing lactose to a level of 80% w/w slowed down chloramphenicol dissolution, 
as the dissolved diluent retards drug release [55]. The interplay between lactose 
content and drug’s BCS class was recently portrayed in a top-down approach 
comparing marketed innovator and generic products with proved bioequivalence. For 
BCS class I and class III drugs relatively large differences in lactose level were 
observed whereas for BCS class II and class IV drugs small variations in these levels 
were noted. The probability of bioinequivalence based on these differences in lactose 
levels between the innovator and generic products was classified as low or BCS class 
I drugs, medium for BCS class II and III drugs and high for BCS class IV drugs [56]. 
Biopharmaceutical Properties 
Lactose can affect bioavailability through a dissolution modification effect. No 
impact on other physiological factors has been reported [56]. Interactions between 
milk proteins and lactose have been described. Low lactose concentrations decreased 
the viscosity of the milk dispersion (lactose assembles around protein molecules) 
whereas high lactose concentrations increased the viscosity of the dispersion 
(reduction in water-protein interactions) [57]. The potential interplay of meal intake 
and lactose on physiological factors and drug release and dissolution has not yet been 
investigated in a biopharmaceutical perspective. 
1.5.1.2 Dicalcium Phosphate 
Calcium phosphate dibasic, or dicalcium phosphate (DP), is an inorganic 
insoluble diluent used in tablet and capsule manufacturing. 
Molecular and Structural Properties 
Two hydration forms of dicalcium phosphate, anhydrous (DPA) and dihydrate 
(DPD), are used in pharmaceutical development [58, 59]. The anhydrous form occurs 
as a triclinic crystal while the dihydrate forms a monoclinic structure [58, 59]. 
Dicalcium phosphate dihydrate presents good flow properties and low hygroscopicity. 
According to temperature (40-50 °C) and humidity (32-75% relative humidity) [60], 
though, it tends to lose water of hydration that may cause chemical instability of APIs 
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in dosage forms [61]. The anhydrous form presents an alternative without 
compromising drug stability. The two forms differ in porosity, as a result of their 
different hydration. The anhydrous form exhibits higher porosity due to the absence 
of water in the crystal structure, leading to its better compressibility and faster 
disintegration [62]. 
Level 
As for lactose, the effect of dicalcium phosphate on drug release is profound 
in high levels of the diluent. Replacing lactose with dicalcium phosphate dihydrate or 
anhydrous resulted in decreased and extended release of alprazolam from matrix 
tablets containing HPMC as well. In binary systems containing different ratios of 
lactose and dicalcium phosphate dihydrate, increasing the amount of the insoluble 
diluent did not impact dissolution rate, and only when, dicalcium phosphate dihydrate 
was the sole diluent and in high level (36.5% w/w) drug dissolution was affected [63]. 
Biopharmaceutical Properties 
The pH difference of the stomach and intestinal contents is expected to affect 
dicalcium phosphate’s behaviour [64], due to its higher solubility in acidic media. In 
a comparative study on the effect of pH on superdisintegrant functionality (discussed 
in sections 1.5.4.1, 1.5.4.2, 1.5.4.3), the influence of different types of diluents on drug 
dissolution was evaluated. Swelling capacity of some disintegrants is lower in acidic 
medium, leading to reduced disintegration and dissolution. When lactose was the 
diluent, the reduced swelling of superdisintegrants caused a decrease in the dissolution 
of hydrochlorothiazide (HCTZ) tablets in acidic medium (0.1 N HCl, pH=1; paddle 
method, 50 rpm, 37 °C). Substituting lactose to DPD led to higher drug release in the 
acidic solution, compared to water and the effect of superdisintegrant swelling to 
reduce dissolution in acidic media was not observed (Figure 1.2) [65]. Although the 
overall dissolution rate of HCTZ was higher in tablets containing lactose compared to 
DPD tablets (even in the acidic medium), this example demonstrates the complex 
interactions between formulation components and their potential to alter dissolution 




Figure 1.2: % HCTZ release versus time from tablets containing A: Croscarmellose 
sodium and Lactose in i. water (light grey bars) and ii. 0.1N HCl (dark grey bars) B: 
Croscarmellose sodium and Dicalcium Phosphate (DP) in i. water (light blue bars) and 
ii. 0.1N HCl (dark blue bars) (mean ±SD, n=6). [modified from [65]] 
1.5.2 Binders 
Binders are typically used in solid dosage form manufacturing to promote 
adequate mechanical strength of granules or tablets. Wet binders are used in wet 
granulation to ensure appropriate granule formation with good flow properties while 
dry binders are incorporated after the granulation step or in direct compression to 
facilitate compaction and formation of strong tablets. Commonly used binders include: 
disaccharides, starches, celluloses and synthetic polymers (polyvinylpyrrolidone, 
polyethylene glycol). 
1.5.2.1 Microcrystalline Cellulose 
Cellulose is a polysaccharide composed by β (1→4) linked D-glucose units forming 




Figure 1.3: Chemical structure of Microcrystalline Cellulose (ChemDraw 
Professional 15.0). 
These microfibrils bond together to create large crystalline regions with 
intervened amorphous parts. Microcrystalline cellulose (MCC) is obtained by 
hydrolytic depolymerisation of cellulose in order to isolate the crystalline regions with, 
usually, a subsequent spray drying step to obtain dry and porous particles [66]. 
Cellulose for MCC production is mainly derived from wood. Different grades of MCC 
with a variety of particle size/particle size distribution, moisture content and bulk 
density are available in the market. 
MCC is mainly used as a binder/filler in tablet manufacturing, with good 
disintegrant and lubricant properties. Its functionality as a binder relates to its ability 
to deform when compression force is applied. MCC particles come in closer contact 
and form multiple hydrogen bonds leading to strong compacts. Potential critical 
material properties of MCC with respect to its functionality as a binder include: 
moisture content, particle size, bulk density, specific surface area, degree of 
polymerization and crystallinity [4]. 
Molecular Properties 
The degree of polymerization may affect tabletability, with highly polymerized 
MCC molecules leading to powders with small particle size and smooth surface. These 
attributes impact flowability (finer fibers with increased adhesiveness) but have a 
positive effect on tablet hardness. Tablets containing MCC with a degree of 
polymerization of 244 and 299 were twice as strong as those produced with an MCC 
with a degree of polymerization of 199 [67]. In general, degrees of polymerization 
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favoring the fibrous structure of the polymer, improve tabletability but compromise 
powder flowability [4]. Impurities in MCC brands can affect drug stability (hydrolysis, 
drug adsorption onto the polymer) [49]. 
Structural Properties 
Two MCC polymorphs, MCC I and MCC II, differing on the hydrogen 
bonding between the microfibrils (parallel and anti-parallel orientation of the MCC 
chain, respectively) have been described. Powder properties of the two polymorphs 
show great variation and a twofold difference of the swelling value of the two 
polymorphs is observed (0.2 mL/g for MCC I vs 0.8 mL/g for MCC II) leading to 
rapid disintegration of MCC II due to the higher water uptake [68]. The degree of 
crystallinity/amorphicity has a similar pattern, and the presence of amorphous regions 
in MCC affects water penetration that could affect tablet dissolution. MCC undergoing 
an extra grinding step to reduce crystallinity and generate amorphous structures led to 
an increase in water penetration owned to hydrogen bonding between the amorphous 
regions and water [69]. MCC crystallinity has an impact on dissolution, as an increase 
in water penetration is noted with lower MCC crystallinity. A decrease of the 
dissolution rate of acetaminophen tablet as MCC crystallinity decreased from 65.5% 
to 37.6% and subsequent increase of the dissolution rate as the degree of MCC 
crystallinity was further reduced (25.8% to 12.1%) has been reported [70]. These 
studies suggest that the crystallinity of MCC could be a critical material attribute that 
should be examined with respect to dissolution. 
Particle Properties 
Particle properties impact tablet hardness and dissolution. A decrease in 
particle size of MCC would increase cohesiveness resulting in production of stronger 
tablets after compression. A 32 μm decrease in MCC particle size (d50) showed a 
statistically significant increase in disintegration time of tablets containing otanabant 
(BCS Class IV drug), spray dried lactose and magnesium stearate [51]. Porosity affects 
disintegration/dissolution, with water penetration in plain MCC tablets of 15% 





When MCC is incorporated into solid dosage forms as a binder/diluent, it 
typically comprises the 20-90% w/w of the tablet [66]. High MCC concentrations, 
may greatly increase tablet hardness leading to problematic disintegration and 
dissolution. For this reason when microcrystalline cellulose is used as a binder, 
inclusion of a disintegrant is recommended to achieve adequate disintegration and 
dissolution. As a polymer, MCC tends to swell in aqueous solution, with swelling 
values of 0.2 mL/g and 0.8 mL/g for MCC I and MCC II, respectively [68]. In high 
MCC concentrations, the increased viscous layer, caused by swelling, will potentially 
affect drug release. 
Biopharmaceutical Properties 
Changing the temperature of the dissolution medium affects MCC 
functionality. Increasing the temperature of the dissolution medium (water; from 20 
°C to 37 °C) resulted in faster swelling and water transport in plain MCC tablets, even 
though, full disintegration did not occur throughout the duration of the experiment at 
both temperatures [71]. Information related to other biopharmaceutical properties of 
MCC have not been reported. 
1.5.2.2 Hypromellose 
Hypromellose, also called hydroxylpropyl methylcellulose (HPMC), is a water 
soluble nonionic cellulosic polymer substituted with methoxy and hydroxypropyl 
groups (Figure 1.4). 
 
Figure 1.4: Chemical structure of Hypromellose (ChemDraw Professional 15.0). 
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HPMC is manufactured by chemical modification of cotton or wood derived 
cellulose. It is used as a wet granulation or dry binder and as a rate controlling release 
polymer in extended release formulations [72]. The effectiveness of HPMC as a 
release modifier is advantageous in reducing dosage frequency and sustaining drug 
blood levels. But it can compromise drug dissolution when used as a binder, where 
controlled release is not necessary expected, as upon contact with aqueous solutions, 
the polymer hydrates and forms a viscous gel layer which is thickened when more 
water penetrates. As the polymer becomes fully hydrated, it tends to relax and 
dissolve, in a process called erosion [73]. Drug release when HPMC forms this viscous 
layer consists of three processes: dissolution in the matrix, diffusion through the gel 
layer and delivery of the drug in the medium as the polymer erodes [74]. Different 
grades of HPMC are available in the market according to particle size distribution, 
viscosity and methoxy:hydroxypropoxyl substitution. These characteristics of HPMC 
along with its particle size affect the functionality of the excipient. 
Molecular Properties 
The degree of polymerization and substitution are critical aspects for HPMC 
performance. Molecular weight and chain length have a direct effect on the viscosity 
of HPMC aqueous solutions. H-bonding between oxygen atoms in ether groups and 
water molecules leads to extension of the polymer and formation of a coiled shaped 
structure. Coiled polymers tend to form more H-bonds, entrap water and form 
entanglements with other coiled molecules resulting in increased resistance to flow. 
Therefore, polymers with high molecular weight tend to swell faster and form viscous 
layers. The gel layer thickness increases with increased molecular weight while 
erosion of the layer is decreased [75]. A counter effect of HPMC molecular weight on 
gel formation has been reported. Increased molecular weight results in improved 
swelling properties but reduces water penetration, as the high number of 
entanglements lead to a less porous layer [76]. Since water penetration affects drug 
release and dissolution, HPMC molecular weight could be considered as a critical 
material property whose variation impacts release and dissolution. When three 
differently substituted HPMC grades were used in acetazolamide (poorly soluble drug) 
tablet (HPMC 2910, HMPC 2208, HPMC 2906; the first two digits indicate the % 
methoxy groups and the two last digits the % of hydroxypropyl group) a decrease in 
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drug release was found with a rank order HPMC 2910> HPMC 2208> HPMC 2906 
[77]. Not only the hydroxypropyl content and the degree of substitution but also the 
substitution pattern affects release and dissolution. Heterogeneity in substitution 
pattern alters the release of the polymer due to hydrophobic interactions between the 
substituents [78] with an expected subsequent drug release alteration [79]. Variation 
in substitution pattern causes batch to batch variability and sourcing from different 
suppliers should be evaluated [80]. 
Particle Properties 
Particle size affects drug release and dissolution through its impact on tablet 
hardness and water penetration. HPMC of small particle size form stronger tablets due 
to increased surface area and interparticle cohesiveness, whereas HPMC of larger 
particles trigger rapid dissolution, as they do not fully occupy space around particles 
leaving voids for water penetration [81]. HPMC particle sizes above 113 μm increased 
dissolution rate of aspirin [82]. Drug release was caused by: disintegration for large 
particle sizes, diffusion for medium sizes and a combination of diffusion and erosion 
for smaller particle sizes. These effects were attributed to the proximity of polymer 
particles and the differences in the porosity of the formed hydrogel [82]. 
Level 
The impact of HPMC properties on dissolution depends on the amount of 
HPMC in the formulation. When used as a binder, HPMC is added in a level of 2-5% 
w/w [72]. Direct impact of HPMC concentrations on dissolution has been reported for 
levels >10 % w/w [83]. The level of the polymer makes solid formulations more prone 
to particle size variation. The faster dissolution observed with higher HPMC particle 
sizes due to their porous arrangement [81], is annihilated in high concentrations as 
more polymer chains are present leaving no spaces for water penetration [81]. 
Biopharmaceutical properties 
From a biopharmaceutical perspective, ionic strength, composition of 
dissolution medium and presence of food are likely to affect HPMC performance. The 
presence of salts in the medium affect the hydration of the polymer. Some salts, cause 
polymer dehydration dependent on salt’s affinity to water of hydration (salting-
in/salting-out effect) and subsequent loss of gel uniformity leading to inconsistent drug 
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release [84]. NaCl interacts with water and affects the sol-gel formation (thermo-
reversible gelation of aqueous polymeric solutions) of HPMC [85]. In an aqueous 
HPMC solution, the hydroxyl groups of the polymer interact with water through 
hydrogen bonding. Upon heating, these bonds are disrupted leaving the hydrophobic 
parts of the polymer exposed to interact with each other with subsequent formation of 
a gel. Increasing NaCl concentrations (0-0.8 M), as salting out ion, shifts this 
thermogelation to lower temperatures [85]. Presence of salts in high concentrations 
will affect gel layer formation and can lead to burst drug release [86]. Low salt 
concentrations impede polymer erosion, which is more pronounced in low viscosity 
grade polymers·[87], leading to decreased drug dissolution. Implications caused by 
the heterogeneity in the gastrointestinal physiological conditions {gastric (35mM 
NaCl) and intestinal contents (100 mM NaCl) and fasted and fed state conditions [88]} 
are expected. 
The behavior of cellulosic polymers can be strongly related to physiological 
temperature. In an intersupplier comparison of HPC batches, differences in dissolution 
rate of HCTZ tablets were reported and attributed to HPC solubility and its cloud point. 
The cloud point, that is the temperature above which a polymer solution becomes 
turbid, relates to polymer’s hydrophilicity with less hydrophilic polymers undergoing 
this transition in lower temperatures, and a less viscous layer is formed in temperatures 
above it. Therefore, when the HPC brand with a cloud point closer to 37°C was used, 
faster dissolution of HCTZ from the tablet formulation was observed [89]. Since HPC 
and HPMC are included in the same polymeric class possessing comparable 
functionality and properties, a similar behavior is expected for HPMC. 
Meal components, such as sugars and fat, interact with HPMC affecting its 
biopharmaceutical properties. The same ionic effect on HPMC dehydration pattern, 
has been found for dietary sugars. Dietary sugars cause dehydration of the polymer 
according to their structure and lactose is one of the most potent disaccharides in 
inducing HPMC dehydration even in low concentration (0.5 M) [90]. In low sugar 
concentrations, the decreased erosion leads to thicker gel layers that delay drug 
diffusion and release on the medium, whereas in higher concentrations, the 
suppression of the gel formation leads to rapid drug release [90]. The presence of milk 
reduced caffeine release from tablets containing HPMC. High fat concentrations, 
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relevant to fat content of the medium, were deposited on these tablets at the early 
stages of gel formation, and the fat layer was still present at later time points. Possible 
coalescence between fat droplets and phase separation of these lipidic compositions 
on the formed gel resulted in reduced drug release [91, 92] Furthermore, 
hydrodynamics of the dissolution apparatus permitted a better understanding of the 
effect of milk on the release from these tablets containing HPMC. With the flow 
through cell apparatus the decrease in dissolution rate is more pronounced due to the 
absence of erosional forces and occurs in lower fat contents than in the basket 
apparatus [91]. These findings suggest that the fed state affects the release from 
formulations containing HPMC. Biorelevant dissolution testing could shed light on 
the complex effect of physiological conditions on excipient functionality and 
release/dissolution. 
Dissolution of low and high viscosity grade HPMC in phosphate buffer pH 6.8 
studied with surface dissolution UV-imaging revealed that for both grades the gel layer 
was formed rapidly within 15 minutes. For the low viscosity polymer, the initial high 
concentrations decreased as the polymer expanded. Then, the gel layer was stabilized 
from the dissolution of undissolved particles (that contribute to the increased polymer 
concentrations in close proximity to the sample). As the polymer expanded, its 
concentration was decreased due to polymer disentanglement forming the diffusion 
layer and the polymer was completely dissolved and diffused in the bulk (Figure 
1.5a). HPMC of higher viscosity showed increased concentrations in the gel layer but 
decreased rate of diffusion and dissolution (Figure 1.5c). When agitation was applied, 
a thinner layer with lower HPMC concentrations and slow diffusion rate were 
observed (Figure 1.5b). The effect of agitation was more pronounced for the low 




Figure 1.5: % released vs time and distance from the sample of HPMC 15 cP in 
stagnant (a.) and 0.5mL/min flow rate (b.) and HPMC 50 cP in stagnant (c.) and 
0.5mL/min flow rate (d.) in phosphate buffer (pH 6.8) with UV dissolution imaging 
(SigmaPlot 13.0). [modified from [74] 
1.5.3 Lubricants 
Lubricants are used in solid dosage forms manufacture to enhance 
processability of intermediate blends and tablets. Friction or cohesiveness between 
particles impose a barrier in powder or tablet flowability affecting content uniformity, 
compaction, tablet hardness and therefore product performance. Lubricants address 
flowability issues, by adherence to die or particle surfaces and reduction of friction or 
cohesiveness leading to adequate flow properties. Lubrication involves the creation of 
a film between surfaces or interfaces in order to reduce cohesion between particles or 
adhesion of particles onto surfaces [93]. The most commonly used lubricants include 
stearates (magnesium, calcium, sodium), talc, waxes and sodium lauryl sulfate. 




1.5.3.1 Magnesium Stearate 
Magnesium Stearate, a salt containing two equivalents of a fatty acid (usually 
stearic and palmitic acid) and a charged magnesium, is manufactured by a reaction 
between fatty acid salts and inorganic salts (Figure 1.6) [94]. 
 
Figure 1.6: Chemical structure of Magnesium Stearate and Magnesium Palmitate 
(ChemDraw Professional 15.0) 
Fatty acids can be bovine or vegetable-derived [95]. Its lubricant effect relates 
to the adherence of the polar moiety on granules or powders while the lipophilic part 
is oriented away from the particle’s surface [96]. Its ability to form a waxy layer 
around particles and tablets leads to reduced water penetration and dissolution can be 
compromised due to its hydrophobicity. Lubrication efficiency and dissolution, are 
inversely related as over-lubrication decreases dissolution rate.  
Molecular Properties 
A maximum of 4-5% in magnesium weight fraction and a minimum of 40% in 
stearic acid weight fraction is described in the USP [97]. Magnesium stearate is a 
mixture of stearic and palmitic salts. The sum of stearic and palmitic acid should 
encounter for the 90% of total weight fraction [98], but the exact ratio of the stearic 
(C-18) and palmitic (C-16) acid, composing the commercial magnesium stearate, is 
not set in the Pharmacopoeia specifications.  
59 
 
Depending on the manufacturing process and humidity, four different hydrates 
of magnesium stearate can be formed (anhydrate, monohydrate, dihydrate, trihydrate), 
leading to different crystal habits with altered functionality [99]. When preparing 
magnesium stearate with a precipitation method, precipitation in pH 9 leads to the 
formation of the dihydrate form, while precipitation in pH 7 or 11 leads to a lower 
hydration state [100]. 
Structural Properties 
The different crystal structures identified for the different magnesium stearate 
hydrates include the plate-shaped structure for the dihydrate and needle-shaped 
structure for the monohydrate and trihydrate form [100-102]. This difference in shape 
is attributed to a change in the angle of inclination of the hydrocarbon chain caused by 
the addition of the water molecule [100]. The different crystalline forms have an effect 
on the magnesium stearate functionality as an excipient. The monohydrate form 
produces tablets with lower variability during tablet manufacturing [99]. The 
dihydrate form acts as better lubricant due to its lamellar shape as it shears readily 
under applied tangential forces [101, 103, 104] and has a lower tendency to cause 
over-lubrication [99]. The irregularity of commercial magnesium stearate shape, 
compared to high purity magnesium stearate and palmitate, relates to reduced lubricant 
properties [104]. 
Particle Properties 
Surface area (SA) and particle size affect magnesium stearate functionality. 
Increasing the SA of the lubricant (due to particle size reduction) leads to higher 
adhesion work and a thin homogeneous layer on particle surface, whereas decreasing 
SA results in enrichment of the surface with lubricant particles [96]. Larger particles 
have less tendency to strongly adhere to particle surfaces leading to less uniform coats. 
In both cases, (strong or thick layer) water will face difficulties in penetrating this 
layer. The high coverage of particle surfaces with the lubricant during blending 
reduces interparticle bonding leading to weakened tablets [105]. Investigation of the 
optimum particle size/SA of magnesium stearate, without compromising any quality 
attributes, is needed as the two extreme levels both may have a negative impact on 




Since magnesium stearate is hydrophobic care should be taken when added in 
solid dosage forms as it can compromise drug release. The amount and the mixing 
time of magnesium stearate in the formulation are critical dissolution variables; 
increased levels and longer mixing time reduces drug dissolution from capsules [94]. 
A range of 0.25-5.0% w/w magnesium stearate is used in drug product development 
[94]. Increasing magnesium stearate level (0.25%-1.0%-5.0% w/w) decreased 
indomethacin dissolution, due to the decreased interfacial area between the dissolution 
medium (acetate buffer pH 5 with 0.1% w/v sodium lauryl sulphate) and the drug 
[106]. Mechanofusion, a process used to coat particles with fine materials, has been 
found beneficial for drug dissolution, as coated particles with magnesium stearate 
exhibited decreased agglomeration and enhanced dissolution [107]. In the case of 
mechanofused magnesium stearate-coated indomethacin powder, drug dissolution 
was enhanced only in the early stages of dissolution, and dissolution reached a plateau 
(~80% drug dissolved) at later stages with slightly higher concentrations achieved only 
for the 0.25 and 1% w/w magnesium stearate [106]. 
1.5.4 Superdisintegrants 
Disintegration is needed in immediate release dosage forms where quick onset 
of action is desired. A single or a combination of mechanisms have been proposed for 
the disintegration of solid formulations. Firstly, swelling of the disintegrant can 
compensate the adhesion forces of other formulation components, causing the tablet 
fragmentation. Furthermore, the porous structure of several disintegrants and their 
ability to absorb water via capillary action (wicking) is a potential mechanism for their 
action. Finally, fragmentation of tablets can be caused from elastic deformation of 
disintegrants under pressure and release of high energy upon exposure to water due to 
the ability of particles to recover their initial structure [108]. Common disintegrants 
used in solid formulations include: starches and modified starches. The introduction 
of low concentrations of superdisintegrants as agents providing disintegration within 
few minutes is optimistic in terms of drug delivery in enhancing the dissolution rate 
of solid formulations [109]. The most notable superdisintegrants include crosslinked 




1.5.4.1 Sodium Starch Glycolate 
Starch is a polysaccharide consisted of amylose and amylopectin, and can be 
extracted and processed for pharmaceutical use by several plants including maize, 
potato, rice, corn. Starch modification can be performed in order to improve its 
functionality as disintegrant. SSG is the sodium salt of the carboxymethyl ether of 
starch (Figure 1.7). 
 
Figure 1.7: Chemical structure of crosslinked Sodium Starch Glycolate (ChemDraw 
Professional 15.0). 
SSG derives from starch (from several sources) after two chemical 
modification processes: substitution to increase hydrophilicity and cross-linking to 
reduce solubility and gel formation upon contact with water [110]. It is used in 
pharmaceutical manufacturing as a superdisintegrant as it acts through rapid swelling 
due to the absorption of large amounts of water leading to fast disintegration [111]. 
The functional mechanism of SSG was revealed by High-Resolution Real-Time 
Magnetic Resonance Imaging (MRI) through investigation of the direction to which 
the tablet expands when disintegration occurs. SSG acts through swelling as an omni-
directional expansion was observed with different grades of SSG [112]. Different 
grades of SSG are available according to particle size distribution, sodium chloride 




The degree of substitution, due to the role of the carboxymethyl group on 
functionality, has to be defined. In USP, the amount of sodium in SSG is set between 
2.8-4.2%, whereas the degree of substitution is not specified [113]. Values for the 
degree of substitution between 0.23-0.32 have been reported [114]. Hydration and 
swelling of SSG leading to fast tablet disintegration, relate to degree of substitution. 
An increase in swelling and water uptake observed as substitution increases from 0.20 
to 0.29 and the opposite effects at higher substitution. An optimum degree of 
substitution value between 0.28-0.29 for faster and higher dissolution of aspirin tablets 
was reported [115]. A higher degree of substitution can lead to increased drug-
excipient interactions as weakly basic drugs can be absorbed onto the polymer [49] 
Crosslinking in SSG, achieved through the phosphate group, leads to a high spacing 
between SSG chains facilitates water penetration and swelling and reduce gel 
formation [109]. The extended swelling of SSG compared to other swelling 
disintegrants is attributed to this type of crosslinking (e.g. croscarmellose is 
crosslinked through esterification which does not allow this high spacing between the 
polymer chains). An increase of 25%-35% of crosslinking, leads to powders with 
increased swelling and water uptake with further increase in crosslinking leading to 
lower swelling and water uptake. An optimum value at medium levels of crosslinking 
(33-35%) for dissolution of aspirin tablets has been reported [115].  
Particle Properties 
Particle size affects disintegrant functionality of SSG, with larger particles 
being more efficient [110]. An approximate threefold increase in particle size of SSG 
resulted in a proportional decrease in disintegration time [116]. It can be speculated 
though that in the case of super-disintegrants, it is questionable whether a change in 
the second disintegration time-scale can have a direct major impact on dissolution. An 
indirect effect of the particle size on dissolution is more likely to be expected through 
its effect on solution’s viscosity. As the particle size of polymers decreases, a more 
viscous layer is formed due to increased interaction with water, creating a barrier for 
drug diffusion and leading to delayed dissolution 
Level 
Typical amount of SSG used in drug formulation ranges between 2%-8% w/w 
[117]. Low SSG levels (0.25%, 0.5% and 1% w/w) in paracetamol tablets resulted in 
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long and varied disintegration times (60min, 40min, 2-15 min, respectively), whereas 
at higher SSG levels (2% and 4% w/w) the disintegration time was consistent within 
one minute [115]. SSG in higher levels (>8% of tablet weight) causes an increase in 
disintegration time due to the formation of a viscous layer which hinders water 
penetration in the formulation, irrespective of the API solubility [111]. 
Biopharmaceutical Properties 
The pH of the medium affects SSG functionality [65]. SSG hydrates as the 
anionic carboxyl group interacts with water [65]. In low pH, the polymer gains its 
neutral form and a less extended interaction with water is expected [65]. In simulated 
gastric media (0.1 N HCl, pH=1) an approximate twofold reduction in the swelling 
value and the water uptake of SSG was observed compared to the values in intestinal 
media (phosphate buffer, pH=6.8) (Figure 1.8). Compacts of SSG with 
spironolactone, filler and lubricant did not show this variation in water sorption in the 
two media, a fact attributed to the crystallinity of the polymer and the reduced water 
accessibility when particles are consolidated in strong compacts [109]. 
 
Figure 1.8: Swelling values of SSG, CCS and crospovidone after 20 minutes 
dispersion of 500 mg of each superdisintegrant in 10 mL of 0.1N HCl (pH=1) (i.) and 
phosphate buffer (pH=6.8) (ii.) at room temperature. [modified from [109]] 
1.5.4.2 Croscarmellose sodium 
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CCS is a cross-linked polymer of carboxy methylcellulose. Wood or cotton-
derived cellulose reacts with sodium hydroxide and sodium monochloroacetate to 
produce the carboxyl methyl cellulose in a degree of substitution of 0.7. The excess of 
monochloroacetate hydrolyzes to glycolic acid which reacts with the sodium carboxy 
methyl group of the polymer and catalyzes the esterification of this group with the 
closest polymer chains leading to the formation of crosslinks (Figure 1.9) [118]. 
 
Figure 1.9: Chemical structure of Croscarmellose sodium (ChemDraw Professional 
15.0). 
It is used in tablet or capsule manufacturing as a super disintegrant acting 
mainly through a combination of swelling and wicking. The swelling mechanism of 
CCS was confirmed by MRI studies, as tablets containing CCS expanded in an omni-
directional way [112]. At initial stages, disintegration depended on tablet density and 
water penetration was reduced as tablet hardness was increased. At later stages, as the 
polymer swells, new pores were formed and water uptake was no longer related to 
tablet density. Stronger solid dosage forms resulted in better disintegration, as their 
less porous structure caused a greater swelling force to be exerted on tablets and 




As swelling of CCS is attributed to the hydration of the carboxy methyl group, 
the degree of substitution defines CCS functionality. Degree of substitution refers to 
the total acidic (acid form) and basic (sodium salt) components of superdisintegrants. 
The basic substituent (level of salt) correlates CCS disintegration to the pH of the 
medium, as CCS turns to its acidic form on low pH with a subsequent loss of its 
swelling ability [119]. Measuring the volume median diameter gave higher values for 
CCS in water compared to HCl 0.1 N [65], indicating a more efficient swelling of the 
sodium salt than the free acid due to higher hydrophilicity. Acid/base ratio and total 
degree of substitution vary along different CCS brands. Brands with higher basic 
substituents exhibit larger settling volumes and higher maximal water uptake and size 
increase. Variation in disintegration times can be attributed to differences in 
composition when all other properties, such as particle size are similar [119]. A higher 
degree of substitution may induce drug-excipient interactions. Exposure of delavirdine 
mesylate tablets containing CCS to high humidity (40 °C, 75% RH) for 8 weeks led 
to a decrease in drug’s dissolution probably from the conversion of delavirdine to its 
free basic form due to an interaction between the carboxyl group of the polymer and 
methanosulfonic acid [120]. 
Particle Properties 
For croscarmellose, as a swelling polymer, a larger particle size is expected to 
lead to enhanced swelling and fast disintegration. Brands of higher particle size of 
different croscarmellose suppliers showed increased settling volumes and water 
uptake [119]. An optimum particle size has not been reported. Since, croscarmellose 
forms a viscous layer upon contact with water, it should be expected that the notion 
that smaller particles sizes will form a more viscous layer due to enhanced interactions 
with water would be applicable 
Level 
In tablet formulations, CCS is used at 0.5%-5.0% w/w to promote fast 
disintegration [118]. As CCS swells upon contact with water, an increase in its fraction 
results in the formation of a viscous gel layer acting as a barrier for product 
disintegration. For aspirin, ascorbic acid and ibuprofen tablets, an optimal 
superdisintegrant concentration of 7% of the tablet weight was reported to give best 
disintegration values and up to this level, disintegration time increased irrespective of 
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drug solubility [111]. Even if the difference in disintegration time is low, dissolution 
can be greatly affected as the drug will have to diffuse through the viscous disintegrant 
layer. 
Biopharmaceutical Properties 
Since CCS is a sodium salt, the pH of the medium affects its ionization. In 
acidic medium, CCS turns to its neutral form with decreased hydrating and swelling 
capacity [65], but to lesser extent than the highly swelling SSG (section 1.5.4.1.) 
(Figure 1.8) [109]. Therefore, the functional profile of CCS in the stomach and small 
intestine is expected to be different. Investigation of the effect of composition and 
level in solid formulations of CCS on solid dosage form disintegration and dissolution 
based on biorelevant approaches would provide an insight on implications for its in 
vivo functionality. CCS may impact drug’s permeability as it binds to Ca2+ cations 
and compromises tight junction integrity; an increased ranitidine permeability in the 
presence of CCS has been reported [121]. 
1.5.4.3 Crospovidone 
Crospovidone is a water-insoluble nonionic polymer consisted of cross-linked 
1-vinyl-2-pyrrolidone monomers (Figure 1.10). 
 
Figure 1.10: Chemical structure of Crospovidone (ChemDraw Professional 15. 
It is manufactured through a popcorn polymerization technique (proliferous 
polymerization) of the initial monomer leading to the formation of porous particles 
[122]. Crospovidone, used in solid dosage form manufacturing as a disintegrant, acts 
via a different mechanism than the swelling starches. When compaction force is 
applied, the polymer deforms. Upon contact with water, it absorbs water via capillary 
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action and regains its normal structure releasing an amount of energy capable to break 
the tablet. This shape recovery was confirmed with MRI as a uni-directional expansion 
of tablet was observed [112]. Crospovidone is considered an excellent excipient 
leading to fast disintegration without compromising dissolution due to its inability to 
form a gel [123]. Several grades of crospovidone are available on market differing in 
particle size distribution (standard, fine, superfine or micronized powder), bulk 
density, hydration capacity and peroxide specifications. 
Molecular Properties 
Crospovidone is not substituted and lacks ionizable groups. Therefore, 
molecular properties of crospovidone are unlikely to affect excipient’s functionality. 
Residual peroxides, though, in crospovidone may affect the stability of oxygen 
sensitive drugs [49]. 
Particle Properties 
Monographs define crospovidone into two broad particle size types: A (coarser 
than 50 μm) and B (finer than 50μm) [124]. For crospovidone, a wicking agent, 
particle size relates to particle porosity. As size increases, the intraparticular porosity 
increases as well leading to larger water uptake and faster disintegration [125]. A more 
thorough consideration of crospovidone particle size specifications could be 
beneficial. Two equivalent grades of crospovidone powder (Polyplasdone XL and 
Kollidon CL) with the same particle size distribution from different suppliers showed 
differences in particle porosity and water uptake. When dicalcium phosphate dihydrate 
was incorporated in HCTZ tablets, the grade with the higher porosity (Polyplasdone 
XL) dissolved 33% of the drug in 15 minutes while its equivalent (Kollidon CL) 
released only 18% in the same time. When Kollidon CL (low porosity crospovidone 
grade) was compared to a grade of lower particle size from the first supplier 
(Polyplasdone XL 10), the latter showed increased liquid uptake and greater HCTZ 
dissolution than the former [125]. Whether this behavior relates to differences in 
particle size or variation in production processes, it designates that equivalent grades 
according to monograph specifications may have different functionality and 




Common levels of crospovidone used in solid dosage forms to provide fast 
disintegration are 2%-5% w/w [126]. The disintegration time of tablets containing 
highly soluble drugs (aspirin and ascorbic acid) and crospovidone decreased until a 
maximum crospovidone level of 8% of tablet weight. Levels higher than 8% w/w led 
to increased disintegration time. When ibuprofen, a poorly soluble drug, was 
formulated with crospovidone in tablet, disintegration time was at its lowest value (30 
s) at 8% of tablet weight with no subsequent increase with increased crospovidone 
level due to a possible effect of crospovidone concentration on tablet hardness. 
Crospovidone levels higher than 8% of tablet weight produce weaker tablets that 
disintegrate faster [111]. The effect of crospovidone on tablet hardness and its relation 
to disintegration should be further investigated. 
Biopharmaceutical Properties 
pH is unlikely to affect crospovidone functionality, as it is a nonionic non 
gelling polymer [65]. The swelling values were found 0.50 mL/g in simulated gastric 
(0.1 N HCl, pH=1) and intestinal (phosphate buffer, pH=6.8) media (Figure 1.8) due 
to the absence of ionization and the low swelling ability of crospovidone [109]. Water 
uptake of disintegrant powder was different in the two media, with values of 0.32 g/s 
and 0.52 g/s in the gastric and the intestinal media, respectively, due to a potential 
uncoiling of the chain in acidic medium [109]. This difference, though, was 
annihilated in compacts containing spironolactone, diluent-binder, disintegrant and 
lubricant and water sorption of these formulations was unaffected by the different pH. 
Disintegration times were higher (500 s and 350 s in 0.1 N HCl pH 1 and phosphate 
buffer pH 6.8, respectively) for lubricated compacts (with magnesium stearate) when 
compared to the unlubricated ones (150 s in both media). For lubricated compacts, 
higher disintegration time was observed in gastric media than in intestinal media 
because of the combination of uncoiled crospovidone chains and reduced water 
penetration caused by the hydrophobic lubricant [109]. 
1.6. Conclusions 
Excipients constitute a major component of solid dosage forms and their use 
covers a variety of functions, from dosage manufacturing to dosage performance. 
Their importance as potential causes for final product variability is recognized and 
efforts in characterizing their critical material attributes have been made. Despite the 
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rising awareness on excipient variability, few reports have addressed their role in drug 
product dissolution. Examining dissolution inconsistencies is essential, since in vitro 
dissolution testing constitutes a predictive tool of in vivo performance apart from its 
role in quality control testing. In this review, potential critical material attributes of 
commonly used excipients have been discussed with respect to product performance. 
Criticality is related to excipient functionality that can be altered according to product 
components and physiological conditions. A great effort still needs to be made to 
delineate the complex effects of physiological factors on product performance. We 
conclude that, despite the challenges imposed, an investigation of the exact excipient 
mechanisms in drug release is of paramount importance in order to adequately 
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Chapter 1 Commentary 
With the introduction of the Quality by Design (QbD) initiative in the pharmaceutical 
industry, the critical factors affecting final product quality need to be identified, 
understood and controlled. The presence of excipients as major components in solid 
oral dosage forms can be challenging for the performance of final products. Excipient 
variability caused by different natural sources, changes in excipient manufacturing 
processes or the inadequate specifications posed by regulatory agencies complicates 
this issue. It follows that approaches to understand and implement excipient variability 
in the QbD concept are needed for the production of robust pharmaceutical 
formulations. The biopharmaceutical implications of excipients on product 
performance need also to be considered in current methodologies as excipients can 
affect or be affected by the heterogeneous composition of the gastrointestinal lumen 
both in vitro and in vivo. The molecular, structural, particle properties and level of 
commonly used excipients in immediate release formulations (diluents, binders, 
lubricants, superdisintegrants) that could affect product performance were presented 
in this chapter. The biopharmaceutical implications of excipients on drug dissolution 
were, as well, considered and demonstrated the necessity to study the role of excipients 
on oral drug performance in a biorelevant perspective. Based on this analysis, 
lubricants (magnesium stearate), binders (hypromellose) and superdisintegrants 
(sodium starch glycolate, croscarmellose sodium, crospovidone) were selected for 
further experimentation, as their direct impact or unclear mechanistic role on drug 




Chapter 2 Preface 
As revealed in Chapter 1, understanding the critical material properties and the 
biopharmaceutical implications of excipients on drug product performance is 
beneficial towards the successful implementation of the Quality by Design (QbD) 
concept in the pharmaceutical development. Lubricants are excipients added in oral 
solid dosage forms to improve intermediate blend or tablet processing during 
manufacturing. Magnesium stearate (MgSt) is a frequently used lubricant in 
immediate release formulations but it can compromise drug dissolution due to its 
hydrophobic nature. Changes, therefore, in the excipient properties and/or excipient 
level in formulations could influence the amount of drug dissolved in the 
gastrointestinal tract and present challenges for oral drug bioavailability. Several 
excipient critical properties (purity -ratio of stearic and palmitic acid-, crystallinity, 
particle size distribution (PSD) and specific surface area (SSA)) are known to affect 
the performance of the excipient and could potentially influence drug dissolution. 
Moreover, as the varying composition of the gastrointestinal tract can affect the 
performance of MgSt, in vitro methodologies assessing the impact of excipients on 
product performance need to simulate the in vivo conditions. The aim of this chapter 
is to investigate the impact of MgSt variability and variation on the apparent solubility 
of drugs with varying physicochemical properties in a biopharmaceutical perspective. 
The generated data, in combination with results obtained from subsequent chapters, 
will be used to create a body knowledge of excipient criticality (with the use of 





Chapter 2. Biopharmaceutical understanding of excipient variability on drug 




Presence of excipients, excipient variability (changes in material attributes) and 
excipient variation (changes in amount) present a challenge for product performance. 
Understanding the biopharmaceutical factors affecting excipient performance is 
recommended for successful implementation of excipient variability on Quality by 
Design (QbD) approaches. The current study investigated the impact of magnesium 
stearate (MgSt) variability on the apparent solubility of drugs with a wide range of 
physicochemical properties (drug ionization, drug lipophilicity, drug aqueous 
solubility). Compendial and biorelevant media were used to assess the role of 
gastrointestinal (GI) conditions on the excipient effects on drug apparent solubility. 
The lipophilic nature of MgSt decreased the apparent solubility of the majority of 
compounds. The reduction in the drug apparent solubility was more pronounced for 
highly soluble and/or highly ionized drugs and in presence of more highly crystalline 
or smaller particle size MgSt. The use of multivariate data analysis revealed the critical 
physicochemical factors and the complex nature of excipient variability on the 
reduction in drug apparent solubility. The construction of a roadmap combining drug 
physicochemical properties and excipient critical material attributed allowed the 
identification of the cases where presence of excipient or excipient variability may 
present risks for oral drug performance. 
 
Keywords: excipient variability, magnesium stearate, drug solubility, 





Excipient variability (changes in material properties) and variation (changes in 
amount) can affect final product quality leading to batch failures, altered 
bioavailability and bioinequivalence within products [1, 2]. The need for successful 
implementation of excipient variability in Quality by Design (QbD) approaches is 
widely recognized. Excipient variability may present challenges in a 
biopharmaceutical perspective as presence of excipients may affect drug stability, 
solubility, permeability and overall product performance [3]. Gastrointestinal factors 
may affect or be affected by excipient performance in pharmaceutical formulations 
[4]. Understanding the biopharmaceutical risks of excipient variability would be 
beneficial towards the development of robust oral solid dosage forms. 
Magnesium stearate (MgSt) is a frequently used lubricant in tablet manufacturing 
due to its excellent properties [5]. Typical excipient levels used in immediate release 
formulations range between 0.25% w/w – 5% w/w [6]. MgSt can compromise drug 
release, as it acts as water repellent [7, 8] through the formation of a hydrophobic film 
around drug particles [9, 10]. MgSt may adhere to metal or powder/granule surfaces 
by its polar Mg2+ [5, 11] while the non-polar fatty acid orients away from the coated 
surface and is responsible for the negative impact on product performance [11] 
(Figure 2.1). Formation of mono or multiparticulate layers around particles by the 
non-polar head of MgSt [12, 13] has also been suggested as a coating approach for 
solid dosage forms. 
 
Figure 2.1: Chemical structure of Magnesium Stearate. (ChemDraw Professional 
15.0) 
MgSt is a mixture of stearic and palmitic salts [4]. Several different hydrates and 
corresponding solid-state forms of MgSt have been identified: anhydrous, 
monohydrate (needle – shape or disordered), dihydrate (plate – shape), trihydrate 
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(needle – shape) [14, 15]. MgSt samples may comprise of crystalline (single or 
combination of 2 or more forms) or amorphous forms [15]. Molecular, structural, 
particle properties and excipient level have been identified as potential critical material 
attributes of MgSt [4]. The purity of MgSt (ratio of stearic and palmitic acid) may 
affect its lubrication efficiency. The delay in the dissolution of a highly soluble drug 
(paracetamol, USP 2 apparatus, 0.1 N HCl pH 1, 25 rpm, 37 °C) was more pronounced 
in the presence of commercial MgSt (pharmaceutical grade mixture of stearic and 
palmitic salts with not less than 40% of stearic acid) compared to high purity MgSt (> 
90% of stearic acid) [9]. The slower drug dissolution was attributed to the formation 
of an extensive hydrophobic layer around particles by commercial compared to high 
purity MgSt. The formation of the hydrophobic layer around particles by MgSt 
depends on the solid-state form of the excipient. Amorphous MgSt hinders the 
formation of a smooth film around particles due to its irregular shape [16]. Milling 
crystalline MgSt breaks its crystal structure leading to amorphous material which 
exhibits poor lubrication efficiency [17]. The significance of the degree of crystallinity 
(CRS) is highlighted as the negative effects of amorphous MgSt on lubrication can 
dominate the lubrication efficiency of the crystalline portion [18]. Coating strength 
and uniformity depend on the particle size distribution (PSD) of the lubricant. Smaller 
particles create a thin but homogenous layer due to higher adhesion force on surfaces 
while larger particles have relatively less tendency to adhere on surfaces creating less 
uniform coats [4]. A statistical evaluation of the factors affecting the lubrication 
efficiency of MgSt identified that for crystalline MgSt, moisture content, hausner ratio, 
PSD (d50) and specific surface area (SSA) were critical material properties [18]. 
Finally, the level of excipient in solid dosage forms may affect the coating efficiency 
of MgSt and its impact on product performance. Pronounced delay in tablet 
disintegration and drug dissolution when increasing the amount of MgSt on 
formulations has been reported as a result of decreased tablet wettability [10]. 
The biopharmaceutical factors affecting the impact of MgSt on product 
performance are not fully investigated. The extent at which MgSt delayed drug 
dissolution was found to depend on the solubility of the active pharmaceutical 
ingredient (API). Dissolution studies (USP 2 apparatus, 0.1 N HCl pH 1, 75 rpm, 37 
°C) of capsules containing drugs of different solubility showed that although MgSt 
presence delayed drug dissolution, the impact was more pronounced for the drug with 
89 
 
the lowest solubility in the dissolution medium [7]. The pH of the solution will affect 
the performance of MgSt due to the ionization pattern of the excipient. The dissolution 
of metformin hydrochloride (USP 2 apparatus, 50 rpm, 37 °C, 900 mL dissolution 
medium) from tablets containing MgSt was slower in acidic (simulated gastric fluid 
without pepsin (SGF) pH 1.2) compared to basic conditions (phosphate buffer pH 6.8) 
[19]. This difference in drug dissolution by MgSt was attributed to the generation of 
stearic acid in acidic media which causes a more pronounced delay on drug dissolution 
due to its lower solubility compared to the salt form [19]. 
The aim of this study was to identify the impact and criticality of MgSt variability 
and variation on drug apparent solubility from a biopharmaceutical perspective. MgSt 
variability and variation were assessed by selecting and characterizing three MgSt 
brands of different grades and/or suppliers to investigate the role of certain critical 
material attributes including: purity (% of stearic and palmitic acid), CRS (intensity of 
diffractograms), PSD (d10, d50, d90), excipient level (low: 2% w/w, high: 5% w/w) on 
drug solubility. The potential biopharmaceutical implications of MgSt variability and 
variation on drug apparent solubility were investigated by choosing compounds of 
varying physicochemical properties (drug ionization, drug lipophilicity, drug aqueous 
solubility) and media (compendial and biorelevant) representing the gastric and 
intestinal conditions. The criticality of certain variables (drug properties, excipient 
presence, medium characteristics) on the impact of MgSt on drug apparent solubility 
was examined with the use of multivariate data analysis (Partial Least Squares (PLS)) 
and the construction of roadmaps. 
2.2. Materials and Methods 
2.2.1. Materials 
APIs: Sulfamethoxazole and paracetamol were obtained from Fisher Scientific 
(UK). Furosemide, itraconazole and dipyridamole were obtained from VWR (UK). 
Ibuprofen, carbamazepine and metformin were obtained from Fagron (UK). 
Excipients: MgSt-BDH was obtained from BDH chemical Ltd (UK). Ligamed MF-2-
V and Ligamed MF-3-V were obtained from Peter Greven (Germany). Chemicals: 
Acetic acid (>99.7%), hydrochloric acid 36.5–38%, HPLC grade methanol, HPLC 
grade acetonitrile, dichloromethane, heptane, pepsin (from porcine) were obtained 
from Sigma-Aldrich (UK). Maleic acid, sodium chloride, sodium hydroxide, 
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potassium phosphate monobasic, sodium dihydrogen orthophosphate dihydrate, 
disodium hydrogen orthophosphate dihydrate, potassium dihydrogen orthophosphate, 
anhydrous sodium sulfate, HPLC grade trifluoroacetic acid, stearic acid >98%, 
palmitic acid >98% were obtained from Fisher Scientific (UK). Boron trifluoride – 
methanol complex 12% in methanol was obtained from VWR (UK). Sodium 
taurocholate (Prodotti Chimici Alimentari S.P.A., Italy), egg lecithin – Lipoid EPCS 
(Lipoid GmbH, Germany), were obtained from the sources specified. Water was ultra-
pure (Milli-Q) laboratory grade. Filters: Whatman® 13 mm cellulose nitrate filters 0.45 
μm pore size and polytetrafluoroethylene (PTFE) 13 mm filter 0.45 μm pore size were 
purchased from Fisher Scientific (UK).  
2.2.2. Instrumentation 
Fisherbrand waterbath (Fisher Scientific, UK), Sartorius BP 210 D balance 
(Sartorius Ltd UK), Buchi R114 Rotavapor (Buchi, Switzerland), SevenCompact 
S210 pH meter (Mettler Toledo, Switzerland), Vortex-Genie 2 vortex mixer 
(Scientific Industries Inc, USA), D8 Advance AXS Bruker Powder diffractometer 
(Bruker Inc., USA), Agilent Technologies 1100 series HPLC system, (quaternary 
pump (G1311A), autosampler (G1313A), thermostatted column compartment 
(G1316A), diode array detector (G1329A), Chemstation software (Agilent 
Technologies, USA)), Chrompack CP-9003 series GC system coupled with a Varian 
4400 integrator (Varian Instruments, USA). 
2.2.3. Methods 
2.2.3.1. Compounds selected for solubility experiments 
The compounds used for the solubility experiments, their physicochemical 
properties (drug ionization, drug lipophilicity, drug aqueous solubility) and their 




Table 2.1: Physicochemical properties and structure of the compounds used for the 





























































2.2.3.2 Media prepared for solubility experiments 
Compendial media (0.1 N HCl pH 1, phosphate buffer pH 6.8) were prepared 
according to the method described in the United States Pharmacopeia [31]. Fasted 
State Simulated Gastric Fluid (FaSSGF) and Fasted State Simulated Intestinal Fluid 
(FaSSIF-V2) were prepared as per literature references [32]. 
2.2.3.3. Design of Experiments (DoE) used for solubility studies 
A full-factorial Design of Experiments (DoE) was performed to determine the 
number of necessary experiments using StatGraphics Centurion XVII (Statpoint 
Technologies Inc, USA). As drug solubility will differ according to the composition 
of the studied media (pH, presence of bile salts), two models for the DoE were 
constructed to discriminate between the effects of excipients on drug solubility in 
compendial (Model 1) and biorelevant conditions (Model 2). The investigated factors 
were: i. compound (Table 2.1), ii. excipient brand (MgSt-BDH, Ligamed MF-2-V, 
Ligamed MF-3-V), iii. excipient level (low, high), iv. medium (gastric, intestinal). The 
impact of each excipient on drug apparent solubility [expressed as the relative increase 
or decrease in presence compared to absence of excipient (Section 2.2.3.6)] was set as 
the response. A total of 96x3 experiments was determined for each model. 16x3 
additional experiments for each model were conducted to determine drug apparent 
solubility in the corresponding media in the absence of excipient. These experiments 
were not included in the DoE as drug solubility in excipient absence was measured 
only for the calculation of relative excipient effects on drug solubility. 
2.2.3.4. Characterization of MgSt 
2.2.3.4.1. Determination of Relative Content of Stearic and Palmitic Acid 
The relative content and total sum of stearic and palmitic acid for each MgSt brand 
were determined after esterification of the fatty acids with methanol/boron trifluoride 
followed by gas chromatography according to the proposed method in the USP 
monograph of MgSt [33]. 
2.2.3.4.2. Powder X-Ray Diffraction 
X-ray powder diffraction (XRPD) measurements for each MgSt brand were 
obtained. Samples were mounted on an acrylic wafer and analysed at λ = 1.5418 Å. 
Samples were measured in reflection geometry in the θ – 2θ configuration over the 
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scan range 2°θ to 40°θ with a 0.12 second exposure per 0.02° increment. The X-rays 
were generated by a Cu long-fine focus tube operated at 40kV and 40mA. Excipient 
CRS was determined by the intensity of diffractograms (counts) at the 5° 2θ scale. 
2.2.3.4.3. Particle Size Distribution and Specific Surface Area 
The PSD of the MgSt brands was measured using laser diffraction in dry dispersion 
mode at a dispersion pressure of 0.5 bar. The cumulative undersized particle 
parameters d10 (μm), d50 (μm) and d90 (μm) were calculated. Morphological evaluation 
of the studied MgSt brands was conducted using Scanning Electron Microscopy 
(SEM). The SSA of the studied MgSt brands was determined using the Brunauer-
Emmett-Teller (BET) method using the nitrogen adsorption method in a relative 
pressure range of 0.05 – 0.30 Pa [34]. 
2.2.3.5. Solubility studies 
Drug solubility studies in absence and presence of excipient were performed in 
triplicate using the shake-flask method [35]. Drug excess and 2% w/w or 5% w/w of 
each excipient were weighed and placed in centrifuge tubes. The amount of excipient 
was determined as follows: i. for poorly soluble drugs, considering an average of 500 
mg tablet weight [36] (which resulted in 9% w/w (low level) and 20% w/w (high level) 
of excipient in the total volume of the physical mixture) and ii. for highly soluble 
drugs, according to the amount of drug excess and the relative ratio of drug-excipient 
based on point (i). The physical mixtures were vortexed for 3 minutes. 5 mL of each 
medium were added in the tubes and the samples were placed in a shaking water bath 
(37 °C, 200 strokes per minute (spm)). At 0.5, 4 and 24 hours (for PRC, SMX, CBZ, 
DPL, IBU) and at 24 hours (for MTF, FRS, ITZ), 500 μL were sampled and filtered 
through PTFE filters (or cellulose nitrate filters for the cases of IBU and CBZ). Filter 
adsorption studies were prior performed in triplicate for each drug. No adsorption 
issues onto the filters used were observed for the studied drugs. Filtered samples were 
further diluted (if needed) with the corresponding medium and analysed by HPLC 
(Table 2.2). Analytical HPLC procedures for drug quantification in the samples were 
modifications of already published methods. Drug quantification was made based on 
calibration curves. Standards were prepared from concentrated stock solutions 
consisting of drug dissolved in MeOH. As changes in the pH of solutions by presence 
of dissolved drug [27] or MgSt [37, 38] may affect drug solubility, the pH of samples 
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after the completion of each experiment was measured. Drug apparent solubility was 
calculated based on the sample drug concentration measured. Solubility values in 
excipient absence measured experimentally for neutral drugs, for weak acids in acidic 
media and for weak bases in basic media determined the intrinsic solubility values. 
Solubility values in absence of excipient measured experimentally in basic media (for 











































































2.2.3.6. Treatment of in vitro solubility data 
The Relative Effect (RE) of each excipient on drug apparent solubility was 
calculated based on equation 2.1: 
𝑅𝐸 =  
(𝑆−𝑆𝑟)
𝑆𝑟
 𝑥 100  (Equation 2.1) 
where 𝑆 and 𝑆𝑟 denote drug apparent solubility in presence and absence (reference 
solubility) of excipient at 0.5, 4 and 24 hours. REs of excipients on drug apparent 
solubility > 25% or < -20% were considered as significant changes in drug apparent 
solubility to assess excipient criticality (this range was selected as a similar range is 
set in order to assess differences in drug exposure after oral administration; i.e. in 
bioequivalence studies) [47]. 
Box plots depicting the impact of excipients on drug solubility at 24 hours for all 
the studied compounds in presence of all the studied MgSt brands or as a function of 
time (0.5, 4 and 24 hours) for PRC, CBZ, SMX, IBU, DPL in presence of MgSt-BDH 
and Ligamed MF-2-V were constructed using Spotfire 7.10.1 (TIBCO software Inc, 
USA). The classification gradient maps portraying the impact of excipients on drug 
apparent solubility as a function of drug aqueous solubility were generated using 
SigmaPlot 13.0 (Systat Software Inc, USA). For the construction of 3D mesh plots 
depicting the impact of excipients (Ligamed MF-2-V, Ligamed MF-3-V) on drug 
apparent solubility as a function of drug ionization and drug lipophilicity, the REs on 
drug apparent solubility were smoothed via the Locally Weighed Scatterplot 
Smoothing (LOWESS) regression to allow better visualization using SigmaPlot 13.0 
(Systat Software Inc, USA). 
In cases where drug intrinsic solubility was not determined experimentally, the 
theoretical intrinsic solubility was calculated using the solubility-pH equations 
(Equations 3.2-3.5) [48]:  
log 𝑆 = log 𝑆𝑜 + log(10
−𝑝𝐾𝑎+𝑝𝐻 +1)  for weak acids (Equation 2.2) 
log 𝑆 = log 𝑆𝑜 + log(10
𝑝𝐾𝑎−𝑝𝐻 +1)   for weak bases (Equation 2.3) 
log 𝑆 = log 𝑆𝑜 + log(10




log 𝑆 = log 𝑆𝑜 + log(10
+ 𝑝𝐾𝑎1− 𝑝𝐻 +  10−𝑝𝐾𝑎2+ 𝑝𝐻 + 1)  for ampholytes 
(Equation 2.5) 
where 𝑆 and 𝑆𝑜 indicate drug solubility at the given pH and the intrinsic solubility, 
respectively. The final pH and experimental solubility values of the ionized drug in 
basic (for weak acids) or acidic media (for weak bases) were used for the calculation 
of the theoretical intrinsic solubility. Theoretical pH-solubility profiles in the 
physiological pH range were constructed to assess if changes in the pH of the medium 
could justify differences in drug solubility by excipient presence. The final pH and 
intrinsic solubility values (experimental or theoretical) were used for the construction 
of the theoretical pH – solubility profiles in the physiological pH range based on 
Equations 2.2-2.5. 
2.2.3.7. Multivariate Analysis of in vitro solubility data 
Excipient REs on drug apparent solubility were correlated to drug 
physicochemical properties (drug ionization, drug lipophilicity, drug aqueous 
solubility), excipient critical material attributes (CRS, PSD, level) and medium 
characteristics (gastric, intestinal) by partial least squares (PLS) regression using the 
XLSTAT software (Microsoft, USA). Two models for the REs of excipients on drug 
apparent solubility in compendial media (Model 1) and biorelevant media (Model 2) 
were constructed. The evaluated variables for both models were categorized according 
to their type as categorical (expressing a category or type) and numerical 
(measurements with numerical meaning). Categorical variables included: i. drug 
solubility (poor, high), ii. excipient level (low, high), iii. medium (gastric, intestinal) 
while numerical parameters included i. % of drug ionized (Fion; calculated based on 
the Henderson – Hasselbalch equation at the pH of each medium), ii. drug lipophilicity 
(log P), iii. excipient CRS, iv. excipient PSD. Excipient REs on drug solubility at 24 
hours were used as the response. The selected interaction terms included each 
excipient property combined with each drug physicochemical property (drug 
ionization, drug lipophilicity, drug aqueous solubility) and medium characteristics 
(gastric, intestinal). Observation diagnostics were performed prior to model analysis 
to identify outliers in the data set. The distance of each observation to the model in the 
Y-plane (DmodY) tool based on PLS residuals was used. Plots of standardized 
DmodY vs each observation were generated and any observation exceeding the 
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maximum tolerance volume in Y (Dcrit(Y)) was considered an outlier [49, 50]. 
Exclusion of outliers was based on: i. deviating cases (positive REs) in solubility 
caused by a shift in the pH of the solution, ii. observations resulting in high variability 
(coefficient of variation (CV%) > 20%) within the triplicate samples (one value from 
the triplicate could be excluded as the outlier analysis could detect these values). PLS 
models generated with and without outlier exclusion (data not shown) confirmed that 
outlier exclusion did not alter the interpretation of results but only enhanced the 
predictive ability of the regression model. The generated models were assessed in 
terms of goodness of fit (R2) and goodness of prediction (Q2). High values of R2 and 
Q2 with a difference not greater than 0.2 - 0.3 were indications of successful models 
[51]. The number of PLS components (lines on the X-space which best approximate 
and correlate with the Y-vector) was based on minimum predictive residual sum of 
squares (PRESS) [51]. From the available components the one at which Q2 reached its 
maximum value was selected [49]. Standardized coefficients were used to show the 
direction (positive or negative) and extent of each variable on the response. The 
significance of the variables was assessed by the variable influence on projection 
(VIP) value. VIP values > 0.8 were considered as moderately influential in the model 
while VIP values > 1 were considered the most influential in the model [51]. A 95 % 
confidence interval was used. 
2.2.3.8. Roadmap Design 
A roadmap design for the identification of potential risks of MgSt variability on 
drug apparent solubility was constructed combining the impact of excipients on drug 
solubility at 24 hours from the solubility studies to excipient (CRS, PSD) and drug 
(drug ionization, drug lipophilicity, drug aqueous solubility) characteristics. Drugs 
were categorized according to drug aqueous solubility and drug lipophilicity (Table 
2.1) and drug ionization (low ionized: F(ion) < 50%, highly ionized: F(ion) > 50%). The 
risk assessment of the impact of excipients on drug apparent solubility was evaluated 
by setting reference range criteria of -20% - 25% [47] on the REs of excipients on drug 
solubility at 24 hours. REs of excipients on drug solubility outside these values (REs 
< -20% or REs > 25%) were considered critical for oral drug performance. 
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2.3. Results and Discussion 
2.3.1. Characterization of MgSt 
2.3.1.1. Determination of Relative Content of Stearic and Palmitic Acid 
The relative content and total sum of stearic and palmitic acid for each MgSt brand 
are presented in Figure 2.2a. The relative content varied between 70%:30% of 
stearic:palmitic acid for MgSt-BDH and Ligamed MF-3-V and 65%:35% of 
stearic:palmitic acid for Ligamed MF-2-V. The total sum of the fatty acids of the 
studied brands was > 99%, within the acceptance criteria of the USP monograph of 
MgSt [33]. As changes in the lubrication efficiency of MgSt have been reported only 
for differences between the stearic and palmitic relative contents higher than 20% [16], 
no impact on drug solubility is anticipated by the small differences in the relative fatty 
acid content of the studied brands. 
 
Figure 2.2: a. Relative content (%) and total sum (%) of stearic and palmitic acid, b. 
XRPD patterns and c. SEM micrographs of the studied brands of MgSt. The different 
brands are shown as: for i. MgSt - BDH (black colour), ii. Ligamed MF-2-V (red 




2.3.1.2. Powder X-Ray Diffraction 
The XRPD patterns of MgSt - BDH, Ligamed MF-2-V and Ligamed MF-3-V are 
shown in Figure 2.2b. The patterns are in accordance with previously reported 
diffractograms [15]. The intensity and sharpness of the peaks at the 3.3° 2θ, 5.5° 2θ 
and 23° 2θ scale revealed higher crystalline portions for Ligamed MF-2-V and 
Ligamed MF-3-V compared to MgSt-BDH. 
2.3.1.3. Particle Size Distribution 
The PSD and SSA analysis of the studied MgSt brands are shown in Table 2.3. 
Ligamed MF-3-V comprised of smaller particles compared to MgSt-BDH and 
Ligamed MF-2-V. SEM micrographs confirmed these findings (Figure 2.2c) as large 
agglomerates were observed for MgSt-BDH and Ligamed MF-2-V. The SSA was 
higher for Ligamed MF-3-V compared to MgSt-BDH and Ligamed MF-2-V, due to 
its lower PSD. Differences in crystallinity between MgSt-BDH and Ligamed MF-2-V 
(expressed by the differences in the intensity and sharpness of diffractogram peaks, 
Figure 2.2b), could justify the lower SSA of MgSt-BDH compared to Ligamed MF-
2-V, despite its lower PSD [52]. 
Table 2.3: Particle size distribution and specific surface area for MgSt-BDH, Ligamed 
MF-2-V and Ligamed MF-3-V. 










MgSt-BDH 1.37 6.61 21.1 4.38 (±0.05) 
Ligamed MF-2-V 2.13 8.88 36.5 15.85 (±0.73) 
Ligamed MF-3-V 1.87 6.92 15.2 20.51 (±0.31) 
 
2.3.2. Solubility studies 
2.3.2.1. Impact of the studied MgSt brands on drug apparent solubility 
The reference drug solubility values at 24 hours in compendial and biorelevant 
media are summarized in Table 2.4. The reference solubility of neutral drugs (PRC, 
CBZ) was not pH-depended, as expected. Higher solubility values were observed in 
biorelevant compared to compendial media for neutral drugs, as the presence of bile 
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salts improves drug solubilization [53]. Weak acids (SMX, FRS, IBU) and weak bases 
(DPL, ITZ) showed a pH-dependent solubility in the physiological pH range due to 
their ionization pattern. The solubility of MTF (weak base) was not pH-depended, as 
drug was fully ionized in the studied conditions [20]. Due the presence of two pKa 
constants (Table 2.1), SMX is ionized in acidic (80% and 50% of drug ionized in 0.1 
N HCl pH 1 and FaSSGF pH = 1.6, respectively) and basic media (92% and 86% in 
phosphate buffer pH 6.8 and FaSSIF-V2 pH = 6.5, respectively). The reference 
solubility values of SMX in acidic media were lower compared to their corresponding 
basic media due to the higher % of ionized drug in basic compared to acidic conditions. 
In media where weak acids or weak bases were unionized, drug solubility at 24 hours 
was higher in biorelevant compared to compendial media due to the presence of 
solubilizing components [53]. In media where weak acids and weak bases (except 
from the case of MTF) are ionized, drug solubility values were higher in the 
compendial compared to the biorelevant conditions, despite the absence of 
solubilizing components. These changes in drug solubility at 24 hours can be 
explained by the differences in the pH between the studied sets of media which result 
in higher % of drug ionized in compendial compared to biorelevant conditions and 
therefore higher reference drug solubility [54]. 
Table 2.4: Reference solubility values (μg/mL) at 24 hours of the studied drugs in 
compendial and biorelevant media. (Mean ± SD, n = 3) 
 Compendial Media Biorelevant Media 





































































*below limit of detection of the analytical method 
The effects of the MgSt brands on the solubility of the studied compounds at 24 










































































































































































































































































































































































































































































































Neutral drugs: Cases of significant decrease in drug solubility at 24 hours (-
65% < REs < -32%) by the studied MgSt brands were observed for the case of PRC. 
For PRC, an increase in the pH of the media was observed in presence of MgSt in 0.1 
N HCl pH 1 (0.1 – 0.6 pH units) and in biorelevant media (0.3 – 5 pH units) due to the 
basic nature of the excipient [37, 38], however changes in the pH of the media cannot 
justify the differences in PRC solubility in MgSt presence at 24 hours (Figure 2.5). 
The reduction in PRC solubility at 24 hours by MgSt can be explained by the decreased 
drug-medium contact in excipient presence [55]. The hydrophobic nature and slow 
dissolution of MgSt from the powder surface [7, 8] which further limit drug dissolution 
and/or drug solubilization could also contribute to the decrease in drug apparent 
solubility. The effects of MgSt-BDH and Ligamed MF-2-V on drug solubility as a 
function of time for one highly soluble (PRC) and 4 poorly soluble drugs (CBZ, SMX, 
IBU, DPL) in compendial and biorelevant media are presented in Figure 2.6. Presence 
of MgSt resulted in pronounced decrease in PRC solubility (–90 % < REs < -60 %) at 
early time points (0.5 and 4 hours) confirming that the reduction in drug solubility by 
MgSt presence relates to the lipophilic nature of the excipient. Significant increase in 
drug solubility at 24 hours was observed in phosphate buffer pH 6.8 for PRC (2% 
MgSt-BDH: RE = 28%) and for CBZ (2% of Ligamed MF-2-V: RE = 29%, Ligamed 
MF-3-V: RE = 27%) and in FaSSIF-V2 for PRC (2% of Ligamed MF-2-V: RE = 27%) 
(Figures 2.3 and 2.4). The observed slight differences in the pH of the media (0 – 0.2 
pH units) due to the presence of MgSt [37, 38] are not expected to affect the solubility 
of neutral drugs (Figure 2.5). As MgSt particles disperse in basic conditions [19], the 
observed increase in drug solubility at 24 hours could be attributed to improved drug 





























































































































































































































































































































































































































































































































































































































































































































































Weak acids: Cases of significant reduction in the solubility of weak acids by MgSt 
presence at 24 hours was observed mainly in basic conditions (SMX: -30% < REs < -
20%, FRS: -40% < REs < -25%, IBU: -50% < REs < -25%) (Figures 2.3 and 2.4). 
For cases where MgSt presence significantly decreased drug apparent solubility, small 
changes in the pH of the acidic media occurred in absence or presence of excipient (± 
0.1 pH units) while the pH of the basic media decreased in absence or presence of 
excipient (0.2 – 0.7 pH units), potentially due to the dissociation of weak acids. The 
construction of the theoretical pH-solubility profiles (Figure 2.5) revealed that in 
cases where MgSt significantly reduced drug solubility at 24 hours, the changes in the 
pH of media in excipient presence cannot justify the changes in drug solubility, as the 
experimental solubility values in excipient presence do not correspond to the 
theoretical solubility values (expected according to the changes in the pH of the 
media). The reduced drug dissolution and/or drug solubilization by the lipophilic MgSt 
[7, 8, 55] can explain the observed reduction in drug apparent solubility by MgSt, as 
in the case of neutral drugs. The impact of MgSt-BDH and Ligamed MF-2-V on the 
SMX and IBU solubility through time (Figure 2.6) showed that the reduction in drug 
solubility by MgSt was higher at early (-80% < REs < -20%) compared to late time 
points (24 hours), even in several cases where MgSt did not significantly alter the 24 
hour drug solubility. This observation confirms that the reduction in drug apparent 
solubility is a result of reduced powder wetting in presence of MgSt. Significant 
increase in the 24 hour drug solubility in acidic media was observed for SMX in 0.1 
N HCl pH 1 (MgSt-BDH: REs of 77% and 52% for the low and high level, 
respectively) and in FaSSGF (2% Ligamed MF-3-V: RE = 34%) (Figures 2.3 and 
2.4). In the aforementioned cases, the pH of the medium in presence was lower (0.1 N 
HCl pH 1: pH = 0.7 in presence of MgSt-BDH, FaSSGF: pH = 1.64 in presence of 
Ligamed MF-3-V) compared to excipient absence (0.1 N HCl pH 1: pH =0.94, 
FaSSGF: pH =1.89). The increase in drug solubility at 24 hours is therefore attributed 
to the change in the pH of the media as experimental and theoretical drug solubilities 
in excipient presence are identical (Figure 2.5) (further investigations of the interplay 
between drugs/excipients and the pH of the medium are needed as MgSt is not 
expected to reduce the pH of the medium). Significant increase in drug apparent 
solubility was also observed in basic conditions for FRS (MgSt-BDH: REs of 47% 
and 71% for the low and high level, respectively) and SMX in phosphate buffer pH 
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6.8 (5% Ligamed MF-2-V: RE = 30%) and for FRS in FaSSIF-V2 (5% Ligamed MF-
3-V: RE = 28%). For the above cases, the reduction in the pH of the medium was 
lower in presence (approximately 0.2 - 0.3 pH units) compared to excipient absence 
(0.2 – 0.6 pH units) potentially due to the basic nature of MgSt [37, 38] and explains 
the differences in drug solubility at 24 hours between excipient absence and presence 
(Figure 2.5). 
Weak bases: Significant reduction in the solubility of weak bases by MgSt 
presence at 24 hours was observed for the majority of cases (MTF: -84% < REs < -
35%, DPL: -67% < REs < -20%, ITZ: -50% < REs < -20%) (Figures 2.3 and 2.4). 
The impact of pH on the solubility of weak bases cannot be evaluated, as the 
theoretical pH-solubility profiles did not follow the exponential increase in drug 
solubility with increasing pH due to in situ salt formation between the drugs and 
counterions of the medium [56] (Figure 2.5). The hydrophobic nature of MgSt [7, 8, 
55] leading to slow drug dissolution and/or drug solubilization could justify the 
decrease in drug apparent solubility. The impact of excipients (MgSt-BDH, Ligamed 
MF-2-V) on the solubility of DPL through time (Figure 2.6) showed a pronounced 
reduction in DPL solubility at early time points only in acidic media confirming the 
negative impact of MgSt on drug dissolution/solubilization (only in presence of 2% 
BDH an increase was observed in DPL solubility at 4 hours in 0.1 N HCl pH 1). For 
weak bases, significant increase in drug solubility at 24 hours by MgSt presence was 
not observed (Figures 2.3 and 2.4). 
The solubility data showed increased variability in the cases where MgSt presence 
significantly affected drug solubility at 24 hours (PRC, MTF: CV% > 40%, highly 
ionized drugs: 20% < CV% < 40%). As working with physical mixtures may yield 
high standard deviations due to the heterogeneous dispersion of the constituents [57, 
58], the increased variability can be attributed to the heterogeneous distribution of 
excipient particles on the powder surface. 
2.3.2.2. Impact of excipients on drug apparent solubility based on drug 
physicochemical properties 
The effects of MgSt on the solubility of neutral drugs, weak acids and weak bases 
at 24 hours as a function of drug ionization and drug lipophilicity in compendial and 




Figure 2.7: Relative effects (%) of MgSt brands on drug solubility at 24 hours as 
a function of drug ionization (%) and drug lipophilicity (log P) in a. compendial and 
b. biorelevant media. The excipients brands are shown as: i. MgSt-BDH (green 
colour), ii. Ligamed MF-2-V (blue colour), iii. Ligamed MF-3-V (red colour). Light 
and dark colours correspond to low and high excipient levels, respectively. Media 
representing gastric and intestinal conditions are presented as: i. acidic media (circles) 
and ii. basic media (squares) 
As both neutral drugs are unionized under the studied media, the higher decrease 
in the apparent solubility of PRC compared to CBZ by MgSt is likely attributed to the 
differences in the lipophilicity of these two compounds (Table 2.1). For weak acids 
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and weak bases, the decrease in drug solubility at 24 hours is pronounced in media 
where drugs are highly ionized (excluding the cases of increased drug solubility at 24 
hours attributed to the change of the pH of the medium). A clear trend between the 
impact of excipients on the apparent solubility of weak acids and bases and drug 
lipophilicity cannot be observed. The decrease in drug solubility at 24 hours by MgSt 
presence was more pronounced with increasing level of drug ionization and/or 
decreasing drug lipophilicity (Figure 2.7). As in these cases a higher number of drug 
molecules can dissolve fast in the surrounding medium, powder surface can saturate 
with the lipophilic MgSt particles leading to decreased drug solubility [19]. The 
classification gradient map (Figure 2.8) depicting the effects of the MgSt brands on 
drug solubility at 24 hours as a function of decreasing drug aqueous solubility in 
compendial and biorelevant media confirms this finding. Presence of MgSt decreased 
the apparent solubility of drugs with high aqueous solubility. For the majority of drugs 
with low aqueous solubility, drug solubility at 24 hours was not affected by excipient 
























































































































































































































































2.3.2.3. Impact of excipients on drug apparent solubility based on 
excipient properties 
2.3.2.3.1. Impact of MgSt crystallinity on drug apparent solubility 
The effects of the studied MgSt brands on drug apparent solubility depended on 
excipient properties. For the majority of cases, significant reduction in drug solubility 
at 24 hours was observed mainly in presence of high crystalline brands (Ligamed MF-
2-V, Ligamed MF-3-V) compared to the low crystalline brand (MgSt-BDH) (Figures 
2.3 and 2.4). In cases where all the studied brands decreased drug solubility at 24 
hours, the reduction in drug solubility was more pronounced by the high crystalline (-
85% < REs < -20%) compared to the low crystalline brand (-70% < REs < -20%). 
Investigation of the impact of the low (MgSt-BDH) and a high crystalline (Ligamed 
MF-2-V) brand on drug solubility through time (Figure 2.6) showed that the 
crystalline brand resulted in the same or higher reduction in drug solubility at early 
time points (0.5 and 4 hours) compared to the less crystalline brand (except from the 
case of SMX in 0.1 N HCl pH 1 and phosphate buffer pH 6.8). The better lubrication 
efficiency of crystalline brands around particles during mixing could explain the more 
pronounced delay on drug dissolution [18]. 
2.3.2.3.2. Impact of MgSt PSD and level on drug apparent solubility 
As the impact of PSD on the lubrication efficiency of MgSt will have greater 
magnitude for crystalline brands [18], the impact of increasing MgSt particle size on 
drug solubility at 24 hours was investigated for the two crystalline MgSt brands 
(Ligamed MF-2-V and Ligamed MF-3-V). The effects of Ligamed MF-2-V and 
Ligamed MF-3-V on drug solubility at 24 hours as a function of drug ionization and 




Figure 2.9: Relative effects (%) of i. Ligamed MF-2-V (blue colour) and ii. Ligamed 
MF-3-V (red colour) on drug solubility at 24 hours as a function of drug ionization 
(%) and lipophilicity (log P). Light and dark colours correspond to low and high 
excipient level, respectively. 
 
Differences in the REs of excipients on drug apparent solubility within the two 
brands are observed in the low drug ionization range. Presence of the low particle size 
brand (Ligamed MF-3-V) reduced the solubility of drugs with log P < 1 in a higher 
extent (REs < -60%) compared to the high particle size brand (Ligamed MF-2-V) (REs 
< -40%) at 24 hours. The higher reduction in drug apparent solubility in presence of 
Ligamed MF-3-V compared to Ligamed MF-2-V can be explained by the creation of 
a stronger and uniform coating around drug particles by MgSt of low particle size [11]. 
The opposite is observed when increasing drug lipophilicity (log P > 4, ITZ). Based 
on our complete data set, presence of MgSt should not affect the solubility of poorly 
soluble unionized drugs at 24 hours (Figure 2.7), therefore further investigations are 
needed to explain why low particle size brands affected the solubility of ITZ in media 
where the drug was unionized. Increasing excipient level resulted in pronounced 
reduction in drug solubility at 24 hours (REs of approximately -10% and -40% for the 
low and high excipient level, respectively) only for Ligamed MF-2-V. As high particle 



































compared to low particle size brands (Ligamed MF-3-V), increasing their amount 
could lead to significant higher drug particle coverage [59]. 
2.3.3. Multivariate Data Analysis of solubility data 
The standardized coefficients of the studied variables and their interactions in 
compendial and biorelevant media are presented in Figure 2.10. The two models 
showed an average predictive power and fit (compendial media: Q2 = 0.5 and R2 = 


















































































































































The statistical analysis reveals that the impact of MgSt on drug apparent solubility 
depends on drug physicochemical properties. Drug ionization (compendial media: 
negative effect, VIP = 2.8, biorelevant media: negative effect. VIP = 2.0) and drug 
aqueous solubility (compendial media: negative effect, VIP = 1.9, biorelevant media: 
negative effect, VIP = 2.8) were influential variables in both sets of media. These 
variables reveal that the slow dissolution of MgSt from powder surface [55] becomes 
the rate limiting step for the dissolution of highly ionized and/or highly soluble drugs. 
Drug lipophilicity was a significant variable in both models with different extent in 
compendial (positive effect, VIP = 1.6) and biorelevant media (negative effect, VIP = 
1.8), indicating that the decrease in the apparent solubility of lipophilic drugs by MgSt 
presence will be pronounced in biorelevant conditions. The pronounced decrease in 
the solubility of lipophilic drugs by MgSt presence in biorelevant media at 24 hours 
can be explained by the improved solubilization of lipophilic molecules due to the 
presence of bile salts [53, 60] which results in the presence of more MgSt particles on 
the surface of the powder. The impact of MgSt on drug apparent solubility relates also 
to excipient properties according to the sets of media used. Excipient CRS was a 
significant variable in the compendial model (negative effect, VIP = 1.1) and reveals 
that the improved lubrication efficiency of crystalline MgSt hinders powder 
wettability [17, 61]. Excipient CRS was not significant in biorelevant media, as 
potentially lubricated particles can be solubilized by the presence of bile salts [53, 60]. 
Excipient level (negative effect, VIP = 0.9) was a critical variable in the biorelevant 
model revealing that the enhanced drug solubilization in biorelevant media [53, 60], 
results in saturation of the powder surface with more MgSt particles when excipient 
level is increased. Medium characteristics (gastric or intestinal conditions) are critical 
on the impact of MgSt on drug solubility in biorelevant media, as indicated by the 
significance of the variable medium (negative effect, VIP = 0.8) in the model. The 
presence of bile salts in high amounts in the biorelevant basic medium leads to 
enhanced powder wettability [53] and saturation of powder surface by excipient 
particles, as explained above. 
The impact of MgSt variability on drug apparent solubility relates to drug 
physicochemical properties, as demonstrated by the significance of certain interactions 
in the studied models. In compendial media, CRS*solubility (negative effect, VIP = 
1.2) and CRS*lipophilicity (positive effect, VIP = 0.9) were significant variables in 
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the model indicating that the reduction in drug solubility at 24 hours by presence of 
crystalline MgSt brands will be more pronounced for highly soluble less lipophilic 
drugs. In biorelevant media, PSD*lipophilicity (negative effect, VIP = 0.9) and 
PSD*solubility (negative effect, VIP = 0.9) were significant interactions in the model 
indicating that the high particle size brands will significantly reduce the apparent 
solubility of highly soluble and/or highly lipophilic drugs. CRS*solubility (negative 
effect, VIP = 0.9) and CRS*lipophilicity (positive effect, VIP = 1.0) were also 
significant interactions in the biorelevant model revealing that the decrease in drug 
solubility at 24 hours by crystalline MgSt brands will be pronounced for highly soluble 
hydrophilic drugs. An interplay between excipient properties was observed in 
compendial media by the significance of CRS*PSD (positive effect, VIP = 1.2) in the 
model. As MgSt brands of lower crystallinity have low lubrication efficiency, 
decreasing MgSt particle size will be critical only for crystalline brands leading to 
higher reduction in drug apparent solubility compared to high PSD brands. 
2.3.4. Road map of MgSt effects on drug apparent solubility 
The roadmap categorizing the excipient REs on drug solubility at 24 hours 
according to excipient and drug properties is presented in Figure 2.11 (cases where 





Figure 2.11: Road map of the effects of the studied excipients on drug solubility at 24 
hours. Red boxes and green boxes indicate significant and insignificant changes in 
drug solubility by excipient presence, respectively. 
 
The impact of MgSt on drug apparent solubility relates to drug physicochemical 
characteristics. Significant changes in drug solubility at 24 hours by MgSt can be 
anticipated for highly soluble drugs, irrespective of drug ionization state (low or highly 
ionized). The effects of the studied MgSt brands on the solubility of poorly soluble 
drugs at 24 hours depend on the state of drug ionization, as significant changes in drug 
solubility by MgSt presence can occur when poorly soluble drugs are highly ionized 
irrespective of their lipophilicity. For poorly soluble/low ionized drugs, MgSt is not 
expected to significantly affect drug apparent solubility, except from the case of 
121 
 
lipophilic drugs (log P > 4) in presence of MgSt brands of high PSD. The construction 
of the roadmap reveals that excipient selection or change needs to be thoroughly 
considered as excipient variability may be problematic for oral drug performance. 
2.4. Conclusion 
Presence of excipients and excipient variability in oral dosage forms can affect 
product performance. MgSt is a commonly used lubricant in immediate release 
formulations but it can compromise drug dissolution. The current study focused on 
identifying the biopharmaceutical implications of MgSt presence and variability on 
drug apparent solubility. Solubility studies showed that for the majority of cases, 
presence of MgSt significantly decreased drug solubility at 24 hours due to its 
hydrophobic nature. The extent of the changes in drug apparent solubility depended 
on the material attributes of the studied MgSt brands, with excipient CRS and PSD 
being the most influential. The complex nature of excipient variability was revealed 
as the effects of excipient properties on drug solubility at 24 hours strongly related to 
drug physicochemical properties (drug ionization, drug lipophilicity, drug aqueous 
solubility) and medium characteristics (pH/presence of bile salts). The use of 
multivariate data analysis and the construction of roadmaps allowed the identification 
of cases where MgSt presence or variability could be challenging for oral absorption. 
This systematic investigation demonstrates the high criticality of MgSt as risks for oral 
product performance and drug absorption could be anticipated when varying MgSt 
properties. 
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Chapter 2 Commentary 
Magnesium stearate (MgSt) is a commonly used lubricant in oral solid dosage forms 
but it can delay drug dissolution as it acts as water repellant. In this chapter, the impact 
of MgSt variability and variation on drug apparent solubility in a biopharmaceutical 
perspective using compendial and biorelevant media was presented. Three MgSt 
brands (MgSt-BDH, Ligamed MF-2-V, Ligamed MF-3-V) of different grades and/or 
suppliers were selected and characterized to identify differences in their critical 
material properties. Differences in excipient crystallinity, particle size distribution 
(PSD) and specific surface area (SSA), that could potentially affect oral drug 
performance, were identified. Presence of MgSt was found to decrease the apparent 
solubility of the majority of compounds due to its hydrophobic nature. The reduction 
in drug solubility at 24 hours by MgSt was more pronounced for highly ionized and/or 
hydrophilic highly soluble drugs, due to the fast saturation of the powder surface with 
MgSt particles. MgSt brands of higher crystallinity or smaller particle size resulted in 
pronounced reduction in drug solubility as well due to their better lubrication 
efficiency. The statistical evaluation revealed that drug physicochemical properties 
(drug ionization, drug lipophilicity, drug aqueous solubility) and excipient critical 
material attributes (crystallinity, PSD) were the most influential factors affecting the 
impact of MgSt on drug apparent solubility. The criticality of MgSt presence and 
variability for oral drug performance was classified with the construction of roadmaps. 
It is concluded that presence of MgSt or changes in MgSt critical material attributes 
can be crucial for oral drug bioavailability and that excipient selection need to be 




Chapter 3 Preface 
Changes in excipient material properties or excipient amount in oral solid dosage 
forms may affect final product quality leading to batch failures or modifying drug 
bioavailability. Hypromellose (HPMC) is a polymeric excipient used as a binder (in 
low levels) or as release controlling agent (in high levels) in oral solid dosage forms. 
The formation of a viscous layer around particles by HPMC presence can delay drug 
release. Numerous studies have demonstrated that changes in the properties of HPMC 
(molecular weight, degree of substitution, substitution pattern, particle size 
distribution, level) can affect drug dissolution and release. Varying HPMC brands in 
pharmaceutical formulations can influence product performance, even in cases where 
the studied brands were considered equivalent. In addition, the ability of HPMC to 
form a viscous layer depends on several gastrointestinal factors, as revealed in Chapter 
1. Understanding therefore the effects of HPMC of varying properties on oral drug 
performance in a systematic approach is beneficial and would facilitate excipient 
implementation in the Quality by Design (QbD) approaches. This chapter focuses in 
examining the biopharmaceutical implications of HPMC variability and variation on 
drug apparent solubility. The use of multivariate data analysis and the construction of 
roadmaps will allow the identification of the potential risks of HPMC presence and 
variability for oral product performance. The results from this chapter will be 
considered as a part for the creation of a data set where excipient presence and 




Chapter 3. Biopharmaceutical understanding of excipient variability on drug 




Identification of the biopharmaceutical risks of excipients and excipient variability on 
oral drug performance can be beneficial for the development of robust oral drug 
formulations. The current study investigated the impact of Hypromellose (HPMC) 
presence and varying viscosity type on the apparent solubility of drugs with wide 
physicochemical properties (drug ionization, drug lipophilicity, drug aqueous 
solubility). The role of gastrointestinal conditions on the impact of excipients on drug 
apparent solubility was assessed with the use of pharmacopoeial (compendial) and 
biorelevant media. Presence of HPMC affected drug apparent solubility according to 
the physicochemical properties of studied compounds. Drug shielding or the formation 
of a viscous layer by the excipient on the powder surface reduced the solubility of 
highly soluble and/or highly ionized compounds and was more pronounced mainly at 
early time points. Increase in the apparent solubility of poorly soluble low ionized 
drugs containing a neutral amine group was observed which may relate to enhanced 
drug solubilization or reduced drug aggregation. The use of multivariate data analysis 
and the design of roadmaps (combining the effects of HPMC on drug solubility at 24 
hours to excipient viscosity and drug physicochemical properties) confirmed the 
importance of drug physicochemical properties on the impact of excipients on drug 
apparent solubility and revealed that changes in the excipient material attributes or 
excipient amount may not be critical for oral drug performance when HPMC is used 
as a binder. 
 






Presence of excipients in oral solid dosage forms is a topic of great interest in terms 
of pharmaceutical Quality by Design (QbD). Further to their intended use, excipients 
may affect the properties and performance of final dosage forms leading to batch 
inconsistencies, altered bioavailability and bioinequivalence of products [1-3]. 
Excipient variability (changes in material properties) and variation (changes in 
amount) constitutes an additional obstacle to robust manufacturing, as changes in 
excipient material properties can undermine the critical quality attributes of the final 
product [4]. Moreover, excipient inertness is questionable as their presence can 
influence oral drug absorption [5, 6]. 
Binders are typically used in solid dosage form manufacturing to promote 
adequate mechanical strength of granules or tablets. Hypromellose, also called 
hydroxypropyl methylcellulose (HPMC), is a polymeric binder used in wet 
granulation [7]. HPMC is a water soluble nonionic cellulosic polymer substituted with 
methoxy and hydroxypropyl groups (Figure 3.1). In addition to its binding properties, 
HPMC is extensively used as a release controlling excipient. This dual functionality 
depends on excipient level (2% w/w – 5% w/w as binder and 10% w/w - 80% w/w as 
release modifier) and viscosity type (high viscosity grades are typically used to control 
drug release) [8]. The effectiveness of HPMC can be influenced by its swelling and 
gelling properties which can delay drug dissolution or release [9, 10]. 
 
Figure 3.1: Chemical structure of Hypromellose (ChemDraw Professional 15.0). 
Molecular properties (molecular weight, degree of substitution, substitution 
pattern), particle properties (particle size distribution) and excipient level have been 
identified as critical material attributes affecting excipient and product performance 
[4]. Molecular weight and excipient level directly relate to the formation of a viscous 
HPMC gel layer. HPMC brands of high molecular weight swell faster and form a 
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thicker viscous layer compared to low molecular weight brands [9, 11, 12]. The 
formation of thick viscous layers when increasing HPMC molecular weight is 
attributed to the slow rate of polymer erosion [9]. Real-time surface dissolution UV 
imaging demonstrated the complex polymeric network formed by high molecular 
weight HPMC brands and the susceptibility of low molecular weight HPMC brands 
to erosion [13]. Due to the proportionality of HPMC molecular weight and viscosity 
of HPMC aqueous solutions, high molecular weight HPMC brands correspond to high 
viscosity HPMC types. The formation and thickness of the gel layer depends also on 
the level of HPMC in solid dosage forms. Increasing the level of HPMC results in a 
concentrated and viscous gel layer either due increased chain entanglement [14] or 
slow polymer erosion rate [15]. A minimum excipient concentration (referred to as 
excipient percolation threshold) under which HPMC cannot form an effective viscous 
layer able to control drug release was reported [16]. The percolation thresholds of 
different viscosity type HPMC brands were similar (20% v/v corresponding to 20% 
w/w) and showed consistent controlled drug release (verapamil HCl, USP 2 apparatus, 
50 rpm, 900 mL, phosphate buffer pH 7.5) from extended release tablets containing 
HPMC [16]. Use of confocal laser scanning microscopy revealed that the early gel 
layer formation depends on the level of HPMC. Hydrophilic matrices containing 5% 
w/w and 10% w/w of HPMC, formed a thin and heterogeneous gel layer initially (5 – 
15 min), which could not be maintained due to the increased water uptake accelerating 
polymer erosion [17].  
Several biopharmaceutical factors affecting the impact of HPMC on product 
performance have been identified. The impact of the viscous HPMC gel layer on drug 
release relates to drug characteristics. Highly soluble drugs are released by diffusion 
through the matrix while poorly soluble drugs by erosion of the matrix [9]. The 
performance of HPMC depends on the composition and properties of the dissolution 
medium. Salts [18], sugars [19] and food components [20] interact with the polymeric 
chains of HPMC and affect the formation of the gel layer. Detailed representation of 
the impact of the aforementioned factors on the excipient performance were provided 
in Chapter 1. Moreover, bile salts were found to affect the thermal transition (gel 
formation) of cellulosic polymers. The hydrophobic parts of bile salts adsorb onto the 
hydrophobic regions of polymers and increase the excipient transition temperature 
upon heating [21, 22]. The pH of the dissolution medium can also affect the 
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swelling/gelling properties of HPMC due to changes in the transport behaviour of 
water into the polymer, despite the non-ionic nature of HPMC. Rapid polymer 
hydration and larger excipient swelling was observed in media of basic (24% increase 
in polymer diameter after 200 min at pH = 6) compared to acidic pH (15% increase in 
polymer diameter after 200 min at pH = 2). The authors highlighted the 
biopharmaceutical consequence of this polymeric response as faster drug release 
should be expected in the acidic gastric compared to the basic intestinal compartment 
[23]. 
The aim of this study was to assess the biopharmaceutical impact and criticality of 
HPMC variability and variation (when used as a binder in immediate release 
formulations) on drug apparent solubility. HPMC variability and variation were 
addressed by selecting three HPMC brands of different viscosity type using two 
different excipient levels (low: 2% w/w, high: 5% w/w). The biopharmaceutical 
implications of HPMC variability on drug apparent solubility were examined by 
choosing compounds of a wide range of physicochemical properties (drug ionization, 
drug lipophilicity, drug aqueous solubility) and media (compendial and biorelevant) 
simulating the gastrointestinal conditions. Multivariate data analysis (Partial Least 
Squares (PLS)) and roadmaps were used to identify the critical role of certain variables 
(drug properties, excipient presence, medium characteristics) on the impact of HPMC 
on drug apparent solubility. 
3.2. Materials and Methods 
3.2.1. Materials 
APIs: Sulfamethoxazole and paracetamol were obtained from Fisher Scientific 
(UK). Furosemide, itraconazole and dipyridamole were obtained from VWR (UK). 
Ibuprofen, carbamazepine and metformin were obtained from Fagron (UK). 
Excipients: HPMC-Sigma was obtained from Sigma Aldrich (UK). Pharmacoat 606 
and Pharmacoat 615 were obtained from Shinetsu (Japan). Chemicals: Acetic acid 
(>99.7%), hydrochloric acid 36.5–38%, HPLC grade methanol, HPLC grade 
acetonitrile, dichloromethane, pepsin (from porcine) were obtained from Sigma-
Aldrich (UK). Maleic acid, sodium chloride, sodium hydroxide, potassium phosphate 
monobasic, sodium dihydrogen orthophosphate dihydrate, disodium hydrogen 
orthophosphate dihydrate, potassium dihydrogen orthophosphate, anhydrous sodium 
sulfate, HPLC grade trifluoroacetic acid were obtained from Fisher Scientific (UK). 
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Sodium taurocholate (Prodotti Chimici Alimentari S.P.A., Italy), egg lecithin – Lipoid 
EPCS (Lipoid GmbH, Germany), were obtained from the sources specified. Water 
was ultra-pure (Milli-Q) laboratory grade. Filters: Whatman® 13 mm cellulose nitrate 
filters 0.45 μm pore size and polytetrafluoroethylene (PTFE) 13 mm filter 0.45 μm 
pore size were purchased from Fisher Scientific (UK). 
3.2.2. Instrumentation 
Fisherbrand waterbath (Fisher Scientific, UK), Sartorius BP 210 D balance 
(Sartorius Ltd, UK), Buchi R114 Rotavapor (Buchi, Switzerland), Mettler Toledo 
SevenCompact S210 pH meter (Mettler Toledo, Switzerland), Vortex-Genie 2 vortex 
mixer (Scientific Industries Inc, USA), Agilent Technologies 1100 series HPLC 
system, (quaternary pump (G1311A), autosampler (G1313A), thermostatted column 
compartment (G1316A), diode array detector (G1329A) and Chemstation software 
(Agilent Technologies, USA) 
3.2.3. Methods 
3.2.3.1. Compounds selected for solubility experiments 
The compounds used for the solubility experiments and their physicochemical 
properties (drug ionization, drug lipophilicity, drug aqueous solubility) were presented 
in Table 3.1. 
Table 3.1: Physicochemical properties and structure of the compounds used for the 
solubility experiments. (ChemDraw Professional 15) 




























































5.66a Low [34] 
*Experimental values 
aSource: DrugBank 
3.2.3.2. Media prepared for solubility experiments 
Compendial media (0.1 N HCl pH 1, phosphate buffer pH 6.8) were prepared 
according to the method described in the United States Pharmacopeia [35]. Fasted 
State Simulated Gastric Fluid (FaSSGF) and Fasted State Simulated Intestinal Fluid 
(FaSSIF-V2) were prepared as per literature references [36]. 
3.2.3.3. Design of Experiments (DoE) used for solubility experiments 
A full-factorial Design of Experiments (DoE) was performed to determine the 
number of necessary experiments using StatGraphics Centurion XVII (Statpoint 
Technologies Inc, USA). As drug solubility will differ according to the composition 
of the studied media (pH, presence of bile salts), two models for the DoE were 
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constructed to discriminate between the effects of excipients on drug apparent 
solubility in compendial (Model 1) and biorelevant conditions (Model 2). The 
examined factors were: i. compound (Table 3.1), ii. excipient brand (Pharmacoat 606, 
Pharmacoat 615, HPMC-Sigma), iii. excipient level (low, high), iv. medium (gastric, 
intestinal). The impact of each excipient on drug apparent solubility [expressed as the 
relative increase or decrease in drug solubility in presence compared to absence of 
excipient (Section 3.2.3.5)] was set as the response. A total of 96x3 experiments was 
determined for each model. 16x3 additional experiments for each model were 
conducted to determine drug apparent solubility in the corresponding media in the 
absence of excipient. These experiments were not included in the DoE as drug 
solubility in excipient absence was measured only for the calculation of relative 
excipient effects on drug solubility. 
3.2.3.4. Solubility studies 
Drug solubility studies in the absence and presence of excipient were performed 
in triplicate using the shake-flask method [37]. Drug excess and 2% w/w or 5% w/w 
of each excipient were weighed and placed in centrifuge tubes. The amount of 
excipient was determined as follows: i. for poorly soluble drugs, considering an 
average of 500 mg tablet weight [38] (which resulted in 9% w/w (low level) and 20% 
w/w (high level) of excipient in the total volume of the physical mixture) and ii. for 
highly soluble drugs, according to the amount of drug excess and the relative ratio of 
drug-excipient based on point (i). The physical mixtures were vortexed for 3 minutes. 
5 mL of each medium were added in the tubes and the samples were placed in a 
shaking water bath (37 °C, 200 strokes per minute (spm)). At 0.5, 4 and 24 hours (for 
PRC, SMX, CBZ, DPL, IBU) and 24 hours (for MTF, FRS, ITZ), 500 μL were 
sampled and filtered through PTFE filters (or cellulose nitrate filters for the cases of 
IBU and CBZ). Filter adsorption studies were prior performed in triplicate for each 
drug. No adsorption issues onto the filters used were observed for the studied drugs. 
Filtered samples were further diluted (if needed) with the corresponding medium and 
analysed by HPLC (Table 3.2). Analytical procedures for drug quantification in the 
samples were modifications of already published methods. Drug quantification was 
made based on calibration curves. Standards were formulated from concentrated stock 
solutions consisting of drug dissolved in MeOH. As changes in the pH of solutions by 
presence of dissolved drug [31] may affect drug solubility, the pH of samples after the 
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completion of each experiment was measured. Drug apparent solubility was calculated 
based on the sample drug concentration measured. Solubility values measured 
experimentally in excipient absence for neutral drugs, for weak acids in acidic media 
and for weak bases in basic media determined the intrinsic solubility values. Solubility 
values measured experimentally in excipient absence in basic media (for weak acids) 













































































3.2.3.5. Treatment of in vitro solubility data 
The Relative Effect (RE) of each excipient on drug apparent solubility was 
calculated based on equation 3.1: 
𝑅𝐸 =  
(𝑆−𝑆𝑟)
𝑆𝑟
 𝑥 100 (Equation 3.1) 
where 𝑆 and 𝑆𝑟 denote drug solubility in presence and absence (reference solubility) 
of excipient at 0.5, 4 and 24 hours. REs of excipients on drug apparent solubility > 
25% or < -20% were considered as significant change in drug apparent solubility to 
assess excipient criticality (this range was selected as a similar range is set in order to 
assess differences in drug exposure after oral administration; i.e. in bioequivalence 
studies) [47]. 
Box plots depicting the impact of excipients on drug solubility at 24 hours for 
all the studied compounds or as a function of time (0.5, 4 and 24 hours) for CBZ and 
DPL were constructed using Spotfire 7.10.1 (TIBCO software Inc, USA). The 
classification gradient maps portraying the impact of the studied brands on drug 
solubility at 24 hours as a function of drug aqueous solubility were generated using 
SigmaPlot 13.0 (Systat Software Inc, USA). For the construction of 3D mesh plots 
depicting the impact of excipients on drug apparent solubility as a function of time 
and drug ionization, solubility data for PRC, SMX, IBU, DPL were smoothed via the 
negative exponential technique to allow better visualization using SigmaPlot 13.0 
(Systat Software Inc, USA). 
In cases where drug intrinsic solubility was not determined experimentally, the 
theoretical intrinsic solubility was calculated using the solubility-pH equations 
(Equations 3.2-3.5) [48]:  
log 𝑆 = log 𝑆𝑜 + log(10
−𝑝𝐾𝑎+𝑝𝐻 +1)  for weak acids (Equation 3.2) 
log 𝑆 = log 𝑆𝑜 + log(10
𝑝𝐾𝑎−𝑝𝐻 +1)   for weak bases (Equation 3.3) 
log 𝑆 = log 𝑆𝑜 + log(10
+𝑝𝐾𝑎2+ 𝑝𝐾𝑎1−2𝑝𝐻 + 10𝑝𝐾𝑎2−𝑝𝐻 + 1) for diprotic bases 
(Equation 3.4) 
log 𝑆 = log 𝑆𝑜 + log(10




where 𝑆 and 𝑆𝑜 indicate drug solubility at the given pH and the intrinsic 
solubility, respectively. The final pH and experimental solubility values of the ionized 
drug in basic (for weak acids) or acidic media (for weak bases) were used for the 
calculation of the theoretical intrinsic solubility. Theoretical pH-solubility profiles in 
the physiological pH range were constructed to assess if changes in the pH of the 
medium could justify differences in drug apparent solubility by excipient presence. 
The final pH and intrinsic solubility values (experimental or theoretical) were used for 
the construction of the theoretical pH – solubility profiles in the physiological pH 
range based on Equations 3.2 -3.5. 
3.2.3.6. Multivariate Analysis of solubility data 
Excipient REs on drug apparent solubility were correlated to drug 
physicochemical properties (drug ionization, drug lipophilicity, drug aqueous 
solubility), excipient critical material attributes (viscosity, level) and medium 
characteristics (gastric, intestinal) by partial least squares (PLS) regression using the 
XLSTAT software (Microsoft, USA). Two models for the REs of excipients on drug 
solubility in compendial media (Model 1) and biorelevant media (Model 2) were 
constructed. The evaluated variables for both models were categorized according to 
their type as categorical (expressing a category or type) and numerical (measurements 
with numerical meaning). Categorical variables included: i. drug solubility (poor, 
high), ii. amine group (absence, presence), iii. excipient level (low, high), iv. medium 
(gastric, intestinal) while numerical parameters included: i. % of drug ionized (Fion; 
calculated based on the Henderson – Hasselbalch equation at the pH of each medium), 
ii. drug lipophilicity (log P), iii. excipient viscosity (cP). Excipient REs on drug 
solubility at 24 hours were used as the response. The selected interaction terms 
included each excipient property combined with each drug physicochemical property 
(drug ionization, drug lipophilicity, drug aqueous solubility) and medium 
characteristics (gastric, intestinal). Observation diagnostics were performed prior to 
model analysis to identify outliers in the data set. The distance of each observation to 
the model in the Y-plane (DmodY) tool based on PLS residuals was used. Plots of 
standardized DmodY vs each observation were generated and any observation 
exceeding the maximum tolerance volume in Y (Dcrit(Y)) was considered an outlier [49, 
50]. Exclusion of outliers was based on: i. deviating cases (positive REs) in solubility 
caused by a shift in the pH of the solution, ii. observations resulting in high variability 
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(coefficient of variation (CV%) > 20%) within the triplicate samples (one value from 
the triplicate could be excluded as the outlier analysis could detect these values). PLS 
models generated with and without outlier exclusion (data not shown) confirmed that 
outlier exclusion did not alter the interpretation of results but only enhanced the 
predictive ability of the regression model. The generated models were assessed in 
terms of goodness of fit (R2) and goodness of prediction (Q2). High values of R2 and 
Q2 with a difference not greater than 0.2 - 0.3 were indications of successful models 
[51]. The number of PLS components (lines on the X-space which best approximate 
and correlate with the Y-vector) was based on minimum predictive residual sum of 
squares (PRESS) [51]. From the available components the one at which Q2 reached its 
maximum value was selected [49]. Standardized coefficients were used to show the 
direction (positive or negative) and extent of each variable on the response. The 
significance of the variables was assessed by the variable influence on projection 
(VIP) value. VIP values > 0.8 were considered as moderately influential in the model 
while VIP values > 1 were considered the most influential in the model [51]. A 95 % 
confidence interval was used. 
3.2.3.7. Roadmap Design 
A roadmap design for identifying potential biopharmaceutical risks of HPMC 
variability on drug apparent solubility was constructed by combining the impact of 
excipients on drug solubility at 24 hours from the solubility studies to excipient 
(viscosity) and drug (drug ionization, drug lipophilicity, drug aqueous solubility) 
physicochemical properties. Drug were categorized according to drug aqueous 
solubility and drug lipophilicity (Table 3.1) and drug ionization (low ionized: F(ion) < 
50%, highly ionized: F(ion) > 50%). The risk assessment of the impact of excipients on 
drug apparent solubility was evaluated by setting reference range criteria of -20% - 
25% [47] on the REs of excipient on drug solubility at 24 hours. REs of excipients on 
drug solubility outside these values (REs < -20% or REs > 25%) were considered 
critical for oral drug performance. 
3.3. Results and Discussion 
3.3.1. Properties of HPMC 
Based on product specifications and certificates of analysis, differences in terms 
of viscosity (cP) for the studied HPMC brands were identified. Pharmacoat 606 (6 cP) 
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and Pharmacoat 615 (15 cP) are low viscosity brands compared to HPMC-Sigma 
(3500 – 5600 cP). The studied polymers belong to the same category of substitution 
type 2910 (28% – 30% of methoxy and 7% - 12% hydroxypropoxyl content). 
3.3.2. Solubility studies 
3.3.2.1. Impact of the studied HPMC brands on drug apparent solubility 
The reference solubility values of the studied compounds at 24 hours in 
compendial and biorelevant media are summarized in Table 3.3. For neutral drugs, 
the reference solubility did not depend on the pH of the studied media (as expected) 
but on the presence of solubilizing components, as increased reference solubilities 
were observed in biorelevant compared to compendial media due to the presence of 
bile salts [52]. Different reference solubility values within acidic and basic media were 
observed for weak acids (SMX, FRS, IBU) and weak bases (DPL, ITZ) due to their 
ionization pattern, except from the case of MTF as drug was fully ionized in all the 
studied conditions [24]. SMX was ionized in both acidic and basic media due to its 
two pKa constants, as explained in Chapter 2. The impact of bile salts on drug 
solubility was demonstrated for weak acids/weak bases in media where drugs were 
unionized (higher solubility values in biorelevant compared to compendial media) 
[52]. For weak acids/weak bases (except from the case of MTF) in media where drug 
are highly ionized, drug solubility values were higher in compendial (0.1 N HCl pH 
1, phosphate buffer pH 6.8) compared to biorelevant media (FaSSGF pH 1.6, FaSSIF-




Table 3.3: Reference solubility values (μg/mL) of the studied drugs at 24 hours in 
compendial and biorelevant media. (Mean ± SD, n = 3) 
 Compendial Media  Biorelevant Media 
Drug 0.1 N HCl 
pH 1 
Phosphate 
buffer pH 6.8 
 FaSSGF FaSSIF-V2 
























































ITZ 11  
(±1) 




*below limit of detection of the analytical method 
The effects of the HPMC brands on the apparent solubility of the studied 
compounds in compendial and biorelevant media are presented in Figures 3.2 and 3.3, 
respectively. 
Neutral drugs: Cases of significant decrease in drug solubility at 24 hours by the 
studied HPMC brands were observed for PRC (Pharmacoat 606: -36% < REs < -20%, 
Pharmacoat 615: -32% < REs < -22%, HPMC-Sigma: -30% < REs < -22%). 
Differences in the apparent solubility of neutral drugs in HPMC presence cannot be 
attributed to the minor changes in the pH of the media (Figures 3.4). The pronounced 
reduction in drug solubility by HPMC at 24 hours is attributed to the slow drug 
dissolution and/or drug solubilization as excipients with slow dissolution rate may 
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shield drug particles from the dissolution medium [54] or the formation of a viscous 
excipient layer on the powder surface [55]. Significant increase in drug apparent 
solubility by the studied HPMC brands was observed for CBZ in compendial media 
(Pharmacoat 606: 32% < REs < 50%, Pharmacoat 615: 28% < REs < 33%, HPMC-
Sigma: 50% < REs < 60%) and in FaSSIF-V2 (REs of approximately 60% for all the 
studied brands). Solubility data of CBZ at 0.5, 4 and 24 hours in absence and presence 
of the studied HPMC brands in compendial and biorelevant media are presented in 
Figure 3.5. The solubility of pure CBZ decreased through time in compendial media 
(350 μg/mL and 250 μg/mL at 0.5 hours and 24 hours, respectively), potentially due 
to drug aggregation [56] or due to the solution mediated phase transformation of CBZ 
from the anhydrate to the dihydrate form [57]. The decrease in CBZ solubility was 
slower in biorelevant media (FaSSGF: 387 μg/mL to 367 μg/mL at 0.5 hours and 24 
hours, respectively, FaSSIF-V2: 307 μg/mL to 280 μg/mL at 0.5 hours and 24 hours, 
respectively). Reduction in CBZ apparent solubility is not observed in presence of 
HPMC, as potentially dissolved polymer particles may enhance drug solubilization 
and delay drug aggregation [58]. Inhibition of the CBZ solution mediated phase 
transformation by hydrogen bonding [59] or by excipient adsorption in the formed 
nuclei/crystals delaying the rate of nucleation and crystal growth [57] could also 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Weak acids: Significant reduction is observed in weak acidic compound solubility 
at 24 hours, especially in basic conditions (Pharmacoat 606: -65% < REs < -20%, 
Pharmacoat 615: -40% < REs < -20%, HPMC-Sigma: -80% < REs < -20%). The 
studied HPMC brands, also significantly decreased SMX solubility in 0.1 N HCl pH 
1 (-50% < REs < -30%) at 24 hours (Figures 3.2 and 3.3). In the cases of significant 
reduction in drug apparent solubility by HPMC presence, small changes in the pH of 
acidic media occurred in absence or presence of excipient (± 0.1 pH units) while the 
pH of basic media in absence or presence of excipient decreased (0.2 – 0.7 pH units) 
(potentially due to the dissociation of weak acids). The experimental solubility values 
in excipient presence at 24 hours were lower compared to theoretical ones (expected 
by the change in the pH of the media) (Figure 3.4). As the pronounced reduction in 
drug apparent solubility by HPMC cannot be explained by the shift in the pH of the 
media, it is attributed to the delay in drug dissolution and/or drug solubilization, as 
explained previously in the case of neutral drugs. Significant increase in drug 
solubility at 24 hours was only observed for FRS in presence of both levels of HPMC-
Sigma in phosphate buffer pH 6.8 (REs of 53% and 41% for the low and high level, 
respectively). Differences in the pH of the medium in presence (reduction of 0.3 pH 
units) and absence of excipient (reduction of 0.2 pH units) were observed. Evaluation 
of the theoretical pH-solubility profile reveals that drug solubility in absence of 
excipient does not correspond to the theoretical drug solubility (expected according to 
the change in the pH of the medium). In presence of HPMC-Sigma, the experimental 
and theoretical solubility values are similar, therefore the increase in drug solubility at 
24 hours in presence of HPMC-Sigma is attributed to the change of the pH of the 
medium and not to a potential drug-excipient interaction (further investigations are 
needed to explain the nature of this change, as shifts in the pH of the media by the 
non-ionic HPMC are not expected). 
 
Weak bases: For the majority of cases, significant reduction is observed in weak 
basic compound solubility at 24 hours by HPMC presence (-50% < REs < -20% for 
all the studied HPMC brands), especially in acidic conditions (Figures 3.2 and 3.3). 
The impact of pH on the apparent solubility of weak bases cannot be evaluated due to 
in situ salt formation between the drugs and counterions of the medium [60] (Figure 
3.4), as explained in Chapter 2. The reduction in drug solubility in HPMC presence at 
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24 hours can be attributed to the slower drug dissolution/solubilization in excipient 
presence compared to absence. Significant increase in drug apparent solubility was 
observed for DPL in phosphate buffer pH 6.8 (38% < REs < 58%) and ITZ in FaSSIF-
V2 (25% < REs < 61%) in presence of all the studied HPMC brands. Solubility data 
of DPL at 0.5, 4 and 24 hours in absence and presence of HPMC in phosphate buffer 
pH 6.8 and FaSSIF-V2 are presented in Figure 3.6. In phosphate buffer pH 6.8, 
increased DPL solubility in presence of HPMC is observed even at early time points 
(0.5 and 4 hours) and can be attributed to intermolecular interactions between the 
amine group of DPL and the hydroxyl group of HPMC which improve drug 
solubilization [61]. Presence of HPMC did not affected the DPL solubility in FaSSIF-
V2 potentially due to the enhanced drug solubilization by the bile salts. ITZ forms a 
supersaturated solution in FaSSIF-V2 due to the micellar solubilization effect of bile 
salts and slowly precipitates with time [62]. The increase in ITZ apparent solubility in 
HPMC presence in FaSSIF-V2 can be attributed to the inhibition of drug precipitation 
by HPMC due to potential interaction of the neutral amine group of ITZ with the 
hydroxyl groups of HPMC. 
The solubility data showed increased variability in the cases where HPMC 
presence significantly affected drug solubility at 24 hours (MTF: CV% > 40%, PRC 
or highly ionized poorly soluble drugs: 10% < CV% < 30%). As working with physical 
mixtures may yield high standard deviations due to the heterogeneous dispersion of 
the constituents [63, 64], the increased variability can be attributed to the 



















































































































































































































3.3.2.2. Impact of excipients on drug apparent solubility based on drug 
physicochemical properties 
The effects of the studied HPMC brands on the solubility of neutral drugs, weak 
acids and weak bases at 24 hours as a function of drug ionization and drug lipophilicity 
in compendial and biorelevant media are presented in Figure 3.7. 
 
Figure 3.7: Relative effects (%) of the studied HPMC brands on drug solubility at 24 
hours as a function of drug ionization (%) and drug lipophilicity (log P) in a. 
compendial and b. biorelevant media. The excipients brands are shown as: i. 
Pharmacoat 606 (green colour), ii. Pharmacoat 615 (blue colour), iii. HPMC-Sigma 
(red colour). Light and dark colours correspond to low and high excipient levels, 
respectively. Media representing gastric and intestinal conditions are presented as: i. 
acidic media (circles) and ii. basic media (squares). 
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For neutral drugs, the different effects of the HPMC brands on drug solubility 
at 24 hours (decrease and increase for the solubility values of PRC and CBZ, 
respectively) are attributed to the differences in drug lipophilicity between the two 
compounds (Table 3.1). For weak acids and weak bases, significant decrease in drug 
apparent solubility was observed in media (compendial or biorelevant) where drugs 
are highly ionized (excluding the cases of increased drug solubility attributed to the 
change of the pH of the medium). A trend between the impact of excipients on drug 
solubility at 24 hours and drug lipophilicity was found for weak bases in biorelevant 
media where drugs are unionized, as increased drug solubility was observed in HPMC 
presence for highly lipophilic drugs. The decrease in drug apparent solubility by 
HPMC presence was more pronounced with increasing level of drug ionization and/or 
decreasing drug lipophilicity (Figure 3.7) which can be explained by the presence of 
an increased number of excipient molecules on the powder surface [54, 65] (as 
explained in Chapter 2). Reduced drug mobility and slower drug diffusion have been 
reported for charged molecules due to interactions with the polymeric chains of HPMC 
[55] and may also have contributed to the decrease in the solubility of ionized 
molecules at 24 hours by HPMC. The classification gradient map depicting the effects 
of the studied HPMC brands on the 24 hour drug solubility as a function of decreasing 
drug aqueous solubility in compendial and biorelevant media is presented in Figure 
3.8. The map confirms that the decrease in drug apparent solubility in presence of 
HPMC was more pronounced for highly soluble drugs which are inherently less 
lipophilic while for poorly soluble drugs, the reduction in drug solubility at 24 hours 



















































































































































































































































3.3.2.3. Impact of excipients on drug apparent solubility based on 
excipient properties 
The effects of the studied HPMC brands on drug solubility as a function of drug 
ionization and time are presented in Figure 3.9 (solubility data of CBZ in compendial 
and biorelevant media and of DPL in phosphate buffer pH 6.8 were not included in 
this visualization, as significant increase in drug solubility was observed). 
 
Figure 3.9: Relative effects of i. Pharmacoat 606 (green colour), ii. Pharmacoat 615 
(blue colour) and iii. HPMC-Sigma (red colour) on drug apparent solubility as a 
function of drug ionization (%) and time (h). Light and dark colours correspond to low 
and high excipient level, respectively. 
 
The decrease in drug apparent solubility by HPMC presence was more pronounced 
at early time points. When HPMC is used at low levels (< 10% w/w) in tablet 
formulations, a heterogeneous viscous HPMC layer is formed initially and cannot be 
maintained due to water penetration [17]. Therefore, the higher reduction in drug 
solubility at early compared to late time points may be explained by the disruption of 
the gel layer by water molecules. The high viscosity brand (HPMC-Sigma) resulted in 
higher reduction in drug solubility at early time points compared to the low viscosity 
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brands (Pharmacoat 606, Pharmacoat 615) which can be explained by the formation 
of a stronger gel layer by the high HPMC viscosity types compared to the low ones 
[9, 11, 12]. Increasing the level of all the studied HPMC brands resulted in higher 
reduction in drug apparent solubility compared to the low excipient level, as the 
increased number of chain entanglements, when increasing excipient level, leads to 
the formation of strong gel layer [14] which further delays drug dissolution and/or 
drug solubilization. 
3.3.3. Multivariate Data Analysis 
The standardized coefficients of the variables in compendial and biorelevant media 
are presented in Figure 3.10. The two models showed a good predictive power and fit 
(compendial media: Q2 = 0.7 and R2 = 0.7, biorelevant media: Q2 = 0.6 and R2 = 0.6). 
The statistical analysis reveals that the impact of HPMC on drug apparent solubility 
strongly depends on the physicochemical properties of the studied brands. Amine 
group (compendial media: positive effect, VIP = 3.2; biorelevant media: positive 
effect, VIP = 2.9) was a significant variable in both models. The variable amine group 
term indicates that pronounced increase in drug solubility at 24 hours in HPMC 
presence is expected for drugs containing a neutral amine group due to a potential 
drug-HPMC interaction which enhances drug solubilization. Pronounced reduction in 
drug apparent solubility is anticipated for highly ionized drugs, potentially due to the 
slower drug mobility and diffusivity by the presence of the viscous HPMC layer [55] 
as indicating by the significance of drug ionization (compendial media: negative 
effect, VIP = 2.2; biorelevant media: negative effect, VIP = 2.3) in both models. In 
biorelevant media, drug lipophilicity (positive effect, VIP = 1.3) and drug solubility 
(negative effect, VIP = 1.2) were also significant variables in the statistical models. 
Both variables indicate that pronounced reduction is expected for highly soluble/less 
lipophilic drugs as the enhanced drug solubilization caused by the presence of bile 
salts can result in saturation of the powder surface by HPMC particles. The statistical 
analysis demonstrates that, when HPMC is used as a binder, excipient variability and 





















































































































































3.3.4. Road map of excipient effects on drug apparent solubility 
The road map categorizing the excipient REs on drug solubility at 24 hours 
according to excipient (HPMC) and drug properties is presented in Figure 3.11 (cases 
where increased drug solubility was caused by a potential shift in the pH of the 
medium were not considered). 
 
Figure 3.11: Road map of the effects of the studied excipients (low viscosity: 
Pharmacoat 606, Pharmacoat 615, high viscosity: HPMC-Sigma) on drug solubility at 
24 hours. Red boxes and green boxes indicate significant and insignificant changes in 
drug solubility by excipient presence, respectively. 
 
The impact of HPMC on drug apparent solubility depends on the physicochemical 
properties of the studied compounds. Significant changes (decrease) in drug solubility 
at 24 hours by HPMC brands of different viscosity type are anticipated for highly 
soluble drugs, irrespective of drug ionization state (low or highly ionized). For poorly 
soluble drugs, the impact of the studied HPMC brands on drug apparent solubility 
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depends on the drug ionization state, as significant decrease in drug solubility at 24 
hours is expected when poorly soluble drugs are highly ionized (irrespective of drug 
lipophilicity). For poorly soluble/low ionized, HPMC is not found to affect drug 
solubility, apart from drugs containing a neutral amine group and for which presence 
of HPMC may result in significant increase in drug apparent solubility. The generated 
roadmap reveals that presence of HPMC may be challenging for oral drug 
performance, as differences in drug apparent solubility caused by the excipient may 
complicate oral drug absorption and bioavailability. 
3.4. Conclusions 
Excipient presence, variability and variation can affect product performance and 
present challenges for oral drug bioavailability. HPMC is a commonly used binder in 
immediate release formulations but can compromise drug dissolution as it forms a 
viscous layer around particles. In this work, the impact of HPMC viscosity type on 
drug apparent solubility was assessed in a biopharmaceutical perspective. Solubility 
studies showed that presence of HPMC can significantly change drug solubility at 24 
hours, but its magnitude depends on drug physicochemical properties. Significant 
reduction in the apparent solubility of highly soluble or highly ionized drugs was 
observed potentially due to the formation of a viscous layer by HPMC. For poorly 
soluble drugs containing a neutral amine group, increase in drug apparent solubility 
was observed in HPMC presence attributed to the enhanced drug solubilization by the 
polymeric HPMC chains. Increasing HPMC viscosity and/or level resulted in 
pronounced decrease in drug solubility especially at early time points, as at the studied 
excipient levels, the formation of a viscous layer is disrupted by water penetration. 
The use of multivariate data analysis and the construction of roadmaps identified the 
cases where HPMC presence may be challenging for oral drug performance. 
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Chapter 3 Commentary 
Hypromellose (HPMC) is a commonly used binder or release controlling agent, when 
used in low and high levels, respectively in oral solid dosage forms. In this chapter, 
the impact of HPMC variability and variation on drug apparent solubility in a 
biopharmaceutical perspective was investigated by selecting three brands of HPMC of 
different viscosity type (Pharmacoat 606, Pharmacoat 615, HPMC-Sigma) in two 
different excipient levels. Compendial and biorelevant media were used to reflect the 
gastrointestinal conditions. For the majority of compounds, presence of HPMC 
decreased drug solubility at 24 hours and was attributed to a drug shielding effect by 
the excipient or the formation of viscous layer. The reduction in drug apparent 
solubility by HPMC was more pronounced for highly ionized and/or highly soluble 
less lipophilic drugs, due to the fast saturation of the powder surface by excipient 
particles. The reduction in drug solubility by HPMC was more pronounced at early 
time points, as at the studied excipient amounts, the initial HPMC viscous layer cannot 
be maintained due to water penetration. Increasing HPMC viscosity or level resulted 
in higher reduction in drug apparent solubility, especially at early time points, as a 
result of the formation of thicker viscous layer delaying drug dissolution from the 
powder surface. Presence of HPMC increased the apparent solubility of poorly soluble 
drugs containing a neutral amine group, as a result of enhanced drug solubilization or 
a drug-excipient interaction delaying drug precipitation. The statistical analysis and 
the contruction of the roadmap revealed that, when HPMC is used as a binder, drug 
physicochemical properties, rather than excipient properties, are the critical factors 




Chapter 4 Preface 
Pharmaceutical Quality by Design (QbD) requires the sound understanding and 
control of excipient variability to assure product safety and efficacy. 
Superdisintegrants are polymeric excipients which provide fast tablet disintegration 
and improve drug dissolution in immediate release formulations. Sodium starch 
glycolate (SSG), croscarmellose sodium (CCS) and crospovidone (CPV) are the most 
frequently used superdisintegrants due to their ability to absorb water through swelling 
(SSG, CCS) or shape recovery (CPV) within seconds. The critical material properties 
and the biopharmaceutical factors affecting the impact of superdisintegrants on oral 
product performance are not well documented. Superdisintegrant interchangeability is 
also questionable as changes in tablet disintegrations and/or drug dissolution have 
been reported despite the use of structurally similar excipients (SSG, CCS). It follows 
that designing in vitro biorelevant methods to gain an indepth knowledge of the 
superdisintegrant effects on oral drug performance is crucial and would pave the way 
towards excipient implementation in the QbD approach. The aim of this chapter is to 
investigate the impact of superdisintegrant presence and variability on drug apparent 
solubility in a biopharmaceutical perspective. The use of multivariate data analysis 
and the construction of roadmaps will allow the identification of cases where 
superdisintegrants can be challenging for oral drug absorption. The results from this 
study, in conjuction with data presented in Chapter 2 and 3, form a broad data set 






Chapter 4. Biopharmaceutical understanding of excipient variability on drug 




The presence of different excipient types/brands in solid oral dosage forms may affect 
product performance and drug bioavailability. Understanding the biopharmaceutical 
risks of excipients on oral drug performance is crucial for the development of products 
with robust in vivo performance. The current study investigated the impact of 
superdisintegrants (sodium starch glycolate (SSG), croscarmellose sodium (CCS), 
crospovidone (CPV)) on the apparent solubility of drugs with different 
physicochemical properties (drug ionization, drug lipophilicity, drug aqueous 
solubility). Compendial and biorelevant media were used to assess the impact of 
gastrointestinal (GI) conditions on the effects of excipients on drug apparent solubility. 
For the majority of compounds, changes in drug apparent solubility in 
superdisintegrant presence were not observed, apart from the cases of highly ionized 
drugs (significant reduction in drug solubility) and/or drugs that aggregate/precipitate 
in solution (significant increase in drug solubility). Excipient variability did not greatly 
affect the impact of excipients on drug solubility. The use of multivariate data analysis 
identified the biopharmaceutical factors affecting excipient performance. Based on 
drug solubility data, the construction of roadmaps revealed that superdisintegrants 
may be of low risk for the impact of excipients on oral drug performance 
(superdisintegrant effectiveness in oral solid dosage forms could still be of high risk 
for oral bioavailability). 
 
Keywords: excipient variability, sodium starch glycolate, croscarmellose sodium, 





Introduction of the Quality by Design (QbD) initiative in pharmaceutical 
development requires the scientific understanding of the components and processes 
affecting final product qualities [1]. The critical role of excipients in product 
performance and oral bioavailability is highlighted as presence of excipients in oral 
formulations may affect the biopharmaceutical profile of drugs with potential 
implications on drug absorption [2, 3]. Excipient variability or variation and the use 
of different excipients with the same intended functionality may further complicate 
the impact of excipients on oral drug bioavailability [4]. The heterogeneous 
composition of the gastrointestinal tract may as well modify the properties and 
functionality of excipients and presents an additional challenge to assess the impact of 
excipients on product performance [4]. 
Superdisintegrants are commonly used in immediate release formulations as they 
promote fast tablet disintegration and improve drug dissolution. Sodium starch 
glycolate (SSG), croscarmellose sodium (CCS) and crospovidone (CPV) are three 
commonly used crosslinked superdisintegrants due to their ability to absorb water 
and/or swell in low concentrations (typically 2% - 8% for SSG [5], 0.5% - 5% for CCS 
[6] and 2% - 5% w/w for CPV [7] in tablet formulations [8]. SSG (Figure 4.1a) and 
CCS (Figure 4.1b) are sodium salts and their ionization state differs between acidic 
(neutral form) and basic (ionized form) conditions, while CPV is a non-ionic polymer 
(Figure 4.1c). Swelling and shape recovery are the main suggested mechanisms by 
which superdisintegrants induce tablet disintegration. Swelling refers to the 
volumetric expansion of excipient particles due to water absorption while shape 
recovery refers to excipient deformation upon contact with water [9]. Real-time 
magnetic resonance imaging identified that SSG and CCS act through swelling while 
CPV through shape recovery [10]. The limited knowledge on superdisintegrant 
molecular structure, interplay with other pharmaceutical components and performance 
in the gastrointestinal conditions is challenging for manufacturers [9]. 
Superdisintegrant interchangeability could be questioned without appropriate 




Figure 4.1: Chemical structure of a. Sodium Starch Glycolate, b. Croscarmellose 
Sodium and c. Crospovidone (ChemDraw Professional 15). 
Molecular properties (composition), particle properties (particle size distribution 
(PSD)) and level have been identified as the critical material attributes affecting 
excipient performance (for CPV, molecular properties were not critical) [4]. For SSG 
and CCS, the degree of substitution and degree of crosslinking are critical functional 
properties. The degree of substitution (presence of the carboxymethyl group) increases 
polymer hydrophilicity and swelling [11]. The degree of crosslinking reduces the 
excipient soluble content which can increase the viscosity of the surrounding medium 
and compromise tablet disintegration [4]. PSD affects the swelling capacity of SSG 
and CCS, as larger particles swell more extensively compared to smaller particles [11]. 
For CPV which exhibits a more porous structure, PSD relates to water uptake as the 
higher porosity of larger particles results in faster water absorption and tablet 
disintegration [12]. Finally, increasing excipient level in tablet formulations leads to 
faster water uptake and tablet disintegration, but care should be taken when using 
gelling superdisintegrants as high excipient levels may result in the formation of 
viscous layers around drug particles [13]. 
The biopharmaceutical implications of superdisintegrants are not fully understood. 
The pH of the medium affects the performance of SSG and CCS due to the ionization 
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pattern of the excipients. The swelling ability of the neutral form is reduced due to its 
low hydration capacity compared to the ionized form [8]. The performance of 
superdisintegrants can also relate to drug physicochemical properties. Electrostatic 
interactions between cationic drugs and the carboxyl group of SSG and CCS are 
known to affect the % of drug recovery during routine drug analysis [14, 15] or delay 
drug release from tablet formulations [16]. Drug-excipient interactions are affected by 
the presence of salts, as high salt concentrations supress the binding of drugs in the 
hydrogels [17]. Adsorption of lipophilic molecules to CPV through hydrophobic 
interactions has been reported [17] that could also affect drug release from 
pharmaceutical formulations. 
The aim of this study was to investigate the biopharmaceutical implications and 
criticality of superdisintegrant variability and variation on drug apparent solubility. 
The impact of excipient variability on drug apparent solubility was studied by 
selecting three SSG brands of different viscosity type and two CCS and CPV brands 
of different PSD. Two excipient levels (low: 2% w/w, high: 5% w/w) were used to 
assess the impact of excipient variation on drug apparent solubility. The 
biopharmaceutical implications of superdisintegrant variability were evaluated by 
choosing compounds with different physicochemical properties (drug ionization, drug 
lipophilicity, drug aqueous solubility) and media (compendial and biorelevant) 
representing the gastric and intestinal compartments. The significance of drug 
properties, excipient presence and medium characteristics on the effects of 
superdisintegrants on drug apparent solubility were investigated with the use of 
multivariate data analysis (Partial Least Squares (PLS)) and the design of roadmaps. 
4.2. Materials and Methods 
4.2.1. Materials 
APIs: Sulfamethoxazole and paracetamol were obtained from Fisher Scientific 
(UK). Furosemide, itraconazole and dipyridamole were obtained from VWR (UK). 
Ibuprofen, carbamazepine and metformin were obtained from Fagron (UK). 
Excipients: Glycolys LV and Glycolys (Roquette, France), Explotab CLV (JRS 
Pharma, USA), Kollidon CL-F and Kollidon CL (BASF-SE, Germany), AcDiSol 
(FMC, USA) and Primellose (DFE Pharma, Germany) were obtained from the 
specified sources. Chemicals: Acetic acid (>99.7%), hydrochloric acid 36.5–38%, 
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HPLC grade methanol, HPLC grade acetonitrile, dichloromethane, pepsin (from 
porcine) were obtained from Sigma-Aldrich (UK). Maleic acid, sodium chloride, 
sodium hydroxide, potassium phosphate monobasic, sodium dihydrogen 
orthophosphate dihydrate, disodium hydrogen orthophosphate dihydrate, potassium 
dihydrogen orthophosphate, anhydrous sodium sulfate, HPLC grade trifluoroacetic 
acid were obtained from Fisher Scientific (UK). Sodium taurocholate (Prodotti 
Chimici Alimentari S.P.A., Italy), egg lecithin – Lipoid EPCS (Lipoid GmbH, 
Germany), were obtained from the sources specified. Water was ultra-pure (Milli-Q) 
laboratory grade. Filters: Whatman® 13 mm cellulose nitrate filters 0.45 μm pore size 
and polytetrafluoroethylene (PTFE) 13 mm filter 0.45 μm pore size were purchased 
from Fisher Scientific (UK). 
4.2.2. Instrumentation 
Fisherbrand waterbath (Fisher Scientific, UK), Sartorius BP 210 D balance 
(Sartorius Ltd, UK), Buchi R114 Rotavapor (Buchi, Switzerland), Mettler Toledo 
SevenCompact S210 pH meter (Mettler Toledo, Switzerland), Vortex-Genie 2 vortex 
mixer (Scientific Industries Inc, USA), Brookfield HA-RVIII viscometer (Brookfield 
Ametek, USA), Agilent Technologies 1100 series HPLC system, (quaternary pump 
(G1311A), autosampler (G1313A), thermostatted column compartment (G1316A), 
diode array detector (G1329A) and Chemstation software (Agilent Technologies, 
USA). 
4.2.3. Methods 
4.2.3.1. Compounds selected for solubility experiments 
The compounds used for the solubility experiments, their physicochemical 
properties (drug ionization, drug lipophilicity, drug aqueous solubility) and their 




Table 4.1: Physicochemical properties and structure of the compounds used for the 
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4.2.3.2. Media prepared for solubility experiments 
Compendial media (0.1 N HCl pH 1, phosphate buffer pH 6.8) were prepared 
according to the method described in the United States Pharmacopeia [29]. Fasted 
State Simulated Gastric Fluid (FaSSGF) and Fasted State Simulated Intestinal Fluid 
(FaSSIF-V2) were prepared as per literature references [30]. 
4.2.3.3. Design of experiments (DoE) used for solubility experiments 
A full-factorial Design of Experiments (DoE) was performed to determine the 
number of necessary experiments using StatGraphics Centurion XVII (Statpoint 
Technologies Inc, USA). As drug solubility will differ according to the composition 
of the studied media (pH, presence of bile salts), two models for the DoE were 
constructed to discriminate between the effects of excipients on drug apparent 
solubility in compendial (Model 1) and biorelevant conditions (Model 2). The 
examined factors were: i. compound (Table 4.1), ii. excipient brand (SSG: Glycolys 
LV, Explotab CLV, Glycolys, CCS: AcDiSol, Primellose, CPV: Kollidon CL-F, 
Kollidon CL), iii. excipient level (low, high), iv. medium (gastric, intestinal). The 
impact of each excipient on drug apparent solubility [expressed as the relative increase 
or decrease in drug solubility in presence compared to absence of excipient (section 
4.2.3.6)] was set as the response. A total of 224x3 experiments was determined for 
each model. 16x3 additional experiments in triplicate for each model were conducted 
to determine drug apparent solubility in the corresponding media in the absence of 
excipient. These experiments were not included in the DoE as drug solubility in 
excipient absence was measured only for the calculation of relative excipient effects 
on drug solubility. 
4.2.3.4. Characterization of superdisintegrants 
4.2.3.4.1. Viscosity measurements 
Samples of each superdisintegrant were prepared as 3% w/v dispersions in water. 
0.5 mL of each sample was loaded into the cup of a rotational viscometer. The 
viscosity of each dispersion was measured every 10 minutes for an hour at 25°C using 
a CPA-40z spindle rotated at a speed of 120 rpm [31]. All experiments were performed 
in triplicate. 
4.2.3.4.2. Particle Size Distribution 
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The PSD of the studied CCS and CPV brands was measured using laser diffraction 
(dry dispersion) and the cumulative undersized particle parameters d10 (μm), d50 (μm) 
and d90 (μm) were calculated (data kindly provided by AstraZeneca). 
4.2.3.5. Solubility studies 
Drug solubility studies in the absence and presence of excipient were performed 
in triplicate using the shake-flask method [32]. Drug excess and 2% w/w or 5% w/w 
of each excipient were weighed and placed in centrifuge tubes. The amount of 
excipient was determined as follows: i. for poorly soluble drugs, considering an 
average of 500 mg tablet weight [33] (which resulted in 9% w/w (low level) and 20% 
w/w (high level) of excipient in the total volume of the physical mixture) and ii. for 
highly soluble drugs, according to the amount of drug excess and the % w/w of 
excipient in the total volume of the physical mixture based on point (i). The physical 
mixtures were vortexed for 3 minutes. 5 mL of each medium were added in the tubes 
and the samples were placed in a shaking water bath (37 °C, 200 strokes per minute 
(spm)). At 0.5, 4 and 24 hours (for PRC, SMX, CBZ, DPL, IBU) and at 24 hours (for 
MTF, FRS, ITZ), 500 μL were sampled and filtered through PTFE filters (or cellulose 
nitrate filters for the cases of IBU and CBZ). Filter adsorption studies were prior 
performed in triplicate for each drug. No adsorption issues onto the filters used were 
observed for the studied drugs. Filtered samples were further diluted (if needed) with 
the corresponding medium and analysed by HPLC (Table 4.2). Analytical HPLC 
procedures for drug quantification in the samples were modifications of already 
published methods. Drug quantification was made based on calibration curves. 
Standards were formulated from concentrated stock solution consisting of drug 
dissolved in MeOH. As changes in the pH of solutions by presence of dissolved drug 
[25] may affect drug solubility, the pH of samples after the completion of each 
experiment was measured. Drug apparent solubility was calculated based on the 
sample drug concentration measured. Solubility values measured experimentally in 
excipient absence for neutral drugs, for weak acids in acidic media and for weak bases 
in basic media determined the intrinsic solubility values. Solubility values measured 
experimentally in excipient absence in basic media (for weak acids) and acidic media 











































































4.2.3.6. Treatment of in vitro solubility data 
The Relative Effect (RE) of each excipient on drug apparent solubility was 
calculated based on equation 4.1: 
𝑅𝐸 =  
(𝑆−𝑆𝑟)
𝑆𝑟
 𝑥 100  (Equation 4.1) 
where 𝑆 and 𝑆𝑟 denote drug solubility in presence and absence (reference solubility) 
of excipient at 0.5, 4 and 24 hours. REs of excipients on drug apparent solubility > 
25% or < -20% were considered as significant change in drug apparent solubility to 
assess excipient criticality (this range was selected as a similar range is set in order to 
assess differences in drug exposure after oral administration; i.e. in bioequivalence 
studies) [42]. 
Box plots depicting the impact of excipients on drug solubility at 24 hours for all 
the studied compounds or as a function of time (0.5, 4 and 24 hours) for CBZ were 
constructed using Spotfire 7.10.1 (TIBCO software Inc, USA). The classification 
gradient maps portraying the impact of the studied brands on drug apparent solubility 
as a function of drug aqueous solubility were generated using SigmaPlot 13.0 (Systat 
Software Inc, USA). 
In cases where drug intrinsic solubility was not determined experimentally, the 
theoretical intrinsic solubility was calculated using the solubility-pH equations 
(Equations 4.2-4.5) [43]:  
log 𝑆 = log 𝑆𝑜 + log(10
−𝑝𝐾𝑎+𝑝𝐻 +1)  for weak acids (Equation 4.2) 
log 𝑆 = log 𝑆𝑜 + log(10
𝑝𝐾𝑎−𝑝𝐻 +1)   for weak bases (Equation 4.3) 
log 𝑆 = log 𝑆𝑜 + log(10
+𝑝𝐾𝑎2+ 𝑝𝐾𝑎1−2𝑝𝐻 + 10𝑝𝐾𝑎2−𝑝𝐻 + 1) for diprotic bases 
(Equation 4.4) 
log 𝑆 = log 𝑆𝑜 + log(10
+ 𝑝𝐾𝑎1− 𝑝𝐻 +  10−𝑝𝐾𝑎2+ 𝑝𝐻 + 1)  for ampholytes 
(Equation 4.5) 
where 𝑆 and 𝑆𝑜 indicate drug solubility at the given pH and the intrinsic 
solubility, respectively. The final pH and experimental solubility values of the ionized 
drug in basic (for weak acids) or acidic media (for weak bases) were used for the 
calculation of the theoretical intrinsic solubility. Theoretical pH-solubility profiles in 
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the physiological pH range were constructed to assess if changes in the pH of the 
medium could justify differences in drug solubility by excipient presence. The final 
pH and intrinsic solubility values (experimental or theoretical) were used for the 
construction of the theoretical pH – solubility profiles in the physiological pH range 
based on Equations 4.2 -4.5. 
4.2.3.7. Multivariate Data Analysis 
Excipient REs on drug apparent solubility were correlated to drug 
physicochemical properties (drug ionization, drug lipophilicity, drug aqueous 
solubility), excipient critical material attributes (viscosity for SSG, PSD for CCS and 
CPV, level) and medium characteristics (gastric, intestinal) by partial least squares 
(PLS) regression using the XLSTAT software (Microsoft, USA). Two models for the 
REs of excipients on drug solubility in compendial media (Model 1) and biorelevant 
media (Model 2) were constructed. The evaluated variables for both models were 
categorized according to their type as categorical (expressing a category or type) and 
numerical (measurements with numerical meaning). Categorical variables included i. 
drug solubility (poor, high), ii. amine group (absence, presence), iii. excipient brand 
(low and high PSD for CCS and CPV), iv. excipient level (low, high), v. medium 
(gastric, intestinal) while numerical parameters included i. % of drug ionized (Fion; 
calculated based on the Henderson – Hasselbalch equation at the pH of each medium), 
ii. drug lipophilicity (log P), iii. excipient brand (viscosity in cP of dispersion after 1 
hour for SSG). Excipient REs on drug solubility at 24 hours were used as the response. 
The selected interaction terms included each excipient property combined with each 
drug physicochemical property (drug ionization, drug lipophilicity, drug aqueous 
solubility) and medium characteristics (gastric, intestinal). Observation diagnostics 
were performed prior to model analysis to identify outliers in the data set. The distance 
of each observation to the model in the Y-plane (DmodY) tool based on PLS residuals 
was used. Plots of standardized DmodY vs each observation were generated and any 
observation exceeding the maximum tolerance volume in Y (Dcrit(Y)) was considered 
an outlier [44, 45]. Exclusion of outliers was based on two criteria: i. deviating cases 
(positive REs) in solubility caused by a pH shift of the solution, ii. observations 
resulting in high variability (coefficient of variation (CV%) > 20%) within the 
triplicate samples (one value from the triplicate could be excluded as the outlier 
analysis could detect these values). PLS models generated with and without outlier 
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exclusion (data not shown) confirmed that outlier exclusion did not alter the 
interpretation of results but only enhanced the predictive ability of the regression 
model. The generated models were assessed in terms of goodness of fit (R2) and 
goodness of prediction (Q2). High values of R2 and Q2 with a difference not greater 
than 0.2 - 0.3 were indications of successful models [46]. The number of PLS 
components (lines on the X-space which best approximate and correlate with the Y-
vector) was based on minimum predictive residual sum of squares (PRESS) [46]. 
From the available components the one at which Q2 reached its maximum value was 
selected [44]. Standardized coefficients were used to show the direction (positive or 
negative) and extent of each variable on the response. The significance of the selected 
variables was assessed by the variable influence on projection (VIP) value. VIP values 
> 0.8 were considered as moderately influential in the model while VIP values > 1 
were considered the most influential in the model [46]. A 95 % confidence interval 
was used. 
4.2.3.8. Roadmap Design 
Roadmap designs for identifying potential biopharmaceutical risks of 
superdisintegrant variability on drug apparent solubility were constructed by 
combining the impact of excipients on drug solubility from the solubility studies to 
excipient (viscosity for SSG, PSD for CCS and CPV) and drug (drug ionization, drug 
lipophilicity, drug aqueous solubility) physicochemical properties. Drugs were 
categorized according to drug aqueous solubility and drug lipophilicity (Table 4.1) 
and drug ionization (low ionized: F(ion) < 50%, highly ionized: F(ion) > 50%). The risk 
assessment of the impact of excipients on drug apparent solubility was evaluated by 
setting reference range criteria of -20% - 25% [42] on the REs of excipient on drug 
solubility at 24 hours. REs of excipients on drug solubility outside these values (REs 
< -20% or REs > 25%) were considered critical for oral drug performance. 
4.3. Results and Discussion 
4.3.1. Characterization of superdisintegrants 
The viscosity data of the studied excipient types and brands are presented in Table 
4.3. The viscosity of a superdisintegrant dispersion with time relates to the degree of 
crosslinking [31]. The SSG dispersions exhibit higher viscosity values compared to 
the CCS or CPV dispersions indicating that the SSG brands contain higher soluble 
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material content compared to the CCS and CPV brands, which increases the viscosity 
of the dispersion over time [9]. The higher degree of crosslinking for Glycolys LV and 
Explotab CLV explains the lower viscosity of their aqueous dispersion compared to 
the dispersion of Glycolys, as fewer polymeric chains are able to dissolve in the 
surrounding medium. Differences in the viscosity of dispersions between the different 
brands of CCS and CPV are not revealed. Experimental data of PSD (kindly provided 
by AstraZeneca) for the studied CCS and CPV brands are summarized in Table 4.4. 
AcDiSol comprised of smaller particles compared to Primellose, therefore the CCS 
brands will be referred as CCS(L) (AcDiSol) and CCS(H) (Primellose) in the sections 
below. Differences in the PSD were also observed for the CPV brands, as the particle 
size of Kollidon CL-F was smaller compared to Kollidon-CL and therefore Kollidon 
CL-F and Kollidon-CL will be referred as CPV(L) and CPV(H), respectively in the 
sections below. 
Table 4.3: Viscosity (cP) of the studied superdisintegrant brands (Mean ± SD) 
Time  
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Table 4.4: Particle size distribution of the studied CCS and CPV brands 
Brand Name d10 (μm) d50 (μm) d90 (μm) 
CCS(L) 12.8 31.9 74.2 
CCS(H) 21.8 52.2 109.8 
CPV(L) 12.1 36.3 117.4 
CPV(H) 15.9 77.6 234.3 
 
4.3.2. Solubility studies 
4.3.2.1. Impact of superdisintegrants on drug apparent solubility 
The reference drug solubility values at 24 hours in compendial and biorelevant 
media are summarized in Table 4.5. From the studied compounds, only weak acid or 
weak bases showed a pH – dependent solubility, as expected (except from the case of 
MTF, as explained in Chapters 2 and 3). For neutral drugs or weak acids/weak bases 
in media where drugs are unionized, reference solubility values were higher in 
biorelevant compared to compendial media, due to the presence of solubilizing 
components [47]. For weak acids or weak bases (except from MTF) in media where 
drugs are highly ionized, the higher % of drug ionized resulted in increased reference 
drug solubilities in compendial (0.1 N HCl pH 1, phosphate buffer pH 6.8) compared 




Table 4.5: Reference solubility values (μg/mL) of the studied drugs at 24 hours in 
compendial and biorelevant media. (Mean ± SD) 
 Compendial Media Biorelevant Media 

































































*below limit of detection of the analytical method 
SSG: The effects of the studied SSG brands on drug solubility at 24 hours in 
compendial and biorelevant media are presented in Figures 4.2 and 4.3, respectively. 
For MTF, in presence of 5% of Glycolys the solubility experiments resulted in the 
creation of a paste due to the high viscosity of the polymer in all media tested, therefore 














































































































































































































































































































































































































































































































Significant reduction in drug solubility at 24 hours by the low viscosity SSG 
brands (Glycolys LV, Explotab CLV) was observed for weak acids in FaSSIF-V2 and 
weak bases in media where drugs are highly ionized (-50% < REs < -20%). The high 
viscosity Glycolys significantly decreased the MTF solubility in FaSSIF-V2 (RE = -
22%, low excipient level) and ITZ solubility in 0.1 N HCl pH 1 (REs of -23% and -
25% for the low and high excipient level, respectively) at 24 hours. Reduction in the 
pH of basic media for weak acids (0.2 – 0.7 pH units) was observed (attributed to the 
drug ionization) in the cases where SSG significantly decreased drug apparent 
solubility. Changes in the pH of the media cannot justify the differences in drug 
solubility at 24 hours for weak acids in excipient presence as experimental drug 
solubility values do not correspond to the theoretical equilibrium solubility values 
(expected by the change in the pH of the medium and the design of the pH-solubility 
profiles) (Figure 4.4). Increase in the pH of acidic media for weak bases (0.2 – 4 pH 
units) was observed in the cases where SSG presence significantly decreased drug 
solubility (attributed to drug ionization) however the impact of pH on the weak basic 
compound solubility at 24 hours cannot be assessed due to in situ salt formation 
between the API and counterions of the medium [49]. Presence of insoluble excipients 
may delay drug dissolution and/or drug solubilization as their insolubility or variable 
“wetting” characteristics result in reduced drug-medium contact [50]. Therefore, the 
observed reduction in drug apparent solubility by SSG could relate to a shielding 
excipient effect on powder surface which further limits drug dissolution and/or drug 
solubilization. Cases of decreased drug solubility at 24 hours were mostly observed in 
presence of low viscosity SSG brands (Glycolys LV, Explotab CLV) compared to the 
high viscosity Glycolys and could be explained by the extensive swelling of low 
viscosity brands [9] which creates a barrier for drug dissolution from the powder 
surface. For neutral drugs, significant increase in drug apparent solubility was 
observed for CBZ in 0.1 N HCl pH 1 (42% < REs < 67%) in presence of all the studied 
brands. Changes in the pH of the media were not observed in the case of CBZ in 
excipient presence or absence. Solubility data of CBZ at 0.5, 4 and 24 hours in absence 
and presence of the studied SSG brands in compendial and biorelevant media are 
presented in Figure 4.5a. The solubility of pure CBZ decreased through time in 
compendial media (350 μg/mL and 250 μg/mL at 0.5 hours and 24 hours, 
respectively), potentially due to drug aggregation [51] or due to the conversion of CBZ 
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anhydrate to CBZ dihydrate in solution (solution mediated phase transformation) [52, 
53]. This reduction in CBZ apparent solubility is not observed in presence of SSG, as 
potentially dissolved polymer particles may enhance drug solubilization and delay 
drug aggregation [54]. Inhibition of the solution mediated phase transformation of 
CBZ in excipient presence due to the interaction of the amine group of CBZ with the 
carboxylic group of SSG (Figure 4.1), could also explain the fact that CBZ solubility 
was not reduced in excipient presence [52, 53] and justify the less pronounced impact 
of SSG in phosphate buffer pH 6.8 compared to 0.1 N HCl pH 1 (as the increased 
excipient hydrophilicity (due to excipient ionization [8]) would decrease the likelihood 
of drug-excipient interaction [55]). For weak acids, significant increase in drug 
solubility at 24 hours was observed in presence of Explotab CLV for SMX in 0.1 N 
HCl pH 1 (high excipient level: RE = 38%) and FRS in phosphate buffer pH 6.8 (REs 
of 44% and 37% for the low and high level, respectively). In both cases, the reduction 
in the pH of the medium was higher in presence (SMX: 0.2 pH units, FRS: 0.3 pH 
units) compared to excipient absence (SMX: 0.06 pH units, FRS: 0.2 pH units). 
Evaluation of the theoretical pH-solubility profiles (Figure 4.4) revealed that in SSG 
presence, the experimental drug solubility corresponds to the theoretical equilibrium 
solubility (expected by the change in the pH of the medium), therefore the 
aforementioned cases of increased solubility are attributed to the shift in the pH of the 
medium (further investigations on the impact of dissolved drugs or excipients on the 
pH of the medium are needed to explain the nature of this change, as reduction in the 
pH of the medium by SSG is not expected). For weak bases, significant increase in 
drug apparent solubility was observed for ITZ in FaSSIF-V2 in presence of the high 
excipient level of low viscosity brands (REs of 42% and 25% for Glycolys LV and 
Explotab CLV, respectively) and both levels of the high viscosity Glycolys (REs of 
approximately 50% for both excipient levels). Changes in the pH of the medium in 
presence of SSG were not observed in this case, despite the ionization pattern of the 
excipient potentially due to the buffer capacity of the medium (10 mM/dpH) [47]. ITZ 
forms a supersaturated solution in FaSSIF-V2 due to the micellar solubilization effect 
of bile salts and slowly precipitates with time [56]. The increase in ITZ solubility at 
24 hours in SSG presence in FaSSIF-V2 can be attributed to the inhibition of drug 
precipitation by the polymeric chains of SSG. The increase in ITZ solubility was more 
pronounced in presence of the high compared to the low viscosity brands, as 
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potentially high viscosity excipients have a better ability in delaying particle 














































































































































































































































































































































































































































































































































































































































































































































































CCS: Cases of significant decrease in the solubility of weak acids and weak 
bases at 24 hours were mostly observed in media where drugs are highly ionized 
(CCS(L): -50% < REs < -20%, CCS(H): -62% < REs < -20%) (Figures 4.6 and 4.7). 
Reduction in drug apparent solubility was also observed for ITZ in FaSSIF-V2 by the 
low level of CCS(H) (RE = -40%) (Figure 4.7). In the cases of significant decrease in 
drug solubility by CCS at 24 hours, changes in the pH of the media (0.2 – 0.7 pH units 
reduction in basic media for weak acids, 0.2 – 4 pH units increase in acidic media for 
weak bases) are attributed to drug ionization and cannot explain the differences in drug 
solubility in presence of CCS (for weak acids) or be evaluated (for weak bases), as 
explained previously in the case of SSG (Figure 4.8). The slow drug dissolution and/or 
drug solubilization by the presence of CCS particles on the surface of the powder could 
justify the pronounced decrease in drug apparent solubility by CCS [50]. Significant 
increase in drug solubility at 24 hours for neutral drugs was observed in the case of 
CBZ in 0.1 N HCl pH 1 (32% < REs < 43% for both levels of CCS(L) and CCS(H)) 
and in phosphate buffer pH 6.8 (RE = 37% for the high level of CCS(L)). As changes 
in the pH of the media in excipient presence were not observed for CBZ, the 
differences in CBZ solubility in presence and absence of CCS are attributed to the 
enhanced drug solubilization or inhibition of drug solution-mediated phase 
transformation by the excipient [55] (Figure 4.5b). For weak acids, significant 
increase in SMX solubility at 24 hours was observed in 0.1 N HCl pH 1 in presence 
of 5% CCS(H) (RE = 45%) and is attributed to the change in the pH of the medium, 
as the reduction in the pH of the medium was higher in presence (0.3 pH units) 
compared to absence of 5% CCS(H) (0.06 pH units) and the experimental and 
theoretical drug solubility in excipient presence are similar (Figure 4.8) (further 
investigations on the impact of dissolved drug or excipient on the pH of the medium 
are needed to explain the nature of this change, as reduction in the pH of the medium 
by CCS is not expected). For weak bases, significant increase in drug apparent 
solubility was observed for ITZ in FaSSIF-V2 in presence of 5% CCS(H) (RE = 31%) 





























































































































































































































































































































































































































































































































































































































































































































































































































































































CPV: Cases of significant reduction in drug solubility at 24 hours by CPV 
presence was observed for weak acids and weak bases in media where drugs are highly 
ionized (CPV(L): -50% < REs < -20%, CPV(H): -40% < REs < -21%) (Figures 4.9 
and 4.10). Reduction in drug apparent solubility was also observed in the case of ITZ 
in FaSSIF-V2 in presence of both CPV brands (-30% < REs < -20%) (Figure 4.10). 
In the case of significant reduction in drug solubility by CPV, the ionization of drugs 
resulted in reduction in the pH of the basic media for weak acids (0.2 – 0.7 pH units) 
or increase in the pH of acidic media for weak bases (0.2 – 4 pH units). The observed 
changes in the pH of the media cannot explain the differences in drug solubility at 24 
hours in CPV presence (Figure 4.11), as explained previously for SSG and CCS. 
Therefore, the pronounced reduction in drug apparent solubility by CPV is justified 
by the presence of the insoluble excipient on the powder surface [50]. For neutral 
drugs, significant increase in drug solubility at 24 hours was observed in the case of 
CBZ in compendial media (25% < REs < 56%) and is attributed to the enhanced drug 
solubilization or inhibition of drug solution mediated phase transformation by the 
excipient (Figure 4.5c) [55]. For weak acids, significant increase in drug solubility at 
24 hours was observed for FRS in phosphate buffer pH 6.8 in presence of both levels 
of CPV(L) (REs ≈ 70%). This pronounced increase in FRS solubility is justified by 
the change in the pH of the medium, as the reduction in the pH of the medium was 
higher in excipient presence (0.4 pH units) compared to excipient absence (0.2 pH 
units) (Figure 4.11) (further investigations are needed to explain the nature of this 
change, as changes in the pH of the medium by the non-ionic CPV are not expected). 
For weak bases, significant increase in the apparent solubility of MTF was observed 
in 0.1 N HCl pH 1 in presence of the high level of CPV(H) (RE = 63%). The increase 
in the pH of the medium in absence and presence of excipient was similar (3 pH units) 
and is attributed to the protonation of MTF. As changes in the pH of the media for 
weak bases cannot be evaluated, further investigations are needed to explain the 
pronounced increase in MTF solubility. 
The solubility data showed increased variability in the cases where 
superdisintegrant presence significantly affected drug solubility (MTF: CV% > 30%, 
PRC or highly ionized poorly soluble drugs: 20% < CV% < 40%). As working with 
physical mixtures may yield high standard deviations due to the heterogeneous 
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dispersion of the constituents [58, 59], the increased variability can be attributed to the 































































































































































































































































































































































































































































































































































































































































































































































































































































































4.3.2.2. Impact of excipients on drug apparent solubility based on drug 
physicochemical properties 
The effects of the studied superdisintegrants on drug solubility at 24 hours as a 
function of drug ionization and drug lipophilicity in compendial and biorelevant media 
are presented in Figure 4.12. 
 
Figure 4.12: Relative effects (%) of the studied SSG (i. Glycolys LV (green colour), 
ii. Explotab CLV (blue colour), iii. Glycolys (red colour)), CCS (i. CCS(L) (blue 
colour), ii. CCS(H) (red colour)) and CPV (i. CPV(L) (blue colour), ii. CPV(H) (red 
colour)) brands on drug solubility at 24 hours as a function of drug ionization (%) and 
drug lipophilicity (log P) in a. compendial and b. biorelevant media. Light and dark 




The reduction in drug apparent solubility by superdisintegrant presence is more 
pronounced in media (compendial or biorelevant) where drugs are highly ionized 
(excluding the cases of increased drug solubility attributed to the change in the pH of 
the medium), potentially due to the presence of a high number of excipient particles 
on the powder surface which limits drug dissolution and/or drug solubilization [50] 
(as explained previously in Chapters 2 and 3). For the ionic superdisintegrants (SSG, 
CCS), interactions between ionized drugs and the excipient polymeric chains [17, 60] 
may also have contributed to the observed reduction in drug solubility at 24 hours. A 
trend between the impact of superdisintegrants on drug solubility and drug 
lipophilicity was not observed, apart from the case of SSG in biorelevant media, where 
increase in drug solubility was observed with increasing drug lipophilicity (when 
drugs are in the low ionization state). The classification gradient maps depicting the 
effects of the studied superdisintegrants on drug solubility at 24 hours as a function of 
drug aqueous solubility in compendial and biorelevant media is presented in Figure 
4.13. A clear trend between the reduction in drug apparent solubility by excipient 







Figure 4.13: Classification gradient maps of the relative excipient effects of the a. 
SSG, b. CCS and c. CPV brands on the solubility of highly and poorly soluble 
compounds at 24 hours. Y-axes are set in an increasing viscosity and level order for 
SSG and increasing particle size and level order for CCS and CPV. The x-axes are set 
in a decreasing drug aqueous solubility order (red colours for highly soluble and blue 
colours for poorly soluble drugs). 
 
4.3.3. Multivariate Data Analysis 
For SSG, the two models showed an average fit (compendial media: Q2 = 0.3, R2 
= 0.4 and biorelevant media: Q2 = 0.5, R2 = 0.6) (Figure 4.14). The statistical model 
reveals that the impact of SSG on drug apparent solubility depends on drug 
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physicochemical properties. Amine group (compendial media: positive effect, VIP = 
2.6, biorelevant media: positive effect, VIP = 2.2) was a significant variable in both 
sets of media indicating that significant increase in drug solubility at 24 hours is 
anticipated in SSG presence for drugs containing a neutral amine due to potential drug-
SSG interaction which improves drug solubilization [55]. Drug ionization 
(compendial media: negative effect, VIP = 2.3, biorelevant media: negative effect, VIP 
= 2.5) was an influential variable in both models indicating that significant reduction 
in drug apparent solubility in SSG presence is expected for highly ionized drugs due 
to the saturation of powder surface with excipient particles [50] or drug-SSG 
interactions [17] which delay drug dissolution and/or drug solubilization. In 
biorelevant media, drug lipophilicity (positive effect, VIP = 1.4) and drug solubility 
(negative effect, VIP = 1.1) were significant variables in the model. These variables 
indicate that pronounced increase in the apparent solubility of poorly 
soluble/lipophilic drugs can be observed in presence of SSG as a result of enhanced 
drug solubilization. The negative effect of drug solubility can also indicate a reduction 
in drug solubility at 24 hours for highly soluble drugs due to the saturation of powder 
surface with excipient particles [50] (as for highly soluble drugs, drug molecules can 
dissolve faster in the medium especially in the presence of solubilizing components 
[47]). The impact of excipient properties on drug apparent solubility was found critical 
only in biorelevant media as demonstrated by the significance of the term exc. brand 
(positive effect, VIP = 1.4) in the model. This term reveals that the increase in drug 
solubility at 24 hours will be more pronounced in presence of high viscosity SSG 
brands as potentially high viscosity excipients have a better ability in delaying particle 

































































































































































































































































































































































































































































For CCS, average fittings (compendial media: Q2 = 0.5, R2 = 0.6, biorelevant 
media: Q2 = 0.2, R2 = 0.3) were obtained (Figure 4.15). Amine group (compendial 
media: positive effect, VIP = 3.0, biorelevant media: positive effect, VIP = 2.4) and 
drug ionization (compendial media: negative effect, VIP = 2.7, biorelevant media: 
negative effect, VIP = 2.8) were significant factors in both sets of media. The variable 
amine group indicates that significant increase in the apparent solubility of drugs 
containing a neutral amine group is expected as a result of the enhanced drug 
solubilization by CCS presence due to a potential drug-CCS interaction which 
improves drug solubilization [55]. The negative effect of drug ionization reveals that 
pronounced reduction in the apparent solubility of highly ionized drugs will be 
anticipated in presence of CCS due to the saturation of the powder surface by excipient 
particles [50] or drug-CCS interactions [17] which limit drug dissolution and/or drug 
solubilization. Excipient properties can be critical factors for the impact of CCS on 
drug solubility in biorelevant media, as demonstrated by the significance of the 
variable excipient level*drug ionization (negative effect, VIP = 1.1) in the model. As 
the presence of solubilizing components improves powder wettability and drug 
solubilization [47], the high number of excipient particles on top of the powder surface 
or the extensive excipient swelling when increasing CCS level will result in higher 
reduction in the apparent solubility of highly ionized drugs. 
For CPV, average fits were observed (compendial media: Q2 = 0.4, R2 = 0.5 and 
biorelevant media: Q2 = 0.2, R2 = 0.3) (Figure 4.16). Drug physicochemical properties 
were critical parameters for the impact of CPV on drug apparent solubility. Amine 
group (compendial media: positive effect, VIP = 3.5, biorelevant media: positive 
effect, VIP = 2.3) was a significant variable in both models indicating that CPV is able 
in inhibiting drug agglomeration [55]. Drug ionization (compendial media: negative 
effect, VIP -1.6, biorelevant media: negative effect, VIP = 1.0) and drug solubility 
(compendial media: negative effect, VIP = 1.1, biorelevant media: negative effect, VIP 
= 0.8) were significant variables in both models. Both variables indicate that 
significant reduction in drug apparent solubility is anticipated in presence of CPV for 
highly ionized or highly soluble drugs, potentially due to the saturation of the powder 
surface with excipient particles [50]. In biorelevant media, drug lipophilicity (negative 
effect, VIP = 1.0) was a significant factor in the model indicating significant reduction 
in the solubility of highly lipophilic drugs in presence of CPV at 24 hours. The 
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enhanced drug solubilization of lipophilic molecules by the presence of bile salts in 
biorelevant conditions [47] may result in saturation of the powder surface with 
excipient particles which further limit drug dissolution and/or drug solubilization. 
Hydrophobic interactions between lipophilic drugs and CPV [17], could also have 
contributed to the delay in drug dissolution in excipient presence. Finally, the 
interaction exc. brand*drug ionization (positive effect, VIP = 1.0) was a significant 
variable in the biorelevant model but further investigations are needed to explain the 
nature of this term. 
4.3.4. Road map of superdisintegrants effects on drug apparent 
solubility 
The road maps categorizing excipient REs on drug apparent solubility according 
to excipient (SSG, CCS, CPV) and drug properties are presented in Figure 4.17 (cases 
where increased drug solubility was caused by a potential shift in the pH of the 
medium were not considered). 
The impact of the studied superdisintegrants on drug apparent solubility relates to 
drug physicochemical properties. Presence of low viscosity SSG brands can be critical 
in oral drug performance for highly ionized drug, irrespective of drug lipophilicity or 
drug aqueous solubility, as indicated by the pronounced reduction in drug solubility at 
24 hours in presence of low viscosity SSG brands (Glycolys LV, Explotab CLV). High 
viscosity SSG (Glycolys) brands will be challenging for the oral performance of 
poorly soluble/highly ionized drugs with log P > 4. For poorly soluble/low ionized 
drugs, presence of SSG is not expected to affect drug solubility, apart from drugs 
containing a neutral amine group and for which SSG presence may result in significant 








Figure 4.17: Road map of the effects of the studied a. SSG, b. CCS and c. CPV brands 
on drug solubility. Red boxes and green boxes indicate significant and insignificant 
changes in drug solubility by excipient presence, respectively. 
 
The criticality of CCS for oral product performance relates to drug ionization as 
significant changes (decrease) in drug apparent solubility in CCS presence are 
expected for highly ionized drugs, irrespective of drug aqueous solubility (highly or 
poorly soluble drugs). Moreover, presence of CCS will be critical for the solubility of 
poorly soluble/low ionized drugs (log P < 2.5) containing a neutral amine group, as 
significant increase in the 24 hour  drug solubility was observed (Figure 4.17b). 
Presence of low particle size CCS brands may be challenging for the apparent 
solubility of poorly soluble/low ionized drug with log P > 4, however its impact on 
drug solubility depends on excipient level (Figure 4.7) 
The impact of CPV on drug apparent solubility depends on drug ionization and 
drug lipophilicity, as significant changes (reduction) in the solubility of highly 
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ionized/highly soluble or highly ionized/poorly soluble drugs with log P < 2.5, 
irrespective of excipient brand used. Presence of CPV can also be critical for the 
apparent solubility of highly lipophilic drugs (log P > 4), irrespective of drug 
ionization state (highly or low ionized), as significant reduction in drug solubility was 
observed by all the studied CPV brands. Finally, presence of CPV may present 
challenges in the oral drug performance of poorly soluble/low ionized drugs with log 
P < 2.5 as significant increase in drug solubility was observed (Figure 4.17c).  
The construction of roadmaps identified the cases where presence of 
superdisintegrants can be critical for oral drug performance. Compared to the other 
two excipient types (lubricants – Chapter 2, binders – Chapter 3), superdisintegrants 
can be considered as excipients of low criticality for product performance when 
considering the impact of excipients on drug solubility (the effectiveness of different 
excipients on tablet disintegration and drug bioavailability also needs to be 
considered). 
4.4. Conclusions 
Excipient variability and interchangeability present challenges in pharmaceutical 
development, as the varying excipient physicochemical properties can affect final 
product quality. Identification of the critical excipient attributes affecting product 
performance is recommended for the successful control of excipient variability 
according to the QbD approach. Presence of superdisintegrants (SSG, CCS, CPV) in 
immediate release formulations is beneficial for promoting fast tablet disintegration 
and drug dissolution but there is a lack of knowledge on the impact of their properties 
on oral drug performance. In this work, the biopharmaceutical implications of 
superdisintegrant variability on drug apparent solubility were investigated. Solubility 
studies using compounds with different physicochemical properties revealed that for 
the majority of cases, presence of superdisintegrants or superdisintegrant variability 
did not significantly affected drug solubility at 24 hours. The significant changes in 
drug apparent solubility related to drug physicochemical properties with reduction 
observed for highly ionized drugs and increased observed for poorly soluble drugs 
containing a neutral amine group. The use of multivariate data analysis and the design 
of roadmaps allowed the identification of the biopharmaceutical factors affecting the 
impact of superdisintegrants on drug apparent solubility. It is concluded that, 
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compared to other excipient types (lubricants, binders), superdisintegrants can be 
considered as of low criticality for presenting implications on oral drug absorption 
(based on drug solubility data). 
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Chapter 4 Commentary 
Superdisintegrants (sodium starch glycolate (SSG), croscarmellose sodium (CCS), 
crospovidone (CPV)) constitute an important excipient class for immediate release 
formulations. This chapter investigated the impact of superdisintegrant presence and 
variability on drug apparent solubility in a biopharmaceutical perspective. Three 
brands of SSG of varying viscosity type (Glycolys LV, Explotab CLV, Glycolys) and 
two brands of CCS (AcDiSol, Primellose) and CPV (Kollidon CL-F, Kollidon CL) of 
different particle size distribution in two different levels were selected to study the 
impact of excipient variability and variation on oral drug performance. Presence of 
superdisintegrants or superdisintegrant variability slightly affected drug solubility at 
24 hours for the majority of compounds. Few cases of significant reduction in drug 
apparent solubility by the studied brands were observed only for highly ionized drugs 
which were attributed to a drug shielding effect on top of the powder surface by the 
excipients . Significant increase in drug solubility at 24 hours in presence of SSG, CCS 
and CPV was observed for poorly soluble drugs containing a neutral amine group and 
may relate to a drug-excipient interaction or improved powder solubilization in 
excipient presence. The use of multivariate data analysis revealed that drug 
physicochemical properties (especially, drug ionization and presence of a neutral 
amine group) are critical for the impact of superdisintegrants on drug solubility. The 
data discussed and presented in Chapters 2, 3 and 4 indicate that excipient presence 
and variability could be critical for oral drug performance however different 
approaches need to be considered according to the studied excipient class, drug 




Chapter 5 Preface 
The succesful implementation of the Quality by Design (QbD) initiative in 
pharmaceutical development would be beneficial in the traditional batch or continuous 
manufacturing leading to the production of robust formulations. Dissolution testing is 
an important tool in QbD approaches providing information on batch quality, 
identifying the impact of gastrointestinal conditions on product performance and 
allowing the development of in vitro-in vivo correlations. Traditional (compendial 
apparatus) or recent advances (surface dissolution UV imaging) on dissolution 
methods provide mechanistic insights on the role of several components or processes 
which could affect drug dissolution. Presence of excipients and excipient variability 
are known to affect drug dissolution both in vitro and in vivo leading to batch 
incosistencies, changes in drug bioavailability and bioinequivalence with products. 
The development of biorelevant dissolution methods to investigate the impact of 
excipients on drug dissolution would be beneficial towards the understanding and 
control of excipient variability in the QbD perspective. This would improve the 
effectiveness of the pharmaceutical manufacturing and would ensure the consistent 
delivery of safe products for patients. Moreover, the construction of design spaces 
would allow the minimization of regulatory constraints which are currently strictly 
addressing the issue of excipient variability. The aim of this chapter is to identify the 
impact of excipient variability on drug dissolution in a biopharmaceutical perspective. 
Compendial/biorelevant media and dissolution apparatuses will be used to address the 
importance of several gastrointestinal conditions on the issue of excipient variability. 
Assessment of excipient criticality in terms of oral drug performance will be 




Chapter 5. Biopharmaceutical implications of excipient variability on drug 
dissolution from immediate release products 
 
Abstract 
Elucidating the impact of excipient variability on oral product performance in a 
biopharmaceutical perspective would be beneficial and allow excipient 
implementation on Quality by Design (QbD) approaches. The current study 
investigated the impact of varying viscosity of binders (hypromellose (HPMC)) and 
superdisintegrants (sodium starch glycolate (SSG)) and particle size distribution of 
lubricants (magnesium stearate (MgSt)) on the in vitro dissolution of a highly and a 
poorly soluble drug from immediate release formulations. Compendial 
(pharmacopoeia buffers) and biorelevant (media simulating the gastrointestinal fluids) 
media and the USP 2 and USP 4 apparatuses were used to assess the exerted excipient 
effects on drug dissolution. Real-time surface dissolution UV imaging provided 
mechanistic insights into disintegration and dissolution of the immediate release 
formulations. Varying the viscosity type of HPMC or SSG did not significantly affect 
drug dissolution irrespective of the compound used. Faster drug dissolution was 
observed when decreasing the particle size of MgSt brand for the highly soluble drug. 
The use of real-time surface dissolution UV Imaging revealed the influential role of 
excipient variability on tablet disintegration, as for the highly soluble drug, tablets 
containing high viscosity HPMC or low particle size MgSt disintegrated faster 
(compared to the control tablets) while for the poorly soluble drug, slower tablet 
disintegration was observed when increasing the viscosity of HPMC (compared to the 
control tablets). Changes in drug dissolution when varying excipients may be 
anticipated if the excipient change has previously affected drug solubility. The use of 
multivariate data analysis revealed the influential biopharmaceutical factors (critical 
excipient types/properties, drug aqueous solubility, medium/hydrodynamic 
characteristics) affecting the impact of excipients on in vitro drug dissolution. 
Keywords: excipient variability, HPMC, sodium starch glycolate, magnesium 





Introduction of the Quality by Design (QbD) initiative in the pharmaceutical 
industry is crucial for the development of robust manufacturing processes and the 
safety of final products. The requirements of a final dosage form are identified from a 
patient perspective and are translated into critical quality attributes (CQAs). Critical 
material attributes (CMAs) of input raw materials and critical process parameters 
(CPPs) for the manufacture of dosage forms must then be controlled to ensure that the 
CQAs are delivered [1]. Control strategies and design spaces are built to cope with the 
variability and/or variation of the factors affecting product manufacturing or 
performance [2]. Implementation of QbD approaches in the traditional pharmaceutical 
development can prevent batch failures and improve cost effectiveness due to the 
scientific understanding and control of the manufacturing processes [1]. The principles 
of QbD could, as well, be beneficial in emerging technologies, such as continuous 
manufacturing, as they will allow the identification, control and monitoring of the 
continuous dynamic processes during development [3]. 
Dissolution testing can be a powerful tool in the QbD concept providing 
information on the critical factors that can affect oral drug absorption [4]. Quality 
control dissolution methods can assess inter-batch consistencies, as they are developed 
to discriminate the critical factors (CMAs or CPPs) affecting the performance of final 
dosage forms [5]. The development of biorelevant dissolution methods demonstrates 
the ability of dissolution testing to delineate the impact of physiological conditions 
(pH of the medium, presence of solubilizing components, fasted vs fed state, 
hydrodynamics) on product performance [6]. Prediction of the in vivo product 
performance through dissolution tests (clinically relevant dissolution methods) can be 
achieved with the development of In vitro-In vivo correlations (IVIVC) that will assist 
in the identification of CQAs and substitute in vivo bioequivalence studies [7]. Media 
(compendial: pharmacopeia buffers, biorelevant: mimicking the composition of the 
gastrointestinal fluids) [8, 9] and apparatus (USP 1: basket assembly, USP2: paddle 
assembly, USP 3: reciprocating cylinder, USP 4: flow-through cell) [10] able to 
simulate gastrointestinal conditions and predict oral product performance have been 
developed to serve the purposes of the dissolution methods. Moreover, recent 
advances in real-time surface dissolution UV-imaging techniques have allowed the 
spatial and temporal visualization of the dissolution phenomena of APIs from 
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compacts [11-13] or dosage forms [14], the role of excipients [15-17] and 
physiological conditions (pH [18, 19], hydrodynamics [15], biorelevant media [20]) 
on drug dissolution. These techniques could provide additional information on the 
mechanisms by critical factors can affect in vitro drug dissolution. 
The critical role of excipient presence, variability (changes in material properties) 
or variation (changes in amount) on product quality is highlighted [21, 22] and it is 
recognized that the effects of excipients on product performance relate to several 
biopharmaceutical factors (gastrointestinal conditions, drug physicochemical 
properties) [23]. Several studies have shown that changes in the physical or chemical 
excipient composition, changes in the amount of excipient used and excipient 
interchangeability affected in vitro drug dissolution [23]. Increasing the viscosity type 
of cellulosic polymers (hydroxypropylcellulose (HPC), 
hydroxypropylmethylcellulose (HPMC)) resulted in slower theophylline release from 
hydrophilic matrix tablets (USP2 apparatus, 900 mL distilled water, 37 °C, 50 rpm 
and 100 rpm for tablets containing HPC and HPMC, respectively) [24, 25]. 
Pronounced delay in the dissolution and release of theophylline from matrix tablets 
(USP1 apparatus, distilled water, 37 °C, 100 rpm) containing magnesium stearate 
(MgSt) was observed with increasing excipient level (1% w/w – 5% w/w) [26]. The 
dissolution profiles of hydrochlorothiazide from tablets containing crospovidone 
brands from two different suppliers (USP1 apparatus, 900 mL 0.1 N HCl pH 1, 37 °C, 
100 rpm) were not similar due to the differences in excipient porosity, despite the 
interchangeability of the studied brands [27, 28]. The implications of excipients on in 
vivo product performance have been highlighted, as changes in drug bioavailability 
and bioinequivalence within products have been attributed to excipient presence [29]. 
Bioequivalence studies failed to show similarity between innovator and generic 
products of alendronate, as the presence of sodium lauryl sulfate in the generic product 
resulted in a 5-fold increase in drug bioavailability [29]. International associations and 
regulatory agencies are strictly addressing the issue of excipient variability on product 
performance. Evaluation of the significance of excipient changes [30] and excipient 
functionality [31, 32] on drug dissolution is needed. Scientific justification that 
excipient changes will not affect formulation quality and performance is required by 
regulatory agencies [33]. Scale-up or post approval excipient changes may or may not 
require in vitro dissolution documentation according to excipient type or amount and 
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drug characteristics (Level 1: deletion of colouring/flavouring agents or changes in 
excipient amount within specified limits do not require additional dissolution 
documentation, Level 2: changes in excipient technical grades or excipient amount 
greater than the Level 1 limits require addition dissolution justification). Failure to 
meet in vitro dissolution criteria requires full dissolution and bioequivalence 
documentation (Level 3) [33]. Excipient changes when requesting biowaivers are also 
considered as excipients may affect drug absorption and it is recommended that test 
products contain qualitatively the same and quantitatively very similar excipients [34, 
35]. 
The aim of this study was to identify the impact of excipient variability on in vitro 
drug dissolution in a biopharmaceutical perspective. Excipient variability was 
assessed by obtaining variants in critical material attributes of binders (hypromellose 
(HPMC) – viscosity type), superdisintegrants (sodium starch glycolate (SSG) – 
viscosity type) and lubricants (magnesium stearate (MgSt) – particle size distribution 
(PSD)) and producing immediate release formulations (control and variant tablets) for 
a highly and a poorly soluble model compound using wet granulation. Dissolution 
studies were performed in compendial and biorelevant media with the USP 2 and USP 
4 apparatus. Real-time surface dissolution UV imaging was also performed to provide 
a mechanistic understanding of the dissolution processes of the manufactured tablets. 
Multivariate data analysis (Partial Least Squares (PLS)) was used to understand the 
effects of certain variables (excipient critical material attributes, drug aqueous 
solubility, medium and hydrodynamic characteristics) on the impact of excipients on 
drug dissolution. 
5.2. Materials and Methods 
5.2.1. Materials 
APIs: Paracetamol and carbamazepine were kindly donated by AstraZeneca. 
Excipients: Mannitol (Pearlitol 160C, Roquette Frères, France), microcrystalline 
cellulose (Avicel PH101, FMC Biopolymer, USA), hypromellose (HPMC) (Methocel 
E5 and Methocel E15, Dow Chemical Company, USA), sodium starch glycolate 
(SSG) (Glycolys and Glycolys LV, Roquette Frères, France), magnesium stearate 
(MgSt) (Ligamed MF-2-V and Ligamed MF-3-V, Peter Greven, Netherlands) were 
purchased by the specified sources. Chemicals: Hydrochloric acid 36.5–38%, HPLC 
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grade methanol, pepsin (from porcine) were obtained from Sigma-Aldrich (UK). 
Maleic acid, sodium chloride, sodium hydroxide, potassium phosphate monobasic 
were obtained from Fisher Scientific (UK). Sodium taurocholate (Prodotti Chimici 
Alimentari S.P.A., Italy), egg lecithin – Lipoid EPCS (Lipoid GmbH, Germany), were 
obtained from the sources specified. Water was ultra-pure (Milli-Q) laboratory grade. 
Filters: Cronus 13 mm regenerated cellulose (RC) syringe filters 0.45 μm were 
purchased from LabHut (UK), Whatman® 24 mm glass fibre filters 0.7 μm pore size 
(GF/F) and Whatman® 24 mm glass microfibre filters 2.1 μm pore size (GF/D) were 
purchased from Fischer Scientific (UK). Glass wool was obtained from Sigma Aldrich 
(UK). 
5.2.2. Instrumentation 
Equipment used included: a Pharmatech drum blender (Pharmatech, UK), a 
ConsigmaTM-1 granulator (GEA Pharma Systems, Belgium), a Quadro Comill 193 
(Ytron Quadro Ltd, UK) equipped with a 1397 μm screen, a turbula blender Type T2F 
(GlenMills Inc., USA), a Kilian Styl’One Evo press (Romaco Kilian, Germany) 
equipped with 11 mm normal ankle cave punches, a Mettler Toledo SR32001 
DeltaRange balance (Mettler Toledo, Switzerland), digital calipers (Mitutoyo Ltd, 
UK), a Sotax HT100 automated tablet tester (Sotax, Switzerland), a Erweka ZT70 
disintegration tester (Erweka GmbH, Germany), a VK-7000 Vankel® USP 2 
apparatus (Vankel® dissolution system, USA) connected with an VK-750D external 
heating circulator (Vankel®, USA), a DFZ720 Erweka® flow-through dissolution 
tester connected to a HKP 720 Erweka® piston pump (Erweka GmbH, Germany), an 
SDi2 surface dissolution UV imaging system (Pion Inc., USA), a UV-Vis 
spectrophotometer (Ocean Optics, USA), a Buchi R114 Rotavapor (Buchi, 
Switzerland), a Mettler Toledo SevenCompact S210 pH meter (Mettler Toledo, 
Switzerland), an Agilent Technologies 1100 series HPLC system, (quaternary pump 
(G1311A), autosampler (G1313A), thermostatted column compartment (G1316A), 




5.2.3.  Methods 
5.2.3.1. Tablet manufacturing 
Granules containing drug, mannitol, microcrystalline cellulose, HPMC, SSG 
(Table 5.1) were prepared by twin screw granulation. Drug and excipients were mixed 
for 30 minutes at 25 rpm. Wet granulation was performed using distilled water as the 
granulation liquid, with a screw speed at 900 rpm, powder mass flow at 15 kg/h and 
liquid mass flow at 100 g/min. Granules were collected and left to dry overnight at 60 
°C (at a drying end point of < 2% moisture loss on drying). Granules were milled at 
2000 rpm with a 1.4 mm mesh to improve granule flow and filling in the die for 
compression. Granules were lubricated with MgSt for 3 minutes with a speed of 30 
rpm. Tablets were manufactured at a compression force of 20 kN for PRC and 15 kN 
for CBZ. 200 tablets for each of the PRC or CBZ batches (control and variant tablets) 
were produced. 
5.2.3.2. Tablet characterization 
The manufactured tablets were characterized in terms of tablet mass, thickness, 
width, hardness and disintegration time. Tablet mass was measured using an analytical 
balance. Tablet thickness and width were measured using digital callipers. Tablets 
hardness was assessed using an automated tablet tester. 10 tablets from each PRC and 
CBZ batches (control and variant tablets) were used to calculate the mean tablet mass 
(mg) ± standard deviation (SD), mean tablet thickness (mm) ±SD, mean tablet width 
(mm) ±SD and mean tablet hardness (N) ±SD. Tablet disintegration time was 
measured with the basket method at 37°C using distilled water as the immersion fluid 
[36]. The disintegration time (time at which tablet particles passed through the mesh 
at the bottom of the basket) was automatically recorded. The mean disintegration time 
(min) ±SD for 6 PRC and 3 CBZ tablets (for each control and variant tablets) was 
determined. 
5.2.3.3. Media used for dissolution studies 
Compendial media (0.1 N HCl pH 1, phosphate buffer pH 6.8) were prepared 
according to the method described in the United States Pharmacopeia [37]. Fasted 
State Simulated Gastric Fluid (FaSSGF) and Fasted State Simulated Intestinal Fluid 






5.2.3.4. In vitro dissolution studies 
5.2.3.4.1. USP 2 apparatus 
Experiments were performed at 37 °C using 500 mL of dissolution medium 
(compendial or biorelevant). The rotational speed of the paddle was set at 50 rpm. 3 
mL samples were withdrawn at 5, 10, 15, 20, 30, 45, 60 min for PRC and 5, 10, 15, 
20, 30, 45, 60, 90, 120, 180, 240 min for CBZ, filtered through RC 0.45 μm pore size 
filters, diluted with the corresponding medium (if needed) and analysed by HPLC. 
Filter adsorption studies were prior performed in triplicate for each drug and 
confirmed no adsorption issues for the studied drugs on the filters used. At each 
sampling time point the volume of the withdrawn samples was replaced with fresh 
corresponding dissolution medium. All experiments were performed in triplicate. 
5.2.3.4.2. USP 4 apparatus 
Experiments were performed at 37 °C using the Ø 12 mm (small) and Ø 22.4 mm 
(large) cells for PRC and the Ø 12 mm (small) cells for CBZ. A 5 mm-size ruby bead 
was positioned in the tip of the cell and 1g (small cells) or 6g (large cells) of 1 mm-
sized glass beads were added. On the top of the cell a GF/F filter was placed for PRC 
and one GF/F filter, 0.15 g of glass wool and one GF/D filter were placed for CBZ. 
The flow rate was set at 4 mL/min. For PRC the closed-loop configuration was used. 
3 mL samples were withdrawn at 5, 10, 15, 20, 30, 45, 60 min, diluted with the 
corresponding medium and analysed by HPLC. At each sampling time points the 
volume of the withdrawn samples was replaced with fresh corresponding dissolution 
medium. For CBZ the open-loop configuration was used. Dissolution samples were 
collected in a volumetric cylinder, samples were diluted with the corresponding 
medium and analysed by HPLC. Cylinders were exchanged at 5, 10, 15, 20, 30, 45, 
60, 90, 120, 180 and 240 min after the beginning of the experiment. All experiments 
were performed in triplicate. 
5.2.3.5. Real – time surface dissolution UV imaging 
Surface dissolution UV imaging was performed using the SDi2 instrument with a 
USP 4 type flow-cell (cell volume: 60.3 mL, cell diameter: 28 mm, effective imaging 
area: 28 x 24 mm2). Dissolution studies of the PRC and CBZ tablets (control and 
variant tablets) were conducted at a flow rate of 6.16 mL at 37 °C using 0.1 N HCl pH 
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1 as dissolution medium for 20 minutes. This flow rate was selected to simulate the 
linear velocity (1 cm/min) in the USP 4 (large cells) when operating at 4 mL/min. 
Dual-wavelength imaging was performed using two Light Emitting Diodes (LEDs) at 
300 and 520 nm for PRC and 320 and 520 nm for CBZ. Drug quantification was also 
assessed by monitoring drug concentrations of the effluent at 1 minute intervals using 
a photodiode array UV-Vis spectrophotometer and used for the construction of the 
dissolution profiles. Drug quantification in the effluent was made based on calibration 
curves (calibration ranges: 2 – 50 μg/mL for PRC, 20 – 150 μg/mL for CBZ). Real-
time surface dissolution UV images showing the disintegration and dissolution 
phenomena of the studied tablets were obtained and processed using the SDi2 analysis 
software v. 3.0.22 (Pion Inc, USA). All experiments were performed in triplicate. 
5.2.3.6. Chromatographic conditions 
Drug quantification in the dissolution samples was performed by HPLC-UV. 
Analytical HPLC procedures were modifications of already published methods for 
PRC [39] and CBZ [40]. A reversed-phase Spherisorb (Waters) C18 column (250 × 
4.6 mm, 5 μm) was used for both drugs. For PRC, the mobile phase consisted of 
methanol and water 20:80 (v/v) and the temperature was kept constant at 20 °C. The 
injection volume was 20 μL and the detection wavelength was at 257 nm. For CBZ, 
the mobile phase was composed of methanol and water 60:40 (v/v) and the 
temperature was kept constant at 25 °C. The injection volume was 100 μL and the 
detection wavelength was at 285 nm. The flow rate was set at 1 mL/min for both drugs 
(isocratic flow). The elution times were 6 min and 4 min for PRC and CBZ, 
respectively. Drug quantification was made based on calibration curves. Standards 
were formulated from concentrated stock solution of drug dissolved in MeOH (PRC: 
2 mg/mL, CBZ: 1 mg/mL). The range of the calibration curves were 10 – 200 μg/mL 
and 10 -150 μg/mL for PRC and CBZ, respectively. 
5.2.3.7. Treatment of in vitro dissolution data 
The cumulative % of drug dissolved in the USP 2 apparatus and USP 4 apparatus 
– closed loop configuration was calculated based on drug quantification from the 
analytical method (HPLC) and the amount of drug in the manufactured tablets. The 
cumulative % of drug dissolved in the USP 4 apparatus - open loop configuration and 
the effluent analysis of the SDi2 was calculated based on drug quantification from the 
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analytical method (HPLC for the samples obtained with the USP 4 apparatus, 
spectroscopy for the samples obtained with the SDi2), the flow rate of the system and 
the amount of drug in the manufactured tablets. The dissolution profiles depicting the 
cumulative % of drug dissolved from the control and variant tablets as a function of 
time were generated using Spotfire 7.10.1 (TIBCO software Inc, USA). The area under 
the curve (AUC) of the dissolution profiles, calculated using the method of trapezoids, 
was used for the characterization of drug dissolution. In cases where the dissolution 
profiles reached a plateau level, the AUC of the dissolution profiles was calculated up 
to the time corresponding to the first experimental datum after the 85% of drug 
dissolution for both the control and variant tablets in each medium [41]. In cases where 
the dissolution profiles did not reach a plateau level, the AUC of the dissolution 
profiles was calculated up to the last experimental time point. The Relative Effect 
(𝑅𝐸𝐴𝑈𝐶) of each excipient variant on the AUCs of the dissolution profiles was 
calculated based on Equation 5.1: 
𝑅𝐸𝐴𝑈𝐶 =  
(𝐴𝑈𝐶𝑇− 𝐴𝑈𝐶𝑅)
𝐴𝑈𝐶𝑅
 𝑥 100 equation 5.1 
where 𝐴𝑈𝐶𝑅 and 𝐴𝑈𝐶𝑇 are the areas under the curve of the dissolution profiles of 
the reference and test product, respectively. Two sets of comparisons were performed. 
In the first set (set 1), the differences in drug dissolution within the studied tablets in 
each medium were examined taking the AUCs of the dissolution profiles of the control 
and variant tablets as reference and test dissolution profiles, respectively. In the second 
set (set 2), differences in drug dissolution within acidic and basic conditions (in 
compendial and biorelevant media) for each tablet batch were investigated taking the 
AUCs of the dissolution profiles in acidic and basic conditions as the reference and 
test dissolution profiles, respectively. Dissolution performance in presence of 
excipients was correlated to the drug apparent solubility in excipient presence using 
the REs of excipients on AUCs of the dissolution profiles and the relative increase or 
decrease in drug solubility by the studied excipients ; the solubility data of PRC and 
CBZ (presented in chapters 2, 3 and 4) in presence of 2% HPMC, 5% SSG or 2% 
MgSt were used. The Relative Effect (𝑅𝐸𝑠) of each excipient on drug solubility were 
calculated based on Equation 5.2: 
𝑅𝐸𝑠 =  
(𝑆−𝑆𝑟)
𝑆𝑟
 𝑥 100  Equation 5.2 
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where 𝑆 and 𝑆𝑟 denote drug solubility in presence of the excipient brand of the 
variant tablets and in presence of the corresponding excipient brand in the control 
tablets. The risk assessment of the impact of excipients on drug dissolution or drug 
solubility was evaluated by setting reference range criteria of -20% - 25% [42] on the 
REsAUC or REsS (this range was selected as a similar range is set in order to assess 
differences in drug exposure after oral administration; i.e. in bioequivalence studies). 
REsAUC or REsS outside these values (REAUC or REsS < -20% or REAUC or REsS > 
25%) were considered critical for oral drug performance. 
5.2.3.8. Statistical analysis of in vitro dissolution data 
5.2.3.8.1. In vitro dissolution profile comparisons 
Dissolution profile comparisons were performed with the use of the f2 (similarity 
factor) assuming the dissolution profiles of the control and variant batches as the 
reference and test dissolution profiles, respectively, according to Equation 5.3: 
𝑓2 =  50 𝑥 log{ [1 + (
1
𝑛
) ∑ (𝑅𝑡 − 𝑇𝑡)2𝑛𝑡=1 ]
−0.5 𝑥 100}  equation 5.3 [41] 
where 𝑅𝑡 and 𝑇𝑡 are the reference and test % cumulative profiles at time t, 
respectively and 𝑛 is the number of sampling points. Evaluation of f2 was considered 
up to the time corresponding to the first experimental datum after the 85% of drug 
dissolution of both the control and variant tablets in each medium [41]. In cases where 
85% of drug dissolution was not reached at the end of the experiment, dissolution 
profile comparisons were performed up to the last experimental time point. Mean data 
sets were used as the coefficient of variation was less than 20% and 10% for early (up 
to 15 min) and late time points, respectively. Differences between the dissolution 
profiles of the test from the reference product were identified setting a 10% difference 
(f2 < 50). 
5.2.3.8.2. Multivariate data analysis of in vitro dissolution data 
Excipient REs on drug dissolution were correlated to excipient critical material 
attributes (viscosity for HPMC and SSG, PSD for MgSt), drug aqueous solubility 
(Drugaq.sol.), medium properties (gastric, intestinal) and hydrodynamics (USP 
apparatus) by partial least squares (PLS) regression using the XLSTAT software 
(Microsoft, USA). Two models for the REs of excipients on the AUCs of the 
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dissolution profiles in compendial media (Model 1) and biorelevant media (Model 2) 
were constructed. The evaluated variables for both models were all categorical and are 
presented in Table 5.2. Excipient REs on the AUCs of the dissolution profiles (set 1, 
section 2.2.6.) were used as the response. The selected interaction terms included each 
excipient variant combined with each drug aqueous solubility (Drugaq.sol.), medium 
property (gastric, intestinal) and hydrodynamic characteristics (USP apparatus). The 
generated PLS models were assessed in terms of goodness of fit (R2) and goodness of 
prediction (Q2). High values of R2 and Q2 with a difference not greater than 0.2 - 0.3 
were indications of successful models [43]. The number of PLS components (lines on 
the X-space which best approximate and correlate with the Y-vector) was based on 
minimum predictive residual sum of squares (PRESS) [43]. From the available 
components the one at which Q2 reached its maximum value was selected [44]. 
Standardized coefficients were used to show the direction (positive or negative) and 
extent of each variable on the response. The significance of the variables was assessed 
by the variable influence on projection (VIP) value. The significance of the variables 
was assessed by the variable influence on projection (VIP) value. VIP values > 0.8 
were considered as moderately influential in the model while VIP values > 1 were 
considered the most influential in the model [43]. A 95 % confidence interval was 
used. 




Drug(aq.sol.)* Poorly soluble Highly soluble 
Medium Gastric Intestinal 
Hydrodynamics USP 2 apparatus USP 4 apparatus 
USP 4 hydrodynamics Small cells Large cells 
HPMC variant HPMC – control tablets HPMC – variant tablets 
SSG variant SSG – control tablets SSG – variant tablets 
MgSt variant MgSt – control tablets MgSt – variant tablets 
* Drug(aq.sol) = Drug aqueous solubility 
233 
 
5.3. Results and Discussions 
5.3.1. Tablet characterization 
The properties of the manufactured PRC and CBZ tablets are presented in Table 
5.3. Tablets of approximately 500 mg mass, 5.5 mm thickness and 11.0 mm diameter 
were produced irrespective of model compound or variant used. Comparison of the 
control tablets of PRC and CBZ showed lower hardness and faster disintegration time 
for the CBZ control tablets which could be explained by the lipophilic nature of CBZ 
(log P = 2.45, source DrugBank). For PRC, the HPMC variant tablets (high HPMC 
viscosity) exhibited lower hardness and faster disintegration compared to the control 
tablets (low HPMC viscosity), as densification of HPMC reduces with increasing 
excipient viscosity [45]. For CBZ, the tablet hardness of the control and the HPMC 
variant tablets were similar. The slower disintegration of the HPMC variant tablets 
compared to the control tablets may be explained by the higher viscosity of the HPMC 
variant [46]. The SSG variant tablets (low SSG viscosity) were softer compared to the 
control tablets (high SSG viscosity) in the case of PRC. As higher degree of 
crosslinking between the hydroxyl groups of SSG reduces the solubility of the polymer 
[47, 48] the lower tablet hardness may be attributed to the decreased polymer 
hydrophilicity or the formation of less hydrogen bonds in the SSG variant compared 
to the control tablets. Differences in tablet hardness between the control and SSG 
variant tablets were not observed for CBZ. Highly crosslinked SSG brands (low SSG 
viscosity) would be expected to lead to faster tablet disintegration due to the increased 
water uptake [49], however, differences in tablet disintegration between the SSG 
variant and control tablets were minor irrespective of model compound. The presence 
of 2% of MgSt may have affected the penetration rate of water into tablets and 
diminish the differences in disintegration time between the studied SSG brands [47]. 
The MgSt variant (low MgSt particle size) produced softer tablets compared to the 
control tablets (high MgSt particle size) for PRC as a result of the better lubrication 
efficiency of the lower particle size of the MgSt variant [50]. The faster disintegration 
of the MgSt variant tablets compared to the control tablets is attributed to its lower 
tablet hardness [51]. No impact on the hardness and disintegration data were found 




























































































5.3.2. In vitro dissolution studies 
5.3.2.1. Control Tablets 
5.3.2.1.1. Highly soluble drug (PRC) 
The dissolution profiles of PRC from the control and variant tablets in compendial 
and biorelevant media in the USP 2, USP 4 (small cells) and USP 4 (large cells) 






Figure 5.1: Cumulative % dissolved of PRC from tablet formulations in compendial 
and biorelevant media using the a. USP 2 apparatus (500 mL, 50 rpm, 37°C), b. USP 
4 apparatus (closed mode, small cells, 500 mL, 4 mL/min, 37°C) and c. USP 4 
apparatus (closed mode, large cells, 500 mL, 4 mL/min, 37°C). The different tablets 
are shown as: i. control tablets (black circles), ii. HPMC variant tablets (blue 
diamonds), iii. SSG variant tablets (green triangles) and iv. MgSt variant tablets (red 
squares). (Mean ± SD, n = 3) 
 
The dissolution of PRC from the control tablets was complete in all experimental 
conditions. In the USP 2 apparatus, the 85% of drug dissolution was reached in 20 min 
in 0.1 N HCl pH 1, phosphate buffer pH 6.8 and FaSSGF and in 15 min in FaSSIF-
V2. The faster drug dissolution in FaSSIF-V2 can be explained by the presence of bile 
salts improving tablet wetting [8]. In the USP 4 apparatus, the 85% of drug dissolution 
from the control tablets was reached in 30 min in 0.1 N HCl pH 1 and in 20 min in 
phosphate buffer pH 6.8, FaSSGF and FaSSIF-V2 when the small cells were used and 
in 30 min in all experimental conditions when the large cells were used. The applied 
hydrodynamics differ between the two studied systems as turbulent flows prevail in 
the USP 2 apparatus [52] while laminar flows exist in the USP 4 apparatus when glass 
beads are used [53]. Comparison of the hydrodynamics between apparatuses is 
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conducted with the use of Reynolds number (ratio of inertial to viscous forces in the 
fluid) which relates to the fluid and linear velocities in the studied apparatuses and 
associates with the mass transfer rates [54]. High fluid velocities (corresponding to 
high Reynolds number) have been reported in the USP 2 apparatus (fluid velocity of 
0.049 m/s from the top surface of the tablet [10]) while the laminar flows in the USP 
4 apparatus results in low fluid velocities (low Reynolds numbers) (small cells: 0.005 
m/s, large cells: 0.001 m/s [54]). In the USP 4 apparatus, the lower linear velocities at 
equivalent flow rates in the large compared to the small cells relate to the increased 
cross-sectional area of the large cells [55]. Therefore, the slower drug dissolution in 
the USP 4 (small and large cells) compared to the USP 2 apparatus and in the USP 4 
apparatus (large cells compared to the small cells) is justified by the differences in 
fluid velocities within the studied apparatuses. The REs of excipients on the AUCs of 
the dissolution profiles between acidic and basic conditions in compendial and 
biorelevant media are presented in Figure 5.2. The positive REsAUC in compendial 
media indicate more complete drug dissolution in basic compared to acidic conditions. 
Presence of SSG or MgSt may lead to slower dissolution in acidic compared to basic 
conditions due to the reduced liquid water uptake by the neutral form of SSG [56] or 
the slower dissolution of stearic acid (dissociation product of MgSt) which limits drug 
dissolution [57] in acidic media. Differences in the REsAUC of excipients between 
acidic and basic media are less pronounced in biorelevant media, as the presence of 
the solubilizing components in these media facilitates tablet wetting and enhances 
drug dissolution [58]. 
 
Figure 5.2: Relative effects of excipients on the AUCs of the dissolution profiles 
between acidic and basic conditions for PRC and CBZ from the control tablets in 
compendial (green colour) and biorelevant (blue colour) media. (Mean ± SD, n = 3) 
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5.3.2.1.2. Poorly soluble drug (CBZ) 
The dissolution profiles of CBZ from the control tablets in compendial and 




Figure 5.3: Cumulative % dissolved of CBZ from tablet formulations in compendial 
and biorelevant media using the a. USP 2 apparatus (500 mL, 50 rpm, 37°C) and b. 
USP 4 apparatus (open mode, small cells, 4 mL/min, 37°C). The different batches are 
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shown as: i. control tablets (black circles, ii. HPMC variant tablets (blue diamonds), 
iii. SSG variant tablets (green triangles) and iv. MgSt variant tablets (red squares). 
(Mean ± SD, n = 3) 
 
In the USP 2 apparatus, the dissolution of CBZ in the studied media was not 
complete (70% - 80% of drug dissolved at 4 hours), due to the lack of sink conditions. 
In the USP 4 apparatus, approximately 85% of drug dissolution was reached after 4 
hours from the control batch as sink conditions were achieved due to the open-loop 
configuration [53]. The REs of excipients on the AUCs of the dissolution profiles 
between acidic and basic conditions revealed slightly more complete drug dissolution 
in basic conditions (2% < REsAUC < 10%) in the studied conditions (Figure 5.2). This 
indicates that the pH dependent performance of certain excipients (SSG or MgSt) will 
be less pronounced for poorly soluble drugs. 
5.3.2.2. HPMC variant 
5.3.2.2.1. Highly soluble drug (PRC) 
Complete drug dissolution from the HPMC variant tablets was observed in the 
studied experimental conditions (Figure 5.1). In the USP 2 apparatus, the 85% of drug 
dissolution from the HPMC variant tablets was reached faster compared to the control 
tablets in 0.1 N HCl pH 1, phosphate buffer pH 6.8 and FaSSGF (15 min vs 20 min 
for the HPMC variant tablets and control tablets, respectively). Differences in the time 
to reach 85% of drug dissolution between the HPMC variant tablets and the control 
tablets were not observed in FaSSIF-V2 in the USP 2 apparatus and in all experimental 
conditions in the USP 4 apparatus (small and large cells). The REs of excipients on 
the AUCs of the dissolution profiles between the HPMC variant tablets and the control 





Figure 5.4: a. Relatives effects of excipients on the AUCs of the dissolution profiles 
between the control and HPMC variant tablets for the dissolution of PRC and CBZ in 
compendial (green colour) and biorelevant (blue colour) media in the studied 
apparatuses. Light and dark colours correspond to acidic and basic conditions, 
respectively (Mean ± SD, n = 3). b. Relative effects of excipients on the AUCs of the 
dissolution profiles between acidic and basic conditions for the dissolution of PRC 
and CBZ from the HPMC variant tablets in compendial (green colour) and biorelevant 
(blue colour) media. (Mean ± SD, n = 3) 
 
Positive REsAUC were observed in all experimental conditions (0.6% < REs < 17%) 
apart from the case of drug dissolution in biorelevant media in the USP 4 apparatus 
(small cells) (REsAUC of -3% and -2.3% in FaSSGF and FaSSIF-V2, respectively). 
The positive REsAUC indicated slightly more complete drug dissolution from the 
HPMC variant tablets compared to the control tablets due to the faster tablet 
disintegration (Table 5.3). The dissolution profiles of the HPMC variant tablets and 
the control tablets were similar (f2 > 50) in all experimental conditions (Table 5.4), 
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indicating that varying HPMC viscosity type is not expected to be critical for the 
dissolution of highly soluble compounds from immediate release formulations . A 
dissolution medium effect in PRC dissolution from the HPMC variant tablets was 
revealed, as drug dissolution was slightly more complete in basic compared to acidic 
conditions in compendial (REsAUC of 24%, 18% and 6% in the USP 2, USP 4 (small 
cells) and USP 4 (large cells) apparatus, respectively) but not in biorelevant media 
(Figure 5.4b). This differences in PRC dissolution in basic compared to acidic 
compendial media is attributed to the presence of SSG and MgSt (as explained in 
3.2.1.1.), therefore it is concluded that changes in the viscosity type of HPMC are not 




Table 5.4: Similarity factors (f2) of the dissolution profile comparisons for PRC and 
CBZ variant tablets in compendial and biorelevant media using the USP 2 and USP 4 
(small and large cells) apparatuses. Bold values indicate significant differences 
between the test and the reference dissolution profiles (f2 < 50). 
    Compendial Media Biorelevant Media 
    
0.1 N HCl pH 
1 
Phosphate 
buffer pH 6.8 
FaSSGF FaSSIF-V2 





62.9 83.8 67.2 70.9 59.5 76.3 85.4 86.2 
SSG 
Variant 
69.7 63.6 64.4 67.3 65.0 65.4 83.6 76.7 
MgSt 
Variant 







55.8 58.8 72.0 56.4 83.5 67.6 71.6 62.1 
SSG 
Variant 
77.7 64.2 62.6 56.8 70.3 59.1 72.3 61.2 
MgSt 
Variant 







65.6 -* 81.5 - 88.9 - 64.6 - 
SSG 
Variant 
66.1 - 80.9 - 91.8 - 87.8 - 
MgSt 
Variant 
58.2 - 61.6 - 63.0 - 56.0 - 
*experiments not performed  
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5.3.2.2.2. Poorly soluble drug (CBZ) 
Approximately, 80% (USP 2 apparatus) and complete (USP 4 apparatus) drug 
dissolution was reached in 4 hours from the HPMC variant tablets (Figure 5.3) 
reflecting the differences of the two dissolution experimental setups in achieving sink 
conditions [53]. The REs on the AUCs of the dissolution profiles for the HPMC variant 
tablets compared to the control tablets were minor in the USP 2 apparatus (-10% < 
REsAUC < 10%) and slightly positive in the USP 4 apparatus (6% < REsAUC < 13%) 
(Figure 5.4a). The dissolution profiles of the HPMC variant tablets and control tablets 
were similar (f2 > 50) irrespective of medium or apparatus used (Table 5.4) revealing 
that varying HPMC viscosity type is not critical for the dissolution of poorly soluble 
drugs. Minor differences in drug dissolution in basic compared to acidic conditions (-
0.5% < REsAUC < 15%) were observed for the HPMC variant tablets (Figure 5.4b).  
5.3.2.3. SSG Variant 
5.3.2.3.1. Highly soluble drug (PRC) 
Drug dissolution was complete from the SSG variant tablets in all experimental 
conditions (Figure 5.1). Differences in the time to reach 85% of drug dissolution 
between the SSG variant and the control tablets were observed only in phosphate 
buffer pH 6.8 and FaSSGF in the USP 2 apparatus (15 min vs 20 min for the SSG 
variant and control tablets, respectively) and in 0.1 N HCl pH 1 in the USP 4 apparatus 
(large cells) (45 min vs 30 min for the SSG variant and control tablets, respectively). 
The REs of excipients on the AUCs of the dissolution profiles between the SSG variant 
tablets and the control tablets were minor in all experimental conditions (-10% < 
REsAUC < 10%) (Figure 5.5a) and dissolution profile comparisons (Table 5.4) 
revealed similarity between the dissolution profiles of the control and SSG variant 





Figure 5.5: a. Relatives effects of excipients on the AUCs of the dissolution profiles 
between the control and SSG variant tablets for the dissolution of PRC and CBZ in 
compendial (green colour) and biorelevant (blue colour) media in the studied 
apparatuses. Light and dark colours correspond to acidic and basic conditions, 
respectively. (Mean ± SD, n = 3). b. Relative effects of excipients on the AUCs of the 
dissolution profiles between acidic and basic conditions for the dissolution of PRC 
and CBZ from the SSG variant tablets in compendial (green colour) and biorelevant 
(blue colour) media. (Mean ± SD, n = 3) 
 
The positive REs on the AUCs of the dissolution profiles from the comparisons of 
dissolution performance in the tested media indicated more complete drug dissolution 
in basic compared to acidic conditions from the SSG variant tablets in compendial 
media (Figure 5.5b). In compendial media, the REs on the AUCs of the dissolution 
profiles of the SSG variant tablets between acidic and basic conditions (USP 2 
apparatus: 15%, USP 4 apparatus (small cells): 38%, USP 4 apparatus (large cells: 
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22%) were more pronounced compared to the control tablets (USP 2 apparatus: 12%, 
USP 4 apparatus (small cells): 32%, USP 4 apparatus (large cells: 10%). These 
differences in drug dissolution between the SSG variant tablets and control tablets may 
be attributed to the fast and extensive swelling of low viscosity SSG in basic media 
[59].  
5.3.2.3.2. Poorly soluble drug (CBZ) 
The dissolution of CBZ from the SSG variant tablets was incomplete (70% - 80%) 
and complete in the USP 2 and USP 4 apparatus, respectively (Figure 5.3). The REs 
on the AUCs of the dissolution profiles of the SSG variant tablets were slightly 
positive in all experimental conditions (4.5 < REsAUC < 14%) apart from the case of 
drug dissolution in FaSSIF-V2 in the USP 2 apparatus (REAUC = -2.5%) (Figure 5.5a). 
The dissolution profiles of the SSG variant tablets and the control tablets were similar 
in all experimental conditions (f2 > 50) (Table 5.4) indicating that varying SSG 
viscosity type is not significant for the dissolution of poorly soluble drugs. Slightly 
more complete drug dissolution in basic compared to acidic conditions was observed 
(3% < REsAUC < 13%) except from the case of drug dissolution in biorelevant media 
in the USP 2 apparatus (REAUC = -6%) (Figure 5.5b).  
5.3.2.4. MgSt Variant 
5.3.2.4.1. Highly soluble drug (PRC) 
Drug dissolution from the MgSt variant tablets was complete in all experimental 
conditions (Figure 5.1). The 85% of drug dissolution from the MgSt variant tablets 
was reached faster compared to the control tablets in compendial media and in 
FaSSGF in the USP 2 apparatus (15 min vs 20 min for the MgSt variant and control 
tablets, respectively). The time to reach 85% of drug dissolved was faster in 0.1 N HCl 
pH 1 (20 min vs 30 min for the MgSt variant and control tablets, respectively) and in 
phosphate buffer pH 6.8 and biorelevant media in the USP 4 apparatus (small cells) 
(15 min vs 20 min for the MgSt variant and control tablets, respectively). No 
differences in the time to reach 85% of drug dissolution were observed in FaSSIF-V2 
(USP 2 apparatus) and in all experimental conditions (USP 4 apparatus (large cells)) 
between the MgSt variant and the control tablets. The REs of excipients on the AUCs 
of the dissolution profiles of the MgSt variant tablets compared to the control tablets 
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were positive (8% < REsAUC < 41%), except from the case of drug dissolution in 
FaSSGF in the USP 4 apparatus (large cells) (REAUC = -0.7%) (Figure 5.6a). The 
positive REsAUC indicate more complete drug dissolution as the low particle size MgSt 
produced softer tablets with faster disintegration (Table 5.3). Drug dissolution from 
the MgSt variant tablets was significantly faster compared to the control tablets in 
phosphate buffer pH 6.8 (f2 = 47.1), FaSSGF (f2 = 43.0) and FaSSIF-V2 (f2 = 41.2) in 
the USP 2 apparatus and in all the studied media in the USP 4 apparatus (small cell) 
(34.0 < f2 < 46.2) (Table 5.4) indicating the criticality of MgSt variability for the 
dissolution of highly soluble drugs. The significant changes in drug dissolution 
between the control and MgSt variant tablets reveal the effects of the applied 
hydrodynamics on the impact of excipient variability on drug dissolution. Significant 
differences in drug dissolution were observed in the USP 2 apparatus and the USP 4 
apparatus (small cells) compared to the USP 4 apparatus (large cells), as the 
discriminatory power of the dissolution method increases with increased fluid 














Figure 5.6: a. Relatives effects of excipients on the AUCs of the dissolution profiles 
between the control and MgSt variant tablets for the dissolution of PRC and CBZ in 
compendial (green colour) and biorelevant (blue colour) media in the studied 
apparatuses. Light and dark colours correspond to acidic and basic conditions, 
respectively (Mean ± SD, n = 3). b. Relative effects of excipients on the AUCs of the 
dissolution profiles between acidic and basic conditions for the dissolution of PRC 
and CBZ from the MgSt variant tablets in compendial (green colour) and biorelevant 
(blue colour) media. (Mean ± SD, n = 3) 
 
In compendial media, more complete drug dissolution (6% < REsAUC < 19%) from 
the MgSt variant tablets in basic compared to acidic conditions was observed revealing 
the pH-depended performance of MgSt (Figure 5.6b). 
5.3.2.4.2. Poorly soluble drug (CBZ) 
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Approximately, 70% - 80% (USP 2 apparatus) and 90% (USP 4 apparatus) of CBZ 
dissolved from the MgSt variant tablets (Figure 5.3). The REs on the AUCs of the 
dissolution profiles of the MgSt variant tablets compared to the control tablets were 
minor in all experimental conditions (-10% < REsAUC < 10%) (Figure 5.6a). 
Dissolution profile comparisons (Table 5.4) revealed that drug dissolution from the 
MgSt variant tablets was similar to the control tablets in all experimental conditions 
(f2 > 50). Slightly more complete drug dissolution was observed in basic compared to 
acidic conditions (2% < REsAUC < 12%) from the MgSt variant tablets (Figure 5.6b).  
5.3.3. Real time surface dissolution UV imaging 
The real-time surface dissolution UV visualization of the 
disintegration/dissolution phenomena for the PRC and CBZ tablets tested is presented 
in Figure 5.7.  
 
Figure 5.7: Real-time surface dissolution UV images for a. PRC and b. CBZ tablets 
in 0.1 N HCl pH 1. 
 
The PRC and CBZ control tablets fully disintegrated at 16 min and 8 min, 
respectively. The dissolution profiles of the PRC and CBZ tablets are presented in 
Figure 5.8. Complete dissolution was not observed for any of the studied drugs. After 
20 min, approximately 70% of PRC and 10% of CBZ dissolved from the control 






Figure 5.8: Dissolution profiles of PRC and CBZ from the i. Control tablets (black 
circles), ii. HPMC variant tablets (blue diamonds), iii. SSG variant tablets (green 
triangles) and iv. MgSt variant tablets (red squares) in 0.1 N HCl pH 1 using surface 
dissolution UV Imaging (SDi2, 6.16 mL/min, 37 °C, open mode). (Mean ± SD, n = 3) 
 
In the case of PRC, tablet disintegration (13 min) (Figure 5.7) and drug dissolution 
(76% of drug dissolved at 20 min) were faster from the HPMC variant tablets 
compared to the control tablets (tablet disintegration at 16 min, 70% of drug dissolved 
at 20 min). These differences could be attributed to the lower tablet hardness of the 
HPMC variant compared to the control tablets (Table 5.3). For CBZ, slower 
disintegration (17 min) and drug dissolution (7% of drug dissolved at 20 min) was 
observed from the HPMC variant compared to the control tablets (tablet disintegration 
at 8 min, 10% of drug dissolved at 20 min). Changing the viscosity type of HPMC did 
not affected the hardness of CBZ tablets (as the impact of excipients on tablet hardness 
was pronounced for the highly soluble drug which inherently produced stronger 
tablets, Table 5.3). Therefore the slower tablet disintegration and drug dissolution 
from the HPMC variant compared to the control tablets could be attributed to the 
differences in the viscosity type of the used HPMC brands. The REs on the AUCs of 
the dissolution profiles revealed minor differences between the studied tablets for PRC 
(REAUC = -13%) and significant slower drug dissolution from the HPMC variant 
tablets (REAUC = -48%) for CBZ due to the slower disintegration (Figure 5.7). The 
disintegration time of the SSG variant tablets was similar to the control tablets for both 
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PRC (16 min) and CBZ (9 min). Differences in drug dissolution when varying SSG 
brand were not observed for any of the studied drugs (PRC: 70% of drug dissolved at 
20 min, CBZ: 10% of drug dissolved at 20 min) and confirmed by the minor REs of 
excipients on the AUCs of the dissolution profiles (PRC: REAUC = -7%, CBZ: REAUC 
= 2%). Faster disintegration was observed for the MgSt variant tablets (11 min) 
compared to the control tablets (16 min) for PRC resulting in significantly faster drug 
dissolution (85% of drug dissolved at 20 min for the MgSt variant tablets compared to 
70% of drug dissolved at 20 min for the control tablets) (REAUC = 65%), that could be 
attributed to the lower tablet hardness of the MgSt variant tablets (Table 5.3). 
Differences in tablet disintegration (9 min) and drug dissolution (9% of drug dissolved 
at 20 min) between the MgSt variant tablets and the control tablets were not observed 
in the case of CBZ, as the hardness of the CBZ tablets was not affected when 
decreasing the particle size of MgSt (Table 5.3). The RE of excipients on the AUCs 
of the dissolution profiles for CBZ was close to the lower limit of the reference range 
criterion (REAUC = -21%) indicating that slight differences in drug dissolution may be 
expected at early time points when varying MgSt. The real-time surface dissolution 
UV imaging confirmed that for immediate release formulations, excipients may alter 
drug dissolution due to their effects on tablet disintegration and/or tablet wetting. The 
impact of excipient variability on drug dissolution depends both on excipient and drug 
characteristics as significant differences were mainly observed for PRC when varying 
the MgSt brand and CBZ when varying the HPMC brand. The disintegration data from 
the real-time surface dissolution UV images are in good agreement with the data from 
the compendial disintegration test (Table 5.3). The results confirm that real-time 
surface dissolution UV imaging can give additional visual insights on tablet 
disintegration and drug dissolution in a biorelevant perspective. 
5.3.4. Correlation of drug solubility and drug dissolution performance 
in presence of excipients 
The REs of excipients on the AUCs of the dissolution profiles of the variant tablets 
as a function of the REs of excipients on drug apparent solubility in compendial and 




Figure 5.9: Relative effects of the studied excipients on the AUCs of the dissolution 
profiles (REAUC) as a function of relative effects of the studied excipients on drug 
solubility (RES) in a. compendial and b. biorelevant media. The drugs are portrayed 
as: i. PRC (circles) and ii. CBZ (squares). The dissolution profiles with the studied 
apparatuses are shown as: i. USP 2 apparatus (blue colour), ii. USP 4 apparatus – small 
cells (red colour) and iii. USP 4 apparatus - large cells (green colour). (Mean ± SD, n 
= 3) 
 
In cases where significant changes in drug apparent solubility were not observed 
when varying excipient brands (-20% < REsS < 25%), drug dissolution was not greatly 
affected by excipient variability, as indicated by the low REs of excipients on the 
AUCs of the dissolution profiles (-20% < REsAUC < 25%). In cases where excipient 
variability significantly altered drug solubility, drug dissolution was affected by the 
excipient change and depended on the applied hydrodynamics. This was the case of 
PRC in presence of MgSt, where the low particle size brand (Ligamed MF-3-V) 
decreased drug solubility to a higher extent compared to the high particle size brands 
(Ligamed MF-2-V). This was attributed to i. the higher lubrication efficiency of the 
low particle size brand around drug particles or ii. drug shielding by the presence of a 
more lipophilic MgSt brand (Chapter 2). The faster drug dissolution relates to the low 
particle size of the MgSt variant brand (Ligamed MF-3-V) as due to its improved 
lubrication efficiency it produced softer tablets. As the hardness of the CBZ control 
tablets was lower compared to the PRC (Table 5.3), the impact of varying MgSt brand 
was not pronounced for the poorly soluble compound. Differences in the dissolution 
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profiles of PRC when varying MgSt brand were more pronounced in the USP 2 
apparatus and USP 4 apparatus – small cell (20% < REsAUC < 41%) compared to the 
USP 4 apparatus – large cells (REsAUC < 20%) due to the differences in the applied 
hydrodynamics, as explained previously (section 2.3.4.1). For the highly soluble drug, 
in the cases where an average correlation between the impact of excipients on drug 
dissolution and drug solubility was observed (REAUC ≈ 20%, close to the upper limit 
of risk assessment criteria), dissolution profile comparisons can still prove differences 
in drug dissolution (Table 5.4). The aforementioned correlations indicate that drug 
solubility studies give an insight on the impact of excipient variability on drug 
dissolution, as for the majority of cases the effects of excipients on drug dissolution 
and drug solubility were well correlated, apart from the case of PRC dissolution in the 
USP 4 apparatus (large cells) when varying MgSt (no significant changes in drug 
dissolution attributed to the low fluid velocities of the system [60]). 
5.3.5. Multivariate data analysis of in vitro dissolution data 
The standardized beta coefficients of the variables in compendial and biorelevant 
media are presented in Figure 5.10. The two models showed a good predictive power 






















































































































































The statistical analysis reveals that the impact of excipient variability on drug 
dissolution depends on the excipient variant. MgSt variant (compendial media, 
positive effect, VIP = 1.7, biorelevant media, positive effect, VIP = 1.6) was a 
significant variable in both models revealing that faster drug dissolution is anticipated 
from tablets containing MgSt of low particle size due to the production of softer tablets 
with faster tablet disintegration compared to tablets containing MgSt of high particle 
size. SSG variant (compendial media: negative effect, VIP = 1.3) and HPMC variant 
(biorelevant media: negative effect, VIP = 1.0) were significant variables in the 
indicated models. The negative effect of these variables reveals that varying SSG or 
HPMC viscosity type may result in slightly slower drug dissolution or that the 
improvement in drug dissolution will be lower when varying the aforementioned 
brands compared to MgSt. The impact of excipient variability on drug dissolution also 
related to drug aqueous solubility as revealed by the significance of the variable 
Drug(aq.sol.) (positive effect, VIP = 1.2) in the biorelevant model. This variable indicates 
that significantly faster drug dissolution when varying excipient types is anticipated 
for the highly soluble drug, as excipient variability may strongly affect tablet 
properties of hydrophilic components (Table 5.3). The significance of the variable 
Drug(aq.sol.) in biorelevant (and not in compendial) media indicates that changes in drug 
dissolution will be pronounced in media where tablets disintegrate fast, due to the 
presence of the solubilizing components which improve tablet wetting [8]. The effects 
of excipient on drug dissolution depends also on the hydrodynamics, as revealed by 
the significance of the USP 4 hydrodynamics (compendial media: negative effect, VIP 
1.3, biorelevant media: negative effect, VIP = 1) in both models. This variable 
indicates that the improvement in drug dissolution by the studied excipients in the USP 
4 apparatus will be less pronounced when the large cells are used, as differences in 
drug dissolution rates cannot be observed in very low fluid velocities [55]. 
The complex nature of excipient variability and its impact on drug dissolution was 
identified by the significance of certain interactions between the studied variables. 
MgSt variant* Drug(aq.sol.) was a significant variable (compendial media: positive 
effect, VIP = 2.1, biorelevant media: positive effect, VIP = 2.4) in both models and 
reveals that the enhancement in drug dissolution by low particle size MgSt brands will 
be pronounced for highly soluble drugs (due to the differences in tablet hardness). SSG 
variant* Drug(aq.sol.) (compendial media: negative effect, VIP = 1.7, biorelevant media: 
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negative effect, VIP = 1.3) and HPMC variant* Drug(aq.sol.) (biorelevant media: 
negative effect, VIP = 1.0) were significant interactions in the models. These 
interactions reveal that the enhancement in drug dissolution when varying SSG or 
HPMC viscosity will be less pronounced for the highly soluble drug, as, generally, 
presence of hydrophilic excipients may improve the dissolution of poorly soluble 
drugs. Finally, SSG variant*hydrodynamics (negative effect, VIP = 1.0) was a 
significant variable in the compendial model revealing that varying SSG variant may 
result in slightly slower drug dissolution or that the improvement in drug dissolution 
will be lower with decreasing flow velocities [55, 60]. 
5.4.  Conclusions 
Dissolution testing plays a key role in QbD approaches assessing the quality and 
biorelevant or clinical performance of final dosage forms. Excipient presence and 
variability may present challenges for oral drug absorption, therefore understanding 
the biopharmaceutical implications of excipients on product performance with the use 
of dissolution tests is beneficial. In this work, the impact of excipient variability of 
binders (HPMC – viscosity type), superdisintegrants (SSG – viscosity type) and 
lubricants (MgSt – PSD type) on the dissolution of a highly and a poorly soluble drug 
from immediate release formulations was assessed in a biopharmaceutical perspective. 
Varying MgSt brand was considered of high criticality for oral drug performance as 
faster dissolution was observed for the highly soluble drug due to the production of 
softer tablets when decreasing the particle size of MgSt. Dissolution profile 
comparisons revealed that MgSt variant tablets would not meet the quality control 
acceptance criteria and could present regulatory implications. The impact of 
hydrodynamics on the effects of MgSt variability on drug dissolution was revealed, as 
increasing flow velocities (for the highly soluble drug) resulted in dissolution methods 
with better discriminatory power. Varying HPMC or SSG grade was of low criticality 
for product performance as similarity was found between the dissolution profiles of 
the control and variant tablets irrespective of the model compound. The pH and 
presence of solubilizing components affected the impact of excipients (especially SSG 
and MgSt) on drug dissolution. Real-time surface dissolution UV imaging revealed 
that varying excipient types/brands can affect tablet disintegration and/or wetting. In 
vitro dissolution data were in good agreement with previous solubility studies in 
presence of excipients showing that changes in drug solubility by excipient variability 
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may indicate significant changes in drug dissolution. Use of PLS revealed the 
significant role of excipient type and material attributes, drug aqueous solubility, 
medium characteristics and hydrodynamic conditions on the excipient effects on drug 
dissolution. The study highlights the effects of excipient variability on product 
performance and the importance of biopharmaceutical considerations for excipient 
selection. 
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Chapter 5 Commentary 
Dissolution testing can be used to assess the criticality of excipient variability on 
product performance in a Quality be Design (QbD) perspective. In this chapter, the 
impact of excipient variability of binders (viscosity type of hypromellose (HPMC)), 
superdisintegrants (viscosity type of sodium starch glycolate (SSG)) and lubricants 
(particle size distribution of magnesium stearate (MgSt)) on the dissolution of a highly 
and a poorly soluble drug was investigated in a biopharmaceutical perspective. 
Dissolution tests were performed in compendial and biorelevant media using 
compendial apparatuses (USP 2 and USP 4 apparatus) and surface dissolution UV 
imaging. The impact of excipients on drug dissolution depended on the excipient type 
used. Significant changes in drug dissolution when varying HPMC or SSG viscosity 
type were not observed for the studied drugs. The high criticality of MgSt was 
demonstrated (as also revealed in Chapter 2). Decreasing the particle size of MgSt 
resulted in faster drug dissolution for the highly soluble drug as a result of the lower 
tablet hardness caused by the lipophilic nature of the excipient. These results 
demonstrate that the impact of excipients on drug dissolution strongly relate to the 
excipient type used and the drug under investigation. The interplay of excipient critical 
material properties and manufacturing processes and their impact on drug dissolution 
was revealed. Differences in drug dissolution, when varying MgSt, were more 
pronounced in apparatuses of high flow velocities indicating that the effects of 
different excipient brands can depend on the gastrointestinal hydrodynamics. 
Additional insights on the impact of excipients on drug dissolution were obtained with 
the use of surface dissolution UV imaging which allowed the real-time visualization 
of tablet disintegration and wetting phenomena. The importance of designing 
biorelevant methods to study excipient criticality was demonstrated with the use of 
multivariate data analysis.  
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Chapter 6 Preface 
Sodium starch glycolate (SSG) and croscarmellose sodium (CCS) are two commonly 
used swelling superdisintegrants that promote fast tablet disintegration in immediate 
release formulations. Their superior performance, compared to natural polymers, is 
attributed to the crosslinking and carboxymethylation of the polymeric chains. 
Differences in the swelling capacity between SSG and CCS, despite their similar 
structure, have been attributed to their varying physicochemical properties. Excipient 
interchangeability, therefore, is questionable as changes in tablet disintegration and 
drug dissolution can be anticipated when varying excipients with the same intended 
functionality. The critical material properties and the biopharmaceutical implications 
of superdisintegrants are not fully understood. The previous chapters focused on 
understanding the effects of superdisintegrant variability on drug apparent solubility 
and drug dissolution. As superdisintegrants act in seconds, use of surface dissolution 
UV imaging (novel approach which allows the spatial and temporal visualization of 
disintegration and/or dissolution phenomena) could give further mechanistic insights 
on superdisintegrant functionality. The aims of this chapter are to assess the swelling 
performance of SSG and CCS with different material properties and identify their 
impact on the dissolution of a highly and a poorly soluble drug using surface 
dissoluton UV imaging. Acidic and basic compendial media will be used to identify 
the role of the pH of the medium on the swelling behaviour of superdisintegrants and 




Chapter 6. Surface dissolution UV Imaging for characterization of 
superdisintegrants and their impact on drug dissolution 
 
Abstract 
Superdisintegrants are a key class of excipients used in immediate release 
formulations to promote fast tablet disintegration, therefore understanding the impact 
of superdisintegrant variability on product performance is important. The current 
study examined the impact of superdisintegrant critical material attributes (viscosity 
for sodium starch glycolate (SSG), particle size distribution (PSD) for croscarmellose 
sodium (CCS)) on their performance (swelling) and on drug dissolution using surface 
dissolution UV imaging. Acidic and basic pharmacopoeia (compendial) media were 
used to assess the role of varying pH on superdisintegrant performance and its effect 
on drug dissolution. A highly soluble (paracetamol) and a poorly soluble 
(carbamazepine) drug were used as model compounds and drug compacts and drug-
excipient compacts were prepared for the dissolution experiments. The presence of a 
swelled SSG or CCS layer on the compact surface, due to the fast excipient hydration 
capacity, upon contact with dissolution medium was visualized. The swelling 
behaviour of superdisintegrants depended on excipient critical material attributes and 
the pH of the medium. Drug dissolution was faster in presence compared to 
superdisintegrant absence due to improved compact wetting or compact disintegration. 
The improvement in drug dissolution was less pronounced with increasing SSG 
viscosity or CCS particle size. Drug dissolution was slightly more complete in basic 
compared to acidic conditions in presence of the studied superdisintegrants for the 
highly soluble drug attributed to the increased excipient hydration capacity and the 
fast drug release through the swelled excipient structure. The opposite was observed 
for the poorly soluble drug as potentially the improvement in drug dissolution was 
compromised by drug release from the highly swelled structure. The use of 
multivariate data analysis revealed the influential role of excipient and drug properties 
on the impact of excipient variability on drug dissolution. 
Keywords: excipient viscosity, excipient particle size, sodium starch glycolate, 





Presence of superdisintegrants in oral solid dosage forms is essential for fast tablet 
disintegration and improved drug dissolution. Sodium starch glycolate (SSG)) and 
Croscarmellose sodium (CCS) (semisynthetic polymers of starch and cellulose, 
respectively) are commonly used as superdisintegrants in tablet manufacturing. The 
main mechanism by which superdisintegrants promote tablet disintegration is swelling 
[1]. Swelling refers to the volume expansion of the superdisintegrant particles upon 
contact with water [1]. The swelling mechanism of SSG and CCS has been confirmed 
with the use of real-time magnetic resonance imaging [2]. 
SSG and CCS are sodium salts and are present as a neutral form in acidic and 
ionized form in basic conditions. They derive from natural polymers after two main 
modification steps (carboxymethylation and crosslinking) of the natural polymer 
chains to improve excipient functionality [1]. Firstly, carboxymethylation (also known 
as degree of substitution) of the natural polymer backbone increases polymer 
hydrophilicity and allows water access into the excipient [3]. Secondly, as natural 
polymers are partially soluble and their dissolution may increase the viscosity of the 
medium, crosslinking of the polymeric chains serves in decreasing the soluble content 
of the polymer. SSG is crosslinked through phosphate groups [4] while CCS through 
ester groups [5] (Figure 6.1). The superior performance of SSG and CCS as tablet 
disintegrants, compared to native polymers, is attributed to these two modification 
steps. 
 
Figure 6.1: Chemical structure of a. Sodium Starch Glycolate and b. Croscarmellose 
Sodium (ChemDraw Professional 15) 
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The extensive and fast swelling of SSG and CCS is demonstrated by the increase 
in their volume median diameter (average volumetric size) upon contact with water 
(123 μm upon contact with water vs 35 μm of the dry excipient powder for SSG, 92 
μm upon contact with water vs 45 μm of the dry excipient powder for CCS) and the 
amount of liquid water uptake (16 g/g and 10 g/g in 120 sec for SSG and CCS, 
respectively) [6]. The differences in the swelling capacity of SSG and CCS, despite 
their similar structure, have been attributed to the difference in their dimensional 
expansion (3-dimensional swelling for SSG, 2-dimensional swelling for CCS) [6, 7] 
and their different crosslinking (the phosphate group of SSG, compared to the ester 
group of CCS, allows for more spacing between the polymeric chains) [7]. Molecular 
properties (degree of substitution, degree of crosslinking), particle properties (particle 
size distribution (PSD)) and level have been identified as potential critical material 
attributes for SSG and CCS affecting product performance [8]. Increasing the degree 
of substitution of SSG and CCS results in faster water uptake and excipient swelling, 
however optimum values need to be defined as high degrees of carboxymethylation 
may result in an increase in the viscosity of the medium [8]. Extensive swelling and 
faster disintegration have been reported when increasing the degree of crosslinking, 
particle size or level in formulations for SSG and CCS [8]. 
The biopharmaceutical implications of superdisintegrant presence or variability on 
product performance are not well known. Gastrointestinal factors may impact the 
performance of superdisintegrants with pH being the most influential due to the 
ionization pattern of SSG and CCS. The hydration capacity of the acid excipient form 
in acidic media is lower compared to the ionized excipient form in basic media leading 
to reduced swelling in acidic conditions [6]. The % increase in the volume media 
diameter in water and 0.1 N HCl pH 1 was 251% and 43%, respectively for SSG and 
104% and 51%, respectively for CCS [6]. The impact of superdisintegrants on product 
performance relates also to drug properties. Interaction of cationic drugs with the 
carboxylic group of CCS can affect routine drug analysis. Loss of the active 
pharmaceutical ingredient (API) from a tablet formulation containing CCS during 
sample treatment can be expected, as low % recovery of drugs (metformin [9], 
escitalopram [10]) from solutions in presence of CCS have been reported due to charge 
drug-excipient interactions. Delay in the dissolution of cationic drugs from immediate 
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release tablets containing SSG and CCS has also been attributed to electrostatic drug-
excipient interactions [11]. 
Current approaches for assessing superdisintegrant performance and variability 
include the determination of: disintegration time of formulations, water uptake of 
powders/tablets, swelling volume of superdisintegrants, exerted force (force inside 
tablets that has to surpass the cohesive tablet forces) during tablet disintegration, 
dissolution rate of drugs, size of generated particles after tablet disintegration [1]. Real 
– time surface dissolution UV imaging is currently used in the pharmaceutical field 
providing additional information on disintegration/dissolution phenomena. This 
technique utilizes a compact flow-cell integrated with a UV-Vis camera and a pump 
for the infusion of the dissolution medium under laminar flow [12]. The measured 
transmittance of light through the cell allows the characterization of the dissolving 
substance spatially and temporally and is useful for the identification of drug intrinsic 
dissolution rates, surface swelling/disintegration/dissolution phenomena, 
concentration gradients and microenvironmental pH changes [13]. Insights in the 
dissolution behaviour of APIs [12], excipients [14] and their interplay [15, 16] have 
been provided with the use of real-time surface dissolution imaging. 
The aims of this study were to assess the swelling performance of 
superdisintegrants with different critical material attributes and the impact and 
criticality of superdisintegrant variability on drug dissolution. Excipient 
characterization and drug dissolution studies in absence and presence of excipients 
were performed with the use of real-time surface dissolution UV imaging. The impact 
of excipient variability on excipient swelling and drug dissolution was studied by 
selecting three brands of SSG of different viscosity type and two brands of CCS of 
different PSD. A highly and a poorly soluble drug were used to assess the interplay of 
excipient variability and drug characteristics on drug dissolution. Studies were 
performed in acidic and basic compendial media to assess the role of pH on 
superdisintegrant swelling and drug dissolution. 
6.2. Materials and Methods 
6.2.1. Materials 
APIs: Paracetamol was obtained from Fischer Scientific (UK). Carbamazepine 
was purchased from Fagron (UK). Excipients: Glycolys LV (low viscosity) and 
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Glycolys (high viscosity) (Roquette, France), AcDiSol (low particle size) (FMC, 
USA), Explotab CLV (low viscosity) (JRS Pharma, USA), Primellose (high particle 
size) (DFE Pharma, Germany) were obtained from the specified sources. Chemicals: 
Hydrochloric acid 36.5–38%, HPLC grade methanol were obtained from Sigma-
Aldrich (UK). Sodium chloride, sodium hydroxide, potassium phosphate monobasic 
were obtained from Fisher Scientific (UK). Water was ultra-pure (Milli-Q) laboratory 
grade. Filters: Polytetrafluoroethylene (PTFE) 13 mm filter 0.45 μm pore size were 
purchased from Fisher Scientific (UK). 
6.2.2. Instrumentation 
Sartorius BP 210 D balance (Sartorius UK Ltd, UK), Mettler Toledo 
SevenCompact S210 pH meter (Mettler Toledo, Switzerland), Vortex-Genie 2 vortex 
mixer (Scientific Industries Inc, USA), Agilent Technologies 1100 series HPLC 
system, (quaternary pump (G1311A), autosampler (G1313A), thermostatted column 
compartment (G1316A), diode array detector (G1329A) and a Chemstation software 
(Agilent Technologies, USA), Actipix SDi300 dissolution imaging system (Paraytec 
Ltd, UK) with an Actipix flow-through dissolution cartridge CADISS-2, Quickset 
Minor® torque screwdriver (Torqueleader, UK). 
6.2.3. Methods 
6.2.3.1. Media used for in vitro dissolution studied 
Compendial media (0.1 N HCl pH 1, phosphate buffer pH 6.8) were prepared 
according to the method described in the United States Pharmacopeia [17]. 
6.2.3.2. Preparation of compacts 
For the excipient characterization, 20 mg of each excipient were poured into the 
sample cup (stainless steel cylinder, inner diameter: 2 mm, height: 2.4 mm) and 
compacted using a manual press at a constant torque of 75 cNm for 5 min [14]. For 
the dissolution studies, compacts of pure APIs (paracetamol (PRC), carbamazepine 
(CBZ)) and compacts of superdisintegrants with the APIs were prepared. 10 mg of 
API (PRC, CBZ) were poured into the sample cup and compacts of pure API (drug 
compacts) were prepared using a manual press at a constant torque of 75 cNm for 5 
min [14]. 10 mg of API and 2% w/w of each excipient (based on typical excipient 
amounts used in immediate release formulations [4, 5] were prepared by vortexing (3 
min) and poured into the sample cup. Compacts of superdisintegrants with APIs (drug-
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excipient compacts) were prepared using a manual press at a constant torque of 75 
cNm for 5 min [14]. 
6.2.3.3. In vitro real-time surface dissolution UV imaging 
Real-time surface dissolution UV Imaging was performed using an Actipix 
SDi300 surface dissolution imaging system with an Actipix flow-through-type 
dissolution cartridge. The flow cell consisted of an Actipix cartridge fitted with a 
quartz cell (7 mm height, 4 mm width, 62 mm length) and a polyetheretherketone 
(PEEK) sample holder. The light source was a pulsed xenon lamp and a band-pass 
filter (detection wavelength ± 10 nm) was used for the selection of the wavelength of 
interest. Dissolution medium was infused into the cell through a syringe pump. A 
temperature control unit was used to maintain constant temperature. The detection area 
of the UV imager was 9 mm2 × 7 mm2 (1280 pixel × 1024 pixel) with a pixel size of 
7 μm × 7 μm. Detailed representation of the instrument has been previously presented 
[12, 18]. 
For the excipient characterization, experiments were performed at 254 nm using 
stagnant conditions for 5 min at 37 °C in 0.1 N HCl pH 1 and phosphate buffer pH 
6.8. In vitro drug dissolution experiments from drug compacts and drug-excipient 
compacts were performed at 280 nm using 1 mL/min flow rate for 20 min at 37 °C in 
0.1 N HCl pH 1 and phosphate buffer pH 6.8. For both the excipient characterization 
experiments and in vitro drug dissolution studies, dark (10 s duration with the lamp 
turned off) and reference (10 s duration with the lamp turned on) images were recorded 
with the flow cell filled with dissolution medium in absence of compact. Data 
collection was initiated and after 60 s data recording was pause and the compacts were 
introduced into the cell. The system was flushed with dissolution media to avoid 
presence of air bubbles in the flow cell and data collection was resumed. Pixel 
intensities within a designated quantification region were converted into absorbance 
values using the Actipix D100 software version 1.8.50805 (Paraytec Ltd, UK). In the 
in vitro drug dissolution experiments, the presence of the swelling excipients (SSG 
and CCS brands) in the quantification regions of the UV image resulted in increased 
scattering or physical blockage of light [18]. In these cases, the eluting sample was 
collected at 1 min intervals and the effluent samples were filtered through PTFE 0.45 
μm pore size filters and analysed by HPLC. Filter adsorption studies were prior 
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performed in triplicate for each drug and confirmed that there were no adsorption 
issues for the studied drugs on the filters used. All experiments were performed in 
triplicate. 
6.2.3.4. Chromatographic conditions 
Dissolution samples (effluent collection) were analysed by HPLC. Analytical 
HPLC procedures were modifications of already published methods for PRC [19] and 
CBZ [20]. A reversed-phase Spherisorb (Waters) C18 column (250 × 4.6 mm, 5 μm) 
was used for both drugs. For PRC, the mobile phase consisted of methanol and water 
20:80 (v/v) and the temperature was kept constant at 20 °C. The injection volume was 
20 μL and the detection wavelength was at 257 nm. For CBZ, the mobile phase was 
composed of methanol and water 60:40 (v/v) and the temperature was kept at 25 °C. 
The injection volume was 100 μL and the detection wavelength was at 285 nm. The 
flow rate was set at 1 mL/min for both drugs (isocratic flow). The elution times were 
6 min and 4 min for PRC and CBZ, respectively. Drug quantification was made based 
on calibration curves. Standards were prepared from concentrated stock solution of 
drug dissolved in MeOH (PRC: 2 mg/mL, CBZ: 1 mg/mL). The range of the 
calibration curves were 10 – 300 μg/mL and 0.5 -50 μg/mL for PRC and CBZ, 
respectively. 
6.2.3.5. Treatment of in vitro dissolution data 
For the characterization of the swelling superdisintegrant behaviour, quantitative 
data of excipient concentration gradients cannot be obtained due to i. the insolubility 
of the studied polymers and ii. the fact that the high absorbance values recorded may 
be attributed to absorbance or scattering of light by the swelled polymer or physical 
blockage of light by undissolved polymer particles [14]. Only qualitative information 
of the rate and extent of swelling can be obtained by the absorbance gradients as a 
function of distance from the center of the sample cup. Absorbance values (Abs) were 
automatically calculated from pixel intensities using the Actipix D100 software 
version 1.8.50805 (Paraytec Ltd, UK). The classification gradient maps depicting the 
swelling behaviour (absorbance values as a function of distance from the center of the 
sample cup) of the studied SSG and CCS brands in 0.1 N HCl pH 1 and phosphate 
buffer pH 6.8 were generated using SigmaPlot 13.0 (Systat Software Inc, USA). The 
cumulative % of drug dissolved was calculated based on the measured drug 
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concentration in the samples (based on the HPLC analytical data) and the amount of 
drug in the compact. The dissolution profiles of the cumulative % of drug dissolved 
as a function time were constructed. Drug dissolution rates (μg/min) at each 1 min 
interval over the duration of the experiments were calculated based on the measured 
drug concentration in the samples (based on the HPLC analytical data) and the known 
flow rate of the dissolution experiments. Graphs depicting drug dissolution rates as a 
function of time (at 1 min intervals) were constructed and the standard deviation (SD) 
of the dissolution rates was presented in the midterm point of the sampling intervals. 
The area under the curve (AUC) of the dissolution profiles up to last experimental 
time (20 min), calculated using the method of trapezoids, was used for the 
characterization of drug dissolution. The Relative Effect (RE) of each 
superdisintegrant on drug dissolution was calculated based on equation 6.1: 
𝑅𝐸 =  
(𝐴𝑈𝐶𝑇− 𝐴𝑈𝐶𝐶)
𝐴𝑈𝐶𝐶
 𝑥 100 equation 6.1 
where 𝐴𝑈𝐶𝑐 and 𝐴𝑈𝐶𝑇 are the areas under the curve of the dissolution profiles of 
the control and test compact, respectively. Two sets of comparisons were performed. 
In the first set (set 1), the differences in drug dissolution between drug compacts and 
drug-excipient compacts in each medium were examined taking the AUCs of the 
dissolution profiles of the drug compact and the drug-excipient compact as control and 
test dissolution profiles, respectively. In the second set (set 2), differences in drug 
dissolution within acidic and basic conditions in each drug-excipient compact were 
investigated taking the AUCs of the dissolution profiles in acidic and basic conditions 
as the control and test dissolution profiles, respectively. The risk assessment of the 
impact of excipients on drug dissolution was evaluated by setting reference range 
criteria of -20% - 25% [21] on the REs of excipients on the AUCs of the dissolution 
profiles (this range was selected as a similar range is set in order to assess differences 
in drug exposure after oral administration; i.e. in bioequivalence studies). REs of 
excipients on the AUCs of the dissolution profiles outside these values (REs < -20% 
or REs > 25%) were considered critical for oral drug performance. 
6.2.3.6. Multivariate data analysis of in vitro dissolution data 
Excipient REs on drug dissolution were correlated to excipient critical material 
attributes (viscosity for SSG, PSD for CCS), drug aqueous solubility (Drugaq.sol.) and 
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medium (acidic, basic) characteristics by multiple linear regression (MLR) using the 
XLSTAT software (Microsoft, USA). Two models for the REs of excipients on the 
AUCs of the dissolution profiles in presence of SSG (Model 1) and CCS (Model 2) 
were constructed. The evaluated variables for both models were all categorical and 
included: i. drug aqueous solubility (Drugaq.sol.) (0: poorly soluble, 1: highly soluble), 
ii. medium (0: acidic, 1: basic), iii. excipient brand (0: low excipient property, 1: high 
excipient property). Excipient REs on the AUCs of the dissolution profiles (set 1, 
section 6.2.3.5) were used as the response. The selected interaction terms included 
each excipient brand combined with each drug aqueous solubility and medium 
characteristics (acidic, basic). The generated MLR models were assessed in terms of 
goodness of fit (R2) and variance inflation factor (VIF). High R2 values and VIF values 
< 5 were indications of successful models with absence of multicollinearity among the 
independent variables [22]. Standardized coefficients were used to show the direction 
(positive or negative) and extent of each variable on the response. The significance of 
the variables was assessed by the p values (p < 0.05 were considered the most 
significant in the model [22]). A 95% confidence interval was used. 
6.3. Results and Discussion 
6.3.1.  Characterization of the swelling behaviour of superdisintegrants 
using real-time surface dissolution UV Imaging 
The studied excipient types and brands have been previously characterized in 
terms of viscosity for SSG and PSD for CCS (Chapter 4). The viscosity after 60 min 
of the aqueous dispersions of Glycolys LV (10.8 cP) and Explotab CLV (12.7 cP) was 
lower compared to Glycolys (20.9 cP), due to their higher degree of crosslinking and 
lower soluble material content [23]. Differences in the PSD of the CCS brands were 
identified, as AcDiSol comprised of smaller particles (d10: 12.8 μm, d50: 31.9 μm, 
d90: 74.2 μm) compared to Primellose (d10: 21.8 μm, d50: 52.2 μm d90: 109.8 μm). 
The swelling behaviour of the studied superdisintegrants as a function of time and 
distance from the centre of the sample cup in 0.1 N HCl pH 1 is presented in Figure 
6.2. Intense signals at the compact location are indications of dense swollen polymeric 
structures [15], as the high absorbance recorded are attributed to light scattering by the 
swelled superdisintegrants or physical blockage of light by undissolved excipient 
particles (as explained in section 6.2.3.5.). The fast excipient swelling was 
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demonstrated as all the studied superdisintegrants swelled at a distance of 1.2 mm 
from the centre of the sample cup at approximately 20 – 40 s irrespective of excipient 
type or brand. For SSG, Glycolys exhibited lower absorbance values (Abs ≈ 1.0 – 1.2 
AU) compared to Glycolys LV and Explotab CLV (Abs ≈ 1.2 – 1.6 AU) probably due 
to the higher soluble content of high viscosity brands [23]. For CCS, the higher 
absorbance values of Primellose (Abs ≈ 1.4 – 1.6 AU) compared to AcDiSol (Abs ≈ 






Figure 6.2: Absorbance values (Abs) of the studied superdisintegrant types and brands 
as a function of distance from the center of the sample cup (mm) in 0.1 N HCl pH 1 
(SDi1, 0 mL/min, 37 °C, 254 nm) presented up to 2.5 min. 
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The swelling behaviour of the studied superdisintegrants as a function of time 
and distance from the centre of the sample cup in phosphate buffer pH 6.8 is presented 
in Figure 6.3. Slightly faster excipient swelling in phosphate buffer pH 6.8 (< 20 s) 
was observed compared to 0.1 N HCl pH 1 (20 – 40 s) explained by the higher liquid 
uptake (0.1 N HCl pH 1: approximately 5 g/g liquid uptake by SSG and CCS after 2 
min , water: 18 g/g and 10 g/g liquid uptake by SSG and CCS, respectively after 2 min 
[6]) and excipient swelling of the ionized excipient form in basic media [6]. The 
absorbance values of the studied brands were lower in phosphate buffer pH 6.8 (SSG 
brands: 0.6 – 1.2 AU, CCS brands: 1.0 – 1.4 AU) compared to 0.1 N HCl pH 1 (SSG 
brands: 1.0 – 1.6 AU, CCS brands: 1.0 – 1.6 AU). We hypothesize that the lower 
absorbance values in the basic compared to the acidic medium relate to the higher 
excipient swelling, as the higher spacing of the swelled polymeric chains [7] could 
decrease the scattering or physical blockage of light. Differences in the absorbance 
values are not observed within the studied SSG brands (Abs ≈ 0.6 – 1.0 AU). For CCS, 
lower absorbance values were observed for AcDiSol (Abs ≈ 1.0 – 1.2 AU) attributed 
to its lower particle size compared to Primellose (Abs ≈ 1.2 – 1.4 AU) [24]. The lower 
absorbance values of the SSG compared to the CCS brands in phosphate buffer pH 
6.8 can indicate a more extensive swelling by SSG, due to the differences in the 
dimensional expansion (3 dimensional swelling (semispherical particles) for SSG and 
2 dimensional swelling (fibrous particles) for CCS upon contact with simulated 
intestinal fluid have been reported [7]) and type of crosslinking (phosphate groups for 
SSG, ester group for CCS) between the two excipient types [7]. The observed 
differences in excipient performance in the studied media indicate that differences in 
tablet disintegration between the stomach and the small intestine are anticipated (due 
to the differences in the pH of these two compartments) and could potentially implicate 





Figure 6.3: Absorbance values (Abs) of the studied superdisintegrant types and brands 
as a function of distance from the center of the sample cup (mm) in phosphate buffer 
pH 6.8 (SDi1, 0 mL/min, 37 °C, 254 nm) up to 2.5 min. 
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6.3.2. Impact of SSG variability on drug dissolution using real-time 
surface dissolution UV Imaging 
6.3.2.1. Highly soluble drug (PRC) 
The dissolution profiles and dissolution rates of PRC from drug compacts (control) 
and drug-SSG compacts in 0.1 N HCl pH 1 and phosphate buffer pH 6.8 are presented 
in Figure 6.4. 
 
 
Figure 6.4: Cumulative % dissolved (top) and dissolution rates (bottom) of PRC from 
compacts in a. 0.1 N HCl pH 1 and b. phosphate buffer pH 6.8 using real-time surface 
dissolution UV imaging (SDi1, 1 mL/min, 37°C) in absence (control: black 
circles/colour) and presence of the studied SSG brands (Glycolys LV: green 
squares/colour, Explotab CLV: blue diamonds/colour, Glycolys: red triangles/colour). 




Approximately 5% of PRC dissolved from the drug compact in 20 min in both 
media. The % of drug dissolved in 20 min from the drug-SSG compacts was increased 
in 0.1 N HCl pH 1 (21%, 23% and 25% of drug dissolved in the presence of Glycolys 
LV, Explotab CLV and Glycolys, respectively) and in phosphate buffer pH 6.8 (22%, 
27% and 21% of drug dissolved in the presence of Glycolys LV, Explotab CLV and 
Glycolys, respectively). The dissolution rate of PRC from drug compacts was slow 
during the experiments in both media studied (dissolution rates of approximately 20 
μg/min and 17 μg/min in 0.1 N HCl pH 1 and phosphate buffer pH 6.8 at 20 min, 
respectively). Drug dissolution from drug-SSG compacts was faster compared to drug 
dissolution from drug compacts in the studied media, especially at early time points 
(1 – 5 min), as indicated by the increased dissolution rates of PRC in excipient 
presence (dissolution rates of approximately 200 μg/min from compacts containing 
Glycolys LV, Explotab CLV and Glycolys at 5 min in both media). This could be 
explained by the fast excipient hydration and swelling (excipient swelling at a distance 
of 1.2 mm from the centre of the sample cup within the first 40s, section 6.3.1) 
improving compact wetting [25]. Compact disintegration may also have contributed 
to the faster drug dissolution from drug-excipient compacts compared to drug 
compacts, as spread particles around the compact surface were observed after the end 
of each experiment only for the drug-excipient compacts. Comparison of the AUCs of 
the dissolution profiles revealed that drug dissolution was more complete in from the 










Figure 6.5: Relative effects of excipients on the AUCs of the dissolution profiles for 
a. PRC and b. CBZ in presence of the studied SSG brands (Glycolys LV: green colour, 
Explotab CLV: blue colour, Glycolys: red colour) in 0.1 N HCl pH 1 and phosphate 
buffer pH 6.8. 
 
Differences in PRC dissolution from drug-SSG compacts in acidic and basic 
conditions for the studied SSG brands were not observed (REs of approximately 5%, 
20% and -20% for Glycolys LV, Explotab CLV and Glycolys, respectively). The 
observed minor REs indicate that the pH-depended swelling performance of SSG 
(section 6.3.1) may not significantly affect the dissolution of a highly soluble drug 
between acidic and basic conditions. 
6.3.2.2. Poorly soluble drug (CBZ) 
The dissolution profiles and dissolution rates of CBZ from drug compacts (control) 
and drug-SSG compacts in 0.1 N HCl pH 1 and phosphate buffer pH 6.8 are presented 





Figure 6.6: Cumulative % dissolved (top) and dissolution rates (bottom) of CBZ from 
compacts in a. 0.1 N HCl pH 1 and b. phosphate buffer pH 6.8 using real-time surface 
dissolution UV imaging (SDi1, 1 mL/min, 37°C) in absence (control: black 
circles/colour) and presence of the studied SSG brands (Glycolys LV: green 
squares/colour, Explotab CLV: blue diamonds/colour, Glycolys: red triangles/colour). 
(Mean ±SD, n =3) 
 
Approximately 0.1% of CBZ dissolved from the drug compact in 20 min in both 
0.1 N HCl pH and phosphate buffer pH 6.8. In 0.1 N HCl pH 1, 2.3%, 1.6% and 1.3% 
of drug dissolved in 20 min in presence of Glycolys LV, Explotab CLV and Glycolys, 
respectively. The % of CBZ dissolved in excipient presence in phosphate buffer pH 
6.8 in 20 min was similar between the different drug-excipient compacts 
(approximately 1.5% of CBZ dissolved from drug-excipient compact containing 
Glycolys LV, Explotab CLV, Glycolys). The rate of drug dissolution from the drug 
compact was slow in both sets of media (dissolution rates of approximately 0.5 μg/min 
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at 20 min in 0.1 N HCl pH 1 and phosphate buffer pH 6.8). CBZ dissolution was faster 
in SSG presence, especially at early time points (1 - 5 min), potentially due to the fast 
excipient swelling or compact disintegration (as explained in the case of PRC). In 0.1 
N HCl pH 1, the dissolution rates of CBZ from drug-excipient compacts were 13 
μg/min, 8.6 μg/min and 6.2 μg/min at 5 min in presence of Glycolys LV, Explotab 
CLV and Glycolys, respectively. The lower amount of drug dissolved in presence of 
Glycolys compared to the low viscosity brands (Glycolys LV, Explotab CLV) may be 
explained by the increase in the viscosity of the medium by high viscosity Glycolys 
[1]. The pronounced differences in the CBZ dissolution rates from compacts 
containing the low and high viscosity SSG brands are diminished at late points. Faster 
CBZ dissolution in presence compared to absence of excipient was also observed in 
phosphate buffer pH 6.8, with the dissolution rates from the three drug-excipient 
compacts being similar (CBZ dissolution rates of approximately 7 μg/min at 5 min in 
presence of the three studied SSG brands). CBZ dissolution in presence of excipient 
was more complete compared to the excipient absence (REs > 25%) (Figure 6.5b). 
Differences in drug dissolution from drug-excipient compacts between acidic and 
basic conditions were observed. For the low viscosity brands (Glycolys LV, Explotab 
CLV), the REs on the AUCs of the dissolution profiles between acidic and basic 
conditions were negative (REs of -45% and -20% for Glycolys LV and Explotab CLV, 
respectively), indicating that the improvement in CBZ dissolution is less pronounced 
in phosphate buffer pH 6.8 compared to 0.1 N HCl pH 1. As superdisintegrants swell 
more extensively in basic compared to acidic conditions due to their ionization [7], the 
presence of a highly swelled layer on top of the sample cup may add a physical or 
diffusive barrier for the release of poorly soluble drugs [18], despite the faster polymer 
water uptake in basic conditions (as explained previously in section 6.3.1). The 
swelling of the high viscosity Glycolys is as well more extensive in basic compared to 
acidic conditions, however comparison of CBZ dissolution profiles from compacts 
containing Glycolys between basic and acidic media reveal slightly more complete 
dissolution in phosphate buffer pH 6.8 (REs of 30%). This positive RE on the AUCs 
of the dissolution profiles may relate to the gelling effects of Glycolys [1] and the 




6.3.3. Impact of CCS variability on drug dissolution using real-time 
surface dissolution UV Imaging 
6.3.3.1. Highly soluble drug (PRC) 
The dissolution profiles and dissolution rates of PRC from drug compacts (control) 
and drug-CCS compacts in 0.1 N HCl pH 1 and phosphate buffer pH 6.8 are presented 
in Figure 6.7. 
 
 
Figure 6.7: Cumulative % dissolved (top) and dissolution rates (bottom) of PRC from 
compacts in a. 0.1 N HCl pH 1 and b. phosphate buffer pH 6.8 using real-time surface 
dissolution UV imaging (SDi1, 1 mL/min, 37°C) in absence (control: black 
circles/colour) and presence of the studied CCS brands (AcDiSol: blue squares/colour, 
Primellose: red diamonds/colour). (Mean ±SD, n =3) 
 
A higher % of drug dissolved in 20 min was observed in excipient presence in 0.1 
N HCl pH 1 (AcDiSol: 23%, Primellose: 14%) and phosphate buffer pH 6.8 (AcDiSol: 
25%, Primellose: 26%) compared to the % of PRC dissolved from the drug compact 
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(5% of drug dissolved in 20 min). Faster drug dissolution was revealed in excipient 
presence compared to excipient absence in both media which may be explained by the 
enhancement in compact wetting or compact disintegration due to the hydrophilicity 
and swelling of CCS [1]. Differences in drug dissolution rates from the studied drug-
CCS compacts were observed at early time points in 0.1 N HCl pH 1 as the dissolution 
rate of PRC was lower in presence of Primellose (98 μg/min of drug dissolved at 5 
min) compared to AcDiSol (182 μg/min of drug dissolved at 5 min), probably due to 
the presence of larger excipient particles (Primellose) on top of the compact surface 
(section 6.3.1). In phosphate buffer pH 6.8 similar drug dissolution was observed 
between the drug-CCS compacts containing AcDiSol and Primellose (dissolution rates 
of approximately 200 μg/min in presence of both CCS brands at 5 min). At late time 
points, the dissolution rate of PRC gradually decreased in presence of the CCS brands 
in both media and any differences in drug dissolution between the studied CCS brands 
were diminished. Comparison of the AUCs of the dissolution profiles of the drug and 
drug-CCS compacts revealed significantly more complete dissolution from compacts 
containing excipient (REs > 25%) (Figure 6.8a).  
 
Figure 6.8: Relative effects of excipients on the AUCs of the dissolution profiles for 
a. PRC and b. CBZ in presence of the studied CCS brands (AcDiSol: blue colour, 
Primellose: red colour) in 0.1 N HCl pH 1 and phosphate buffer pH 6.8. 
 
Differences in drug dissolution from drug-AcDiSol compacts between acidic and 
basic conditions were not observed, as revealed by the REs of AcDiSol on the AUCs 
of the dissolution profiles between acidic and basic conditions (RE = 10%). Drug 
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dissolution from the drug-Primellose compacts was significantly more complete in 
phosphate buffer pH 6.8 compared to 0.1 N HCl pH (RE = 97%), potentially due to 
the presence of larger excipient particles in 0.1 N HCl pH 1. 
6.3.3.2. Poorly soluble drug (CBZ) 
The dissolution profiles and dissolution rates of CBZ from drug compacts and 
drug-CCS compacts in 0.1 N HCl pH 1 and phosphate buffer pH 6.8 are presented in 
Figure 6.9.  
 
 
Figure 6.9: Cumulative % dissolved (top) and dissolution rates (bottom) of CBZ from 
compacts in a. 0.1 N HCl pH 1 and b. phosphate buffer pH 6.8 using real-time surface 
dissolution UV imaging (1 mL/min, 37°C) in absence (control: black circles/colour) 
and presence of the studied CCS brands (AcDiSol: blue squares/colour, Primellose: 




CBZ dissolution reached approximately 1.8% and 1.5% from compacts containing 
AcDiSol and Primellose, respectively in 0.1 N HCl pH 1 and 1.3% and 1.0% in 
phosphate buffer pH 6.8. The fast excipient swelling at early time points (section 6.3.1) 
resulted in faster drug dissolution from drug-CCS compacts compared to the drug 
compacts in both sets of media, especially at early time points. Drug dissolution was 
slower in presence of Primellose (7 μg/min and 5 μg/min in acidic and basic 
conditions, respectively) compared to AcDiSol (9 μg/min and 7 μg/min in the acidic 
and basic medium, respectively), probably due to the presence of larger excipient 
particles (Primellose) on top of the compact surface (section 6.3.1). Differences in 
drug dissolution between the studied brands were smaller at late time points. In 
presence of excipient, drug dissolution was significantly more complete compared to 
the control sample in both experimental conditions (REs > 25%) (Figure 6.8b). The 
enhancement in CBZ dissolution by CCS presence was more pronounced in acidic 
compared to basic conditions (REs on the AUCs of the dissolution profiles between 
acidic and basic conditions of -30% and -20% for AcDiSol and Primellose, 
respectively). The faster water uptake of the excipients in basic media [7] would be 
expected to result in faster drug dissolution due to the improved compact wetting, 
however this is not observed as potentially the presence of a swelled layer on top of 
the compact surface created a physical or diffusive barrier delaying drug release [18]. 
6.3.4. Multivariate data analysis of in vitro dissolution data 
The standardized coefficients of the variables for the SSG and CCS model are 





Figure 6.10: Standardized coefficients corresponding to the studied variables (and 
their interactions) for SSG (blue colour) and CCS (red colour). * denotes coefficients 
with p < 0.05. (Mean, - SE) 
 
For SSG, excipient brand (negative effect, p = 0.043), Drugaq.sol. (negative effect, 
p < 0.001) and medium (negative effect, p = 0.047) were the critical variables in the 
model. The negative effect of the excipient brand indicates that increasing the viscosity 
type of SSG resulted in less pronounced dissolution enhancement compared to the low 
viscosity SSG brands. Enhanced compact wetting by low viscosity SSG brands is 
expected due to their faster water uptake and higher swelling [26]. Formation of 
gelling layer by high viscosity SSG brands which delays drug dissolution [1] could 
also explain this finding. The impact of varying SSG viscosity was more pronounced 
for the poorly soluble drug, indicated by the significance of the variable Drugaq.sol. in 
the model, as poorly soluble drugs will benefit more by an improvement in compact 
wetting. The negative effect of the variable medium reveals the pronounced 
enhancement in drug dissolution by SSG presence in acidic compared to basic 
conditions (especially, for the poorly soluble drug). 
For CCS, excipient brand (negative effect, p = 0.016) and Drugaq.sol. (negative 
effect, p = 0.006) were critical variables in the model. Increasing the particle size of 
CCS will result in less pronounced improvement in drug dissolution probably due to 
the formation of physical or diffusive barrier for drug dissolution by larger excipient 
particles. The negative effect of the variable Drugaq.sol. indicates that the improved 
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wetting or compact disintegration by CCS presence will contribute more to the 
dissolution of poorly soluble drugs. The use of real – time surface dissolution imaging 
in combination with the multivariate data analysis revealed that CCS variability may 
be critical for the initial stages of drug dissolution, which could not be observed solely 
by the solubility experiments (chapter 4). 
6.4. Conclusions 
Superdisintegrant variability and interchangeability may be challenging for oral 
product performance, as the presence of superdisintegrants in pharmaceutical 
formulations directly affects drug dissolution. In this study, the use of real – time 
surface dissolution UV imaging confirmed the fast swelling ability of SSG and CCS. 
The swelling of the aforementioned superdisintegrants, however, depended on the 
critical material attributes and the pH of the dissolution medium. Excipient 
interchangeability could be challenging for oral product performance, as the swelling 
behaviour of SSG and CCS differed within media of different pH. Presence of 
superdisintegrants in compacts containing highly and poorly soluble compounds 
resulted in significantly faster drug dissolution for both drugs probably due to the 
enhanced compact wetting or compact disintegration by the hydrophilic excipients. 
Excipient properties affected the extent of drug dissolution, as pronounced dissolution 
enhancement was observed by low viscosity SSG or low particle size CCS brands, 
especially for the poorly soluble drug. In superdisintegrant presence, an interplay 
between drug aqueous solubility and medium characteristics was found that could 
affect product performance. For the highly soluble compound, the increased hydration 
capacity of superdisintegrants resulted in faster drug dissolution in basic compared to 
acidic conditions. The opposite was observed for the poorly soluble drug, as 
potentially the presence of swollen structure on top of the compact surface limited 
drug dissolution. SSG viscosity type, CCS particle size and drug aqueous solubility 
were considered critical biopharmaceutical factors affecting the performance and the 
impact of superdisintegrant variability on drug dissolution. 
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Chapter 6 Commentary 
Sodium starch glycolate (SSG) and croscarmellose sodium (CCS) are 
superdisintegrants used in immediate release formulation to promote fast tablet 
disintegration. In this chapter, the swelling performance and impact on drug 
dissolution of three different viscosity SSG brands (Glycolys LV, Explotab CLV, 
Glycolys) and two different particle size distribution (PSD) CCS brands (AcDiSol, 
Primellose) were investigated using surface dissolution UV imaging. The fast and 
extensive excipient swelling was demonstrated, especially in basic conditions where 
the excipients are highly ionized. Differences in the swelling behaviour between SSG 
and CCS were revealed in both media, indicating that excipient interchangeability 
need to be thoroughly considered. Dissolution studies for a highly and a poorly soluble 
drug revealed faster and more complete dissolution in excipient presence for the 
studied drugs, attributed to the improved compact wetting or compact disintegration. 
The properties of SSG and CCS mostly affected the dissolution of the poorly soluble 
drug, as slightly faster drug dissolution was observed in presence of low viscosity SSG 
or low particle size CCS. The improvement in the dissolution of the highly soluble 
drug was more pronounced in the basic compared to the acidic medium in SSG or 
CCS presence as the fast excipient swelling improved powder solubilization. The 
opposite was found for the poorly soluble drug, as potentially the presence of a swelled 
layer on top of the powder surface delayed drug release. The need for the 
biopharmaceutical evaluation of the impact of excipients on drug dissolution was 
demonstrated as the enhancement in drug dissolution in excipient presence depended 




Conclusions and Future Perspectives 
Conclusions 
The QbD initiative requires the scientific understanding of the components and 
processes whose variability may affect final product qualities. Excipients constitute a 
large portion of pharmaceutical formulations and excipient variability or variation may 
affect oral drug bioavailability. Identification of the critical biopharmaceutical factors 
of excipients on oral drug performance would be beneficial for the development of 
robust formulations. 
A literature review (chapter 1) identified the critical material attributes 
(molecular/structural/particle properties, level) of key excipient types commonly used 
in immediate release formulations. The need for investigating the biopharmaceutical 
implications of excipient variability was demonstrated. Based on this analysis, 
lubricants (MgSt), binders (HPMC) and superdisintegrants (SSG, CCS, CPV) were 
selected for further experimentation as their direct impact and their unclear 
mechanistic role on drug dissolution was highlighted. 
Differences in drug apparent solubility in presence of varying excipient types and 
brands that could further complicate the rate and extent of drug absorption in vivo, 
were demonstrated (Chapters 2-4). MgSt and HPMC were flagged as excipients of 
high criticality for oral drug performance as significant changes in drug solubility at 
24 hours were observed for the majority of compounds. Excipient effects on drug 
solubility strongly related to excipient critical material attributes, drug 
physicochemical properties (drug ionization, drug aqueous solubility) and medium 
characteristics (gastric, intestinal). The potential risks of excipient presence or 
variability on drug apparent solubility that could be critical for product performance 
were demonstrated with the use of multivariate data analysis and the design of 
roadmaps. 
The impact of excipient variability was extended on drug dissolution and it was 
revealed that implications on product performance may be expected according to 
excipient type and drug characteristics (Chapter 5). Significantly faster dissolution 
was observed for a highly soluble compound when decreasing the particle size of MgSt 
with potential implications on quality control tests, regulatory approvals and drug 
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bioavailability. The experimental in vitro conditions need to be carefully selected, as 
the discriminatory power of the dissolution method depended on hydrodynamic 
characteristics. Varying HPMC or SSG viscosity type was not found critical for drug 
dissolution. A mechanistic understanding of the impact of excipient variability was 
provided with the use of real – time surface dissolution imaging. 
Finally, the effects of critical excipient material attributes on the swelling performance 
and on drug dissolution for two commonly used superdisintegrants (SSG, CCS) were 
visualized with the use of real – time surface dissolution (Chapter 6). Excipient 
swelling depended on excipient (viscosity, PSD) and medium (pH) characteristics. 
The improvement in the dissolution of a highly and a poorly soluble drug by the 
excipients was imaged and attributed to the improved compact wetting or compact 
disintegration. An interplay between excipient, drug, medium characteristics and the 
extent of dissolution enhancement was revealed. 
Summarizing, the critical properties and biopharmaceutical factors that may present 
risks for oral drug performance for three excipient types (lubricants, binders, 
superdisintegrants) have been identified. The results indicate that presence of 
excipients and excipient variability can influence drug dissolution in vitro. Changes in 
the amount of drug dissolved in the gastrointestinal lumen can be anticipated that could 
result in treatment failure or patient harm. The design of biorelevant methods to 
evaluate excipient criticality enables the appropriate selection of excipients and results 
in the production of robust formulations with the minimization of the potential in vivo 
risks. Moreover, the scientific understanding of the impact of excipients on drug 
product performance can improve the effectiveness of the pharmaceutical 
manufacturing processes reducing batch inconsistencies and failures, improving the 
cost effectiveness and resulting in a faster industrial response to market demands or 
shortages. Finally, the effective control of excipient variability on product 
performance through the creation of design spaces will minimize the regulatory 
constraints leading to fast product approvals without compromising patient safety. 
Future Perspectives 
In this project, the criticality of excipients and excipient variability for oral drug 
performance was demonstrated and a strong interplay between excipient critical 
material attributes, drug physicochemical characteristics, medium and hydrodynamic 
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characteristics was found. The results of this thesis could be considered as a good 
starting point for the construction of design spaces (according to the principles of the 
QbD initiative) demonstrating the limits within which changes in product performance 
by excipient variability or variation are not anticipated. 
Towards this goal, further investigations are needed to delineate the changes in drug 
solubility in excipient presence. Use of material characterization techniques such as 
Raman spectroscopy, Differential Scanning Calorimetry, X-Ray Powder Diffraction 
etc, to identify potential structural changes in the physical mixtures or drug-excipient 
interactions could enhance the understanding of the observed effects of excipients on 
drug solubility in a molecular level. The use of surface dissolution UV imaging for 
other excipient types (binders, lubricants) would also be beneficial. Moreover, 
collection of additional data is necessary to properly outline and characterize the 
impact of excipient variability on product performance. This could be achieved by 
widening the range of the studied excipient properties (more than 2 levels) and 
broadening the data sets with other excipient types and/or drug with various 
physicochemical properties (e.g. drug ionization). Work should also focus in the 
investigation of other dosage forms (e.g. extended release formulations) as variability 
in more complex excipients (coating systems, release controlling agents, solubilizers) 
could be detrimental for oral drug absorption. Finally, as the varying composition of 
the gastrointestinal tract was found critical for the impact of excipients and excipient 
variability on drug dissolution, designing biorelevant tests simulating the fed state 
conditions (use of milk-based media, Fed State Simulated Gastric Fluid, Fed State 
Simulated Intestinal Fluid) could expand current knowledge and delineate the 
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